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Thesis Summary 
Human hypertension is known to have a large heritable component. However, 
the identification of the genetic factors is complicated, because the disease is 
complex and multi-factorial. Human essential hypertension (HTN) affects 25-35% 
of the adult population in developed countries and it is the leading risk factor 
for many cardiovascular diseases that are associated with high morbidity and 
mortality rates worldwide. Linkage analysis and genome-wide association study 
(GWAS) have been used as strategies to investigate the genetic basis of HTN. 
Linkage analysis has failed to identify convincing candidate genes for HTN, 
however, GWAS studies have reported several candidate genes for HTN. 
 
The identification of causative genes for HTN has been facilitated by the use of 
rats that have been selectively bred for high blood pressure. The stroke-prone 
spontaneously hypertensive rat (SHRSPGla) is an excellent model for human 
cardiovascular disease. Previously, a genome-wide scan between SHRSPGla and 
normotensive Wistar Kyoto (WKYGla) rats identified quantitative trait loci (QTL) 
on chromosomes 2, 3 and 14 for blood pressure, pulse pressure and cardiac 
mass, respectively. These QTLs were validated by the construction of 
chromosome 2, 3 and 14 congenic strains. 
 
This research project attempts to identify the genetic determinants of SHRSPGla 
phenotypes by using mRNA and micro(mi)RNA expression profiling data, in 
combination with the genome sequence of the SHRSPGla and WKYGla, to facilitate 
human translational studies for hypertension and vice versa.  
 
In chapter 3, we implemented Partek® batch effect removal tool to improve 
previously analysed heart transcriptomic data analysis between parental strains 
and chromosome 14 congenic strains at 3 different ages. The new improved 
analysis was able to accurately capture (a) the significant expression of 
osteopontin, a previously identified positional candidate gene for cardiac mass 
and (b) the phenotype of WKY.SPGla14a strain using disease analysis of ingenuity 
pathway analysis (IPA). Furthermore, we integrated salt-challenged renal gene 
expression profiling data of parental strains from two platforms with 
chromosome 3 congenic (SP.WKYGla3d) and sub-congenic (SP.WKYGla3f) strains. 
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This new workflow using Partek® genomics suite, identified 3 novel positional 
candidate genes for pulse pressure and salt-induced pulse pressure. In addition, 
cluster analysis was carried out using BiolayoutExpress3D on renal gene 
expression profiling data between parental strains with chromosome 2 congenic 
strain (SP.WKYGla2a) at different time points. The WKYGla expression pattern 
identified (109) cluster sharing similarities with the SP.WKYGla2a expression 
pattern when compared to the SHRSPGla. Cluster 109 includes 4 positional 
candidate genes for blood pressure; ATPase, class VI, type 11B (Atp11b), 
phosphoinositide-3-kinase, regulatory subunit 1 (Pik3r1), glutathione S-
transferase mu 7 and glutathione S-transferase mu 1 (Gstm1). Gstm1, was 
previously identified as a functional and positional candidate gene for 
hypertension in the SHRSPGla, providing proof of concept for our analysis. IPA 
analysis on cluster 109 identified genes and pathways associated with traits 
observed in the SHRSPGla. Quantitative real-time polymerase chain reaction 
(qRT-PCR) confirmed the differential expression of Atp11b and Pik3r1 between 
parental strains and SP.WKYGla2a at 21 weeks of age salt-challenged. In addition, 
we ran BiolayoutExpress3D cluster analysis across multiple tissues between young 
(5 weeks of age), adult (16 weeks of age) and mature (21 weeks of age) parental 
strains. IPA analysis on the identified clusters implicated genes with 
cardiovascular system function, molecular transport (young, adult and mature 
animals), nervous system function, and inflammatory response (only at adult and 
mature animals). Atp11b, which is responsible for ion transport, was implicated 
in all clusters at different hypertensive stages. Guanylate cyclase 1, soluble, 
alpha 3 (Gucy1a3) implicated in cluster 104 at severely hypertensive stage was 
the only gene that is already known to cause hypertension. qRT-PCR confirmed 
the differential expression of Atp11b in heart and kidney tissues. In this chapter, 
we were able to identify positional genes for the SHRSPGla phenotype that were 
not implicated by our previous workflows and gene expression analysis tools.  
 
In chapter 4, Next Generation Sequencing (NGS) of SHRSPGla and WKYGla was 
carried out, generating 1,163,332 single nucleotide polymorphisms (SNP), 
213,130 insertions and deletions of DNA segments (INDEL). A notable feature of 
the data included uneven distribution and density between SHRSPGla at 27x and 
WKYGla at 26x coverage assembled to Brown Norway (BN) RGSC 3.4. Structural 
analysis in the SHRSPGla and WKYGla identified thousands of large deletions as 
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well as copy number variation (CNV) of duplication and deletion. Genomic 
variants were annotated with Ensembl version 69 to prioritise sequence variants 
based on their predicted effect and to identify genes affected by large structural 
variants that are unique to each rat strain. Sequence variants between our 
strains (a) were higher in intergenic/ intronic regions compared to exonic 
regions including in our QTL regions on chromosomes 2,3 and 14, (b) IPA 
functional analysis on sequence variants implicate networks, diseases and 
pathways that regulate cardiovascular disease, and (c) has high sensitivity and 
specificity in detecting three variants data by different sequencing technologies. 
The new BN reference improved NGS coverage by at least 0.50x in both strains, 
detecting additional sequence variants with more defined predicted effect 
annotation with Ensembl version 71 when compared to BN reference RGSC 3.4. 
Also we attempted to isolate stroke candidate genes by isolated sequence 
variants unique to SHRSPGla compared to non-stroke prone 27 rat genomes 
against BN RGSC 3.4. SHRSPGla unique sequence variants were further prioritised 
by (a) deleterious protein coding sequence, (b) QTLs for blood pressure and 
stroke from our and other hypertensive rat strains, (c) in-common with published 
sequence variants of SHRSPIzm strain. Examples of the prioritised sequence 
variants included (a) a frameshift variant within Atp11b caused by a deletion of 
28 bp, and (b) a common SNP between SHRSP strains identified in our analysis 
causing a stop gain in stromal interaction molecule 1 that acts as calcium 
channel regulator which identified as candidate gene for stroke in SHRSPIzm. The 
latter emphasised the importance of integrating sequence variants from all 
SHRSP strains, as they share high proportion of SNPs, to prioritise stroke 
causative variants.  
 
In chapter 5, we investigated the types of genomic variants that are likely to 
have an influence on the cardiac and renal transcriptomic output between 
SHRSPGla and WKYGla using IPA. Overall, all genomic variants types are likely to 
correlate with transcriptomic data. Furthermore, we customised commercial 
microarray gene expression array to our rat strains by removing probes where 
their target sequence harbour sequence variants to avoid false positive results. 
The customised Affymetrix analysis of renal transcriptomic data has an impact 
on overall results when compared to the default analysis. Nevertheless, the 
customisation of Illumina array showed that true positive genes would be 
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removed as well. We presented a reductive and integrative strategy called "Swiss 
cheese" model that integrates proteins coding variants, QTL regions, 
transcriptomic data between SHRSPGla and WKYGla was able to identified 
positional candidate genes for the SHRSPGla phenotype. Moreover, we integrated 
the SHRSPGla unique sequence with published brain gene profiling data and 
prioritised 39 stroke candidate genes in the SHRSPGla. The SHRSPGla was assessed 
as model for HTN by integrating human GWAS candidate genes for blood pressure 
with our transcriptomic data, QTLs for blood pressure and sequence variants 
between from SHRSPGla and WKYGla. This demonstrated human GWAS candidate 
genes for blood pressure are (a) conserved and mapped to rat blood pressure 
QTLs (b) half of these genes harbour sequence variants and some are 
differentially expressed in our rat strains tissues. Gucy1a3-Gucy1b3 were 
prioritised for translation study as they map to chromosome 2 congenic interval 
with functional sequence variants and differentially expressed in heart and/or 
kidney between SHRSPGla and WKYGla. We also investigated differences in renal 
miRNAs in human hypertension and in the SHRSPGla using NGS technology. Human 
miRNA studies were able to implicate miRNAs associated with kidney damage. 
Whereas, in our rat studies, specifically between SP.WKYGla2c* versus SHRSPGla, 
we implicated miRNAs targeting positional candidate genes such as Gstm1 and 
Gucy1a3. Finally, we integrated cardiac gene expression profiling from SHRSPGla 
and WKYGla and publically available human heart failure data that led to the 
translation of SPARC related modular calcium binding 2, cardiac response to 
stress and wound healing, from our rat strain to human. 
 
In summary, we implemented, improved and integrated high-throughput genomic 
variants with transcriptomic data that identified and prioritised miRNA, genes, 
clusters and pathways that may underline pathophysiological processes in the 
SHRSPGla that can enhance the current knowledge of human patho-physiological 
mechanisms of cardiovascular disease and eventually lead to novel therapeutic 
targets.  
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1.1 Cardiovascular Disease 
According to the World Health Organization, cardiovascular disease (CVD) is the 
major leading cause of death in world accounting for 30% (17.3 million people) 
of worldwide deaths in 2008 (WHO, 2012). CVD encompasses a range of 
pathological conditions that affects cardiovascular system components; heart 
and blood vessels (Nichols et al., 2013). Coronary heart disease and 
cerebrovascular disease (stroke) are the main forms of CVD, representing the 
world's first (7.3 million people) and second (6.2 million people) most common 
causes of death, respectively (WHO, 2012). A number of controllable risk factors, 
including environmental, life style choices, and medical conditions, have been 
identified for developing CVD, and vary from poor nutrition, physical inactivity, 
smoking, high alcohol consumption, air pollution, obesity, to high blood 
pressure/cholesterol, and diabetes (Yusuf et al., 2004; Yusuf et al., 2014). 
Ageing, sex, family history, and ethnicity have been identified as non- 
controllable risk factors for developing CVD (Roger et al., 2012). During the last 
30 years, intervention and prevention of CVD risk factors have led to rapid 
reduction of the premature mortality rates in developed countries including the 
UK (Nichols et al., 2013).  
1.1.1 Blood Pressure 
Blood is a bodily fluid that delivers important substances such as oxygen, 
nutrients and hormones to all cells, tissues, organs and transports toxic 
metabolic waste products such as carbon dioxide away from those cells, tissues 
and organs. The force exerted by the blood flow within blood vessels is called 
blood pressure. Blood pressure is usually measured in millimetres of mercury 
(mmHg) and recorded as a fraction with the maximum pressure following systole 
of the left ventricle of the heart over the minimum pressure that accompanies 
diastole- hence, it varies depending on the cardiac output and the total vascular 
resistance. Blood pressure is also classified as systolic, which is the highest 
measurement of the pressure in arteries during heart contraction, whereas, 
diastolic blood pressure is the lowest measurement of pressure in arties when 
the heart relaxes (Strandberg & Pitkala, 2003). Pulse pressure is the difference 
between systolic and diastolic blood pressure measurements (Sesso et al., 2000). 
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Blood pressure readings vary between normal healthy individuals, however, an 
ideal pressure level in adults is suggested to be 120 systolic over 80 diastolic 
mmHg (Chobanian et al., 2003; Frese et al., 2011). 
1.1.2 Regulation of Blood Pressure 
The transportation of various molecules, such as gases, nutrients and 
metabolism by-products across cells and organ tissues within an organism, is 
performed via circulation. This makes blood circulation a function indispensible 
for life maintenance, and therefore, its regulation has to be tightly controlled. 
Several physiological factors partake in the regulation of blood pressure; renal, 
neural, vascular and endocrine systems, in combination with homeostatic 
mechanisms, interplay in order to respond to changes induced by environmental 
factors, including diet, stress and physical activity. Cardiovascular homeostasis 
can be interrupted by common factors, such as change in posture, or increased 
physical activity. If such changes are not compensated, they can result in 
reduced blood pressure, and in severe cases, reduced oxygen delivery to vital 
organs such as the heart and the brain. 
 
Normal blood pressure is regulated and maintained by a number of interacting 
physiological mechanisms involving neural, vascular, endocrine, and renal 
systems (Figure 1-1). Sudden changes in blood pressure are detected by the 
sympathetic and the parasympathetic nervous systems, offering a rapid response 
to fluctuations in blood pressure. The baroreceptor reflex system plays a vital 
role in the compensation of rapid blood pressure changes (Stauss, 2002). 
Baroreceptors can be located at the carotid sinus, the aortic arch, and the right 
atrium, and they can have both circulatory and renal effects. For instance, when 
the blood pressure is high, baroreceptors inhibit cardiac, renal and vasomotor 
sympathetic afferents to restore normal blood pressure. Baroreceptors have the 
opposite effect when a sudden drop in blood pressure is detected (Reviewed by 
Guyenet, 2006). Furthermore, stimulation of the sympathetic nervous system 
induces release of adrenaline and noradrenaline from the adrenal, causing 
increased flow resistance in the vessels (and therefore, increased blood 
pressure) via α – receptors signalling (Reid, 1986; Guyenet, 2006). 
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Figure  1-1 Physiological regulation of blood pressure. 
Schematic summarising the principle physiological mechanisms of RAAS, capillary fluid shift, Kinin-kalikrein system, baroreceptor reflexes, carotid and aortic 
chemoreceptors, endothelium, and natriuretic peptides that all regulate and maintain blood pressure. 
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Chemoreceptors that monitor the levels of oxygen and carbon dioxide (via pH 
sensing) also play a role in blood pressure regulation and are located close to the 
carotid sinus and aortic arch (Fletcher et al., 1992). 
 
Endothelin (ET), a 21 amino acid peptide that is produced by the vascular 
endothelium from a 39 amino acid precursor, can also regulate blood pressure 
and vascular tone by maintaining the balance between vasoconstriction (e.g 
endothelin) and vasodilation (e.g endothelium-derived relaxing factor such as 
Nitric Oxide) (Kohan et al., 2011). 
Another endogenous blood pressure regulation mechanism is regulated by the 
release of aldosterone. In response to angiotensin II (see paragraph 1.1.2.1 for 
more details), or elevated potassium levels within the serum, aldosterone is 
released by the adrenal cortex, inducing (a) the retention of sodium, and (b) the 
excretion of potassium, via the renal system. This osmotic change leads to 
increased fluid retention, and therefore, increased blood pressure (Freel & 
Connell, 2004).  
Finally, the capillary fluid shift mechanism can also regulate blood pressure by 
exchanging blood and fluids across capillary membranes.  
 
1.1.2.1 Kidney blood pressure regulation; the renin angiotensin aldosterone 
system (RAAS) 
Kidneys are considered the most important organ in regulating long term blood 
pressure. They regulate body fluid volume and osmolality by removing excess 
salt (such as sodium, potassium and chloride) and water out of the blood mass, 
and turn them into urine (Guyton, 1991). The most important mechanism by 
which kidneys exert the long-term control of blood pressure and volume 
homeostasis is the renin angiotensin aldosterone system (RAAS) (Hall, 1991). 
RAAS is one of the major regulators of blood pressure (Figure 1-2). RAAS 
hormonal cascade begins with renin secreted by juxtaglomerular kidney in 
response to low blood volume and/or a decrease in blood pressure (Guyton, 
1991). Renin in the blood stream cleavesangiotensinogen (secreted by the liver) 
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to form angiotensin I (Reid, 1998). Angiotensin I is then converted to angiotensin 
II, a vasoconstrictor and major active product of the RAAS, by angiotensin 
converting enzyme (ACE) that is found mainly within the lungs (Cambien et al., 
1992). Angiotensin II will increase blood pressure and stimulate aldosterone 
secretion from the adrenal glands causing renal tubular re-absorption of sodium 
and chloride, water retention and vascular contractions. This action is mediated 
by angiotensin II binding to AT1 receptors, whereas the interaction between 
angiotensin II and AT2 receptor have the opposite effect stimulating 
vasodilation. Angiotensin 1-7 peptide is another vasodilator with 
cardioprotective effects generated by ACE homologue (ACE 2) and probably ACE 
as well either directly via angiotensin II or indirectly via Angiotensin 1-9 peptide 
(Reviewed by Re, 2004; Schindler et al., 2007). 
A number of research groups are investigating the utilisation of the function of 
angiotensin II in RAAS system to stimulate hypertension and hypertrophy in 
animal models to identify and validate therapeutic targets. More specifically, the 
Nicklin group focuses on in vitro function of angiotensin 1-7 and 1-9, as well as 
the in vivo effect of the peptides on myocardial infarction and in hypertension 
mouse models via gene editing or direct peptide infusion in order to explore 
novel therapeutic options (Flores-Munoz et al., 2012; Clarke et al., 2013). 
 
Finally, the adrenal glands also partake in blood pressure regulation via the 
secretion of epinephrine and norepinephrine. These hormones cause 
vasoconstriction of arteries and veins, increasing heart rate and as a 
consequence, blood pressure. 
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Figure  1-2 The renin angiotensin aldosterone system. 
RAAS hormonal cascades showing the relationship between renin, angiotensin peptides and 
converting enzymes and their role in regulation of blood pressure (Adapted from Re, 2004). 
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1.2 Essential Hypertension 
Human essential hypertension (HTN) is the leading cause for CVD; it is 
characterised by chronically elevated arterial blood pressure of an unknown 
cause and is associated with high morbidity and mortality rates (Caulfield et al., 
2003). A study by Lawes et al., 2008 found several attributes to high blood 
pressure worldwide, including approximately 13.5% of premature deaths, 47% of 
ischaemic heart disease, and 54% of stroke. During recent decades, HTN 
prevalence has increased dramatically; according to the American Heart 
Association, about 77.9 million (1 out of every 3) adults have high blood pressure 
in the USA (Roger et al., 2012), while in Europe it varies among countries from 
25-35% of the adult population (Ruppert & Maisch, 2003; Joffres et al., 2013). 
HTN is diagnosed when average blood pressure readings for systolic and diastolic 
are 140/90 mmHg, respectively (Table 1). 
HTN is a multi-factorial disease in which multiple genes and environmental 
factors contribute; resulting in a complex, multi-factorial disease in which the 
genetic parameters have not been clarified and the genetic susceptibility 
variants have not been determined (Ruppert & Maisch, 2003). HTN accounts for 
approximately 90-95% of all cases of hypertension, whereas secondary 
hypertension, which is caused by identifiable secondary pathological conditions, 
accounts for approximately 5-10% of all cases of hypertension (Faselis et al., 
2011). 
Table  1-1 Blood pressure classification for adults. 
 
(Table adapted from Chobanian et al., 2003) 
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1.2.1 Environmental Risk Factors 
A number of inter-related environmental factors have been found to be 
responsible for 80% of hypertension (Beilin, 2004). These include obesity (calorie 
excess), insulin resistance, high alcohol consumption, physical inactivity, mental 
stress/depression, cigarette smoking, caffeine intake, vitamin D deficiency, low 
potassium intake, low calcium intake, and high salt intake (in salt-sensitive 
patients). 
 
The prevalence of obesity-associated hypertension in United States of America 
among adults is 60%-70% (Must et al., 1999). A strong association has been 
observed between increased body mass index and the frequency of hypertension 
within the middle-aged population (Timpson et al., 2008). This might be due to 
the fact that body weight and blood volume are correlated; an increase in body 
weight will increase the cardiac output (for more blood) thus, increasing the 
pressure on blood vessels. Nevertheless, the mechanism in which obesity can 
lead to hypertension is by the activation of the sympathetic nervous system and 
RAAS (Rahmouni et al., 2005). Furthermore, obesity can cause insulin resistance, 
a condition where cells fail to response to normal insulin (a hormone with 
vasodilatory properties), which can cause hypertension (Salvetti et al., 1993). In 
addition, insulin resistance can be caused by vitamin D deficiency that also 
predispose to hypertension by inhibiting renin, which subsequently activates 
RAAS (Lee, 2008). 
 
1.2.1.1 Salt Sensitivity 
Salt sensitivity is defined as ≥10 mmHg rise in blood pressure during salt-loading, 
which is then expected to reduce, compared to a salt-depleted state. High salt 
intake is a major risk factor for HTN, and the rest of CVDs. An International 
Study of Salt and Blood Pressure (INTERSALT) examined urinary sodium excretion 
level with blood pressure. The study found a significant positive association 
between increased sodium excretion and blood pressure (Stamler et al., 1989). 
Studies on hypertension prevalence among populations have observed that 
nations with natural food diets that are low in sodium have a lower rate of 
hypertension, compared to industrialised nations that mainly consume processed 
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food that is high in sodium (Adrogue & Madias, 2007). These findings are further 
supported by observations from dietary intervention approaches in hypertensive 
patients, in which reduction in sodium intake has been found to lower blood 
pressure (Sacks et al., 2001). The possible ways high sodium intake can induce 
hypertension includes sodium retention by impairing the ability to excrete 
sodium and to impact the RAAS which suppresses angiotensin II function leading 
to an increase in cardiac output and pressure on arteries walls (Drenjancevic-
Peric et al., 2011). 
 
A study from Ji et al., 2008, following screening for variations in three genes: 
SLC12A3 (NCCT), SLC12A1 (NKCC2) and KCNJ1 (ROMK) from members of the 
Framingham Heart Study, demonstrated that many rare alleles that affect kidney 
sodium handling are involved in blood pressure variation. They also identified 
new alleles that benefit health, however, they are under purifying selection.  
 
Animal studies have identified candidate genes for salt-sensitive hypertension in 
Dahl salt-sensitive rats using zinc-finger nuclease technology. For example Jin et 
al., 2014 provided evidence that voltage-gated proton channel, HV1, acts as a 
sodium sensor and promotes superoxide production in medullary thick ascending 
limb of Dahl salt-sensitive rats (Jin et al., 2014).  
 
1.2.2 Genetic risk factors 
The genetic determinants of HTN have been estimated to be 30% - 50% of the 
blood pressure variation among individuals (Lifton, 1996; Marteau et al., 2005). 
Family and twin studies indicate that the heritability of systolic blood pressure is 
approximately between 15 to 40%, while that of diastolic blood pressure is 
approximately 15 to 30% (Feinleib et al., 1977; Mongeau et al., 1986; Staessen et 
al., 2003). In addition, hypertension sibling recurrent risk (a measure of familial 
aggregation of hypertension) for a person who has an older sibling with 
hypertension are 1.2-1.5 times more likely to be diagnosed with hypertension 
than the general population (Caulfield et al., 2003).  
HTN is rarely due to monogenic mutations inherited by Mendelian forms; it is 
widely believed that it results from the inheritance of a number of susceptibility 
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genes, in addition to the involvement of multiple environmental determinants 
(Marteau et al., 2005). 
1.2.2.1 Mendelian forms of inheritance 
A number of monogenic or Mendelian forms of hypertension have been 
identified, in which most share a common pathway of increased distal tubular 
re-absorption of sodium and chloride and volume expansion that suppresses 
plasma renin activity (Garovic et al., 2006). 
1.2.2.1.1 Glucocorticoid-Remediable Aldosteronism 
 
Glucocorticoid-remediable aldosteronism is an autosomal dominant disorder 
characterised by an early onset of hypertension with normal or elevated 
aldosterone levels. This is the result of chimeric gene duplication from unequal 
cross over between 11b-hydroxylase (CYP11B1) and aldosterone synthase gene 
(CYP11B2), causing aldosterone synthase to be expressed in the adrenal gland 
under the regulation adrenocorticotropin. This eventually increases both sodium 
re-absorption and potassium secretion (Lifton et al., 1992; Simonetti et al., 
2012). 
1.2.2.1.2 Apparent Mineralocorticoid Excess 
 
Apparent mineralocorticoid excess is an autosomal recessive disorder 
characterised by an early onset of hypertension with hypokalaemia, metabolic 
alkalosis, low renin and aldosterone. This is a result of a mutated 11 β - 
hydroxysteroid dehydrogenase type 2 enzyme causing high concentrations of 
cortisol in the kidney that activates the mineralocorticoid receptor resulting in 
aldosterone like effect and leads to hypertension (Wilson et al., 1995; Simonetti 
et al., 2012). 
1.2.2.1.3 Liddle Syndrome 
 
Liddle syndrome is an autosomal dominant disorder, characterised by an early 
onset of hypertension, with hypokalaemia, metabolic alkalosis, and low levels of 
renin and aldosterone. It is believed that this phenotype is the a result of 
mutated sodium channel, non-voltage-gated 1, beta and/ or gamma subunit 
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causing an increased epithelial sodium channel mediated sodium re-absorption 
leading to hypertension (Shimkets et al., 1994; Hansson et al., 1995; Snyder et 
al., 1995; Simonetti et al., 2012). 
1.2.2.1.4 Hypertension with Brachydactyly 
 
Hypertension with brachydactyly is an autosomal dominant disorder, 
characterised by shortened finger bones with hypertension that develops and 
progress into severe hypertension that closely resembles HTN. It has been 
suggested that a structural variation within chromosome 12 between p12.2-
p11.2 region results in impaired baroreceptor reflex function of blood pressure 
buffering that may leads to hypertension (Schuster et al., 1996; Jordan et al., 
2000; Pereda et al., 2013). 
1.2.2.1.5 Pseudohypoaldosteronism type II 
 
Pseudohypoaldosteronism type II, also known as Gordon’s syndrome, is an 
autosomal dominant disorder characterised by hypertension, hyperkalaemia, 
hyperchloraemia, and metabolic acidosis. This is the result of mutation in either 
one of the two serine-threonine kinase genes, WNK1 and/or WNK4, causing an 
increase in sodium re-absorption resulting in hypertension (Wilson et al., 2001). 
Boyden et al., 2012 showed that kelch-like 3 and cullin 3 are also causative 
genes for Gordon’s syndrome. 
1.2.2.2 Identifying candidate genes associated with HTN 
Identifying candidate genes in multi-factorial complex diseases, such as HTN, is 
much more difficult when compared to monogenic disorders. Linkage analysis 
and genome-wide association study (GWAS) are the main approaches used to 
identify candidate genes in HTN.  
Linkage analysis is used to locate quantitative trait loci (QTLs) when the disease 
causing genes are unknown. This is done by using known polymorphic markers 
and linking them to the disease in family studies. Any genetic marker can be 
used including single nucleotide polymorphism (SNP) and/or microsatellites 
(nucleotide repeats within the genome). 
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One of the notable linkage studies to identify QTLs for HTN in large families with 
affected members, has been carried out by the Medical Research Council BRItish 
Genetics of HyperTension (BRIGHT). Genome wide scans of 3599 individuals 
identified a significant QTL for HTN on chromosome 6q with a logarithm of the 
odds (LOD) score of 3.21 (>3.0 is usually used as cut-off for significant linkage) 
and genome-wide significance (p=0.042), and other suggestive QTLs on 
chromosomes 2q, 5q and 9q with LOD scores higher than 1.57 (but lower than 
3.0) with genome-wide significance (p=0.017) when assessed under a locus-
counting strategy (Caulfield et al., 2003). When the number of affected 
participants were increased in follow-up studies, a significant QTL on 
chromosome 5q13 for HTN and novel suggestive QTLs were identified (Munroe et 
al., 2006). Binder (2007), reviewed a number of linkage studies and showed that 
QTLs associated with HTN were implicated in all autosomal chromosomes. 
Nevertheless, QTLs associated with hypertension on chromosomes 1, 2, 3, 17 and 
18 were reported by at least two linkages studies (Binder, 2007). Recently, 
research groups are moving away from linkage analysis due to (a) usually the 
identified QTL regions are large and contain many genes which are more 
laborious to investigate (poor genetic resolution in the centimorgan range), (b) 
the detecting power of linkage analysis in common alleles that have low 
penetrance is poor (Padmanabhan et al., 2008), (c) inappropriate marker density 
in linkage analysis studies can lead to loss of information (McBride et al., 2006), 
and d) genetic recombination may result in misleading statistical probability.  
GWAS is a more preferred approach to identify polygenic disease susceptibility 
genes by comparing large number of SNP or microsatellite markers across the 
whole genome between patients and controls in a population (no need for family 
studies) (Ruppert & Maisch, 2003). GWAS using a large number of SNPs by the 
Wellcome Trust Case Control Consortium (WTCCC) failed to identify convincing 
candidate genes for HTN (Burton et al., 2007). This might be due to (a) GWAS 
principle is based on the idea that a single gene is the causative reason of the 
phenotype; whereas, HTN involves multiple complex interactions of genes, gene-
environment (Ruppert & Maisch, 2003), and ethnic diversity in populations 
(Padmanabhan et al., 2008), (b) it has been suggested that the standards that 
define the controls could be more strict , in order to increase the phenotypic 
distance between the "hypercontrols" and the affected individuals, increasing 
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the chance of finding genetics association (Delles et al., 2008a), (c) GWAS 
demonstrate a small portion of the total heritability, and in order to be used for 
a successful study the samples should be large, carefully dissected phenotype 
and from homogeneous populations (Amos, 2007). 
Successful GWAS studies were reviewed in Simino et al., 2012 in which more 
than 50 genes were identified as candidate genes for blood pressure and HTN. 
Some of the published GWAS data were combined to create a more powerful 
meta-analysis to prioritise candidate genes for blood pressure and HTN. Meta-
analysis was performed using the the Global Blood Pressure Genetics (Global 
BPgen) consortium study, which took into account data from 34,433 subjects 
(Newton-Cheh et al., 2009), with Cohorts for Heart and Aging Research in 
Genome Epidemiology (CHARGE) consortium in 29,136 subjects (Levy et al., 
2009) revealed genome-wide significance (P < 5 × 10− 8) for systolic, diastolic 
blood pressure, and hypertension (Table 1-2). Moreover, GWAS studies have good 
genetic resolution (usually in the kilobase range) in which the SNPs associated 
with HTN are next to a few genes or sometime within a gene giving an insight 
into possible pathogenesis pathways based on known function. For instance, 
Padmanabhan et al., 2012 predicted possible pathways of the GWAS candidate 
genes for blood pressure and HTN based on their known function, which is 
helpful in uncovering novel mechanisms (Table 1-3). It is essential to note that 
although human GWAS studies for hypertension demonstrated blood pressure 
susceptibility genes, nevertheless, the associated SNPs have modest effect on 
blood pressure (< 1 mmHg), explaining a small fraction (approximately 3%) of 
blood pressure heritability within populations, and fall mainly outside the gene 
coding regions (Hindorff et al., 2009). 
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Table  1-2 Meta-analysis of Global BPgen and CHARGE of significant Loci for Systolic and 
Diastolic Blood Pressure and Hypertension. 
 
(Table adapted from Levy et al., 2009) 
 
Table  1-3 Possible pathways of GWAS candidate genes for blood pressure and HTN. 
 
(Table adapted from Padmanabhan et al., 2012) 
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1.2.3 Endothelial Dysfunction in HTN 
Endothelial dysfunction can be the cause, as well as consequence of HTN. As a 
result, elucidating the underlying mechanisms in endothelial dysfunction is 
necessary. NO production and bioavailability by vascular endothelium is critical 
for blood flow regulation and the vasodilation (Mensah, 2007). NO is formed by 
enzymatic action of endothelial NO synthase (eNOS), although, uncoupled eNOS, 
as well as nicotinamide adenine dinucleotide phosphate-oxidase (NADPH), and 
xanthine oxidases, are important sources for reactive oxygen species (ROS). 
These are chemically reactive molecules containing oxygen produced as by-
products of normal physiological oxidation/reduction (redox) reactions, which 
are involved in cell signalling and homeostasis (Hancock et al., 2001). Under 
normal conditions, the rates of ROS production of free radicals and normal 
cellular defences are balanced. However, imbalances in ROS production, called 
oxidative stress, can lead to changes in vascular structure and function. In HTN, 
a number of ROS-dependent mechanisms for hypertension have been identified 
(Endemann & Schiffrin, 2004). These include (a) decreased NO bioavailability 
and/or vascular tone; NO reacts with superoxide producing peroxynitrite that 
has lower vasodilator effect than NO and will also increase ROS production, (b) 
vascular inflammation; Increase in inflammatory cytokines (e.g. interleukin-6 
(IL-6), tumor necrosis factor alpha (TNF-α) influences the adhesion molecules 
(e.g. intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion 
molecule-1 (VCAM-1) in a ROS-sensitive (pathological) manner leading to 
increased endothelial layer permeability which will inhibit normal endothelial 
function. This leads to the synthesis of pro-inflammatory and pro-thrombotic 
factors and increased endothelin-1 secretion that will also increase ROS 
generation (c) vascular remodelling; NO bioavailability and vascular 
inflammation over time, which will eventually lead to vascular stiffness 
(remodelling) (Reviewed by Delles et al., 2008b; Montezano & Touyz, 2011). 
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Figure  1-3 ROS sources and oxidative stress effects on the vasculature. 
ROS regulates a number of important cellular functions and generated by enzymatic (such as 
NADPH) and non-enzymatic (such as angiotensin II (AngII), endothelin-1 (ET-1) pathways due to 
physical factors and/or genetic factors. The former includes changes in the blood flaw and the latter 
due to polymorphisms of oxidative stress related genes such as NADPH oxidases (NOX), nitric 
oxide synthase 3 (NOS3), and etc. When the ROS generation exceeds endogenous antioxidant 
mechanism (oxidative stress) will result in a number of deleterious changes, mainly loss of NO 
bioavailability and vascular inflammation (Original diagram constructed from information within 
Delles et al., 2008b; Montezano & Touyz, 2011). 
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1.2.4 Treatments for hypertension 
Findings from epidemiological, prevalence and intervention studies of 
environmental risks factors associated with hypertension (Stamler et al., 1989; 
Salvetti et al., 1993; Must et al., 1999; Sacks et al., 2001; Beilin, 2004; Adrogue 
& Madias, 2007; Lee, 2008; Timpson et al., 2009) suggest that better life style 
choices, such as good diet, exercise, and reasonable consumption of alcohol, 
tobacco and caffeine, can lead to reduction in blood pressure reducing CVD risk. 
Nevertheless, pharmacologic therapy is required for the management of blood 
pressure in hypertensive patients.  
Recently, panel members appointed to the Eighth Joint National Committee (JNC 
8) with expertise in hypertension, cardiology, pharmacology, clinical trials, 
evidence-based medicine, informatics, and development, and implemented 
clinical guidelines in systems of care released 2014 evidence-based guidelines for 
the management of high blood pressure in adults (James et al., 2014). Although, 
other management guidelines for the pharmacological management of 
hypertension have been already into practice, such as the collaboration between 
the British Hypertension Society and The National Institute for Health and Care 
Excellence (NICE) in 2013 (NICE, 2013). Drugs listed in Table 1-4 are for 
hypertensive patients with varying ages and ethnicity groups and include 
complications from other diseases from two management guidelines. Although, 
different guidelines have different strategy in managing hypertension, the first 
in-line drug usually used to treat high blood pressure is a thiazide diuretic, which 
increase sodium and water excretion by the kidneys. Diuretic drugs show a 
consistent drop in blood pressure in patients with an African origin, which may 
be due to increased susceptibility of salt sensitivity putting hypertensive 
patients with African origin at risk to develop hypokalaemia (Gibbs et al., 1999). 
Therefore, angiotensin receptor blocker, or ACE inhibitor, is prescribed instead, 
Both reduce the production of angiotensin II allowing for blood vessels to widen 
thus reduce blood pressure, which is also beneficial for hypertensive patients 
with diabetes and chronic kidney disease (Molnar et al., 2014). Severely 
hypertensive patients (with stage 2 hypertension) might require drug 
combinations therapy to achieve normal blood pressure control (James et al., 
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2014). However, in all cases, current anti-hypertensive drugs therapy do not 
provide permanent (long-term) effect on lowering blood pressure. 
 
Table  1-4 Hypertensive guidelines for drug therapy in adults. 
 
(Table adapted from NICE, 2013; James et al., 2014) 
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1.2.5 HTN end-organ damage  
When HTN is not treated it can cause end-organ damage, including left 
ventricular hypertrophy and stroke.  
1.2.5.1 Left ventricular hypertrophy 
Chronically elevated cardiac workload can lead to thickening of the left 
ventricle myocardium leading to left ventricular hypertrophy (LVH). This cardiac 
remodelling can be caused by (a) physiological factors; such as reaction of 
exercise/physical training (athletic hypertrophy), which is reversible (b) 
pathological factors; high blood pressure (hypertension), aortic valve stenosis 
(does not open fully) and insufficiency (does not close tightly), and/or by 
underlying mechanisms in patients with dilated cardiomyopathy (by increased 
filling of the heart left ventricle) and coronary artery disease (as the 
myocardium compensates for the ischemic or infarcted tissue) (reviewed by 
Bauml, 2010). Furthermore, genetics, age, sex, race, body mass index and 
stimulation of sympathetic nervous systems and RAAS are factors havecrucial 
roles in the pathogenesis of LVH (Gradman & Alfayoumi, 2006). Left ventricular 
mass index (LVMI) measurement, is calculated by measuring left ventricular mass 
corrected for body size, with specific cut-off levels to diagnose LVH (Reviewed 
by Bauml, 2010). LVH is not a disease per se; however, it is an important 
predictor for hypertrophic cardiomyopathies, heart failure, stroke that can lead 
to sudden death (Gradman & Alfayoumi, 2006). Therefore, understanding the 
genetic influence and developmental mechanisms of LVH is essential.  
One of the important components in the development of LVH is the initiation of 
myocardial fibrosis (abnormal excess of fibroblasts cells in the cardiac muscle) in 
response to increased stress on the left ventricular wall by stimulating 
cardiomyocytes, collagen formation and fibroblasts. The fibrosis increases 
myocardial mass, lowering the blood volume in the left ventricular during 
diastole (diastolic dysfunction), and eventually, impairing the heart to relax 
between contractions (Kahan & Bergfeldt, 2005). The development of LVH has 
been associated with the sympathetic nervous system, and RAAS via 
norepinephrine and angiotensin II, respectively, where both (a) to be increased 
in LVF patients effect increased in LVH patients (Gonzalez et al., 2002; Schlaich 
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et al., 2003) (b) enhances fibrosis mediated by transforming growth factor β1 in 
cardiac fibroblasts (Akiyama-Uchida et al., 2002; Gonzalez et al., 2002). A 
number of hypertrophic cardiomyopathy causing genes that encodes sarcomeric 
proteins (basic unit of muscle) were identified; nevertheless, the underlying 
mechanism in which these genes cause LVH is not known yet (Maron, 2002).  
1.2.5.2 Stroke 
Stroke is defined as the interruption of blood supply to the brain, causing 
permanent brain damage that can lead to mental and physical disability, and 
even sudden death. Stroke can be the result of a rupture of a blood vessel 
(haemorrhagic stroke) and/or a blockage in an artery by clots (ischaemic stroke) 
(Alqadri et al., 2013). Hypertension is one the main risk factors for ischaemic 
stroke, which is the second leading, cause of death (WHO, 2012). This suggests 
the importance of understanding the genetic controls and mechanisms of stroke 
development. Human GWAS were successful in identifying a few candidate genes 
that may cause stroke; however, the implicated genes have not yet been 
functionally characterised (Fornage et al., 2011; Traylor et al., 2012). Animal 
studies show that angiotensin II receptors (AT1 receptor and AT2 receptor) are 
involved in the pathogenesis (increasing oxidative stress as a result of AT1 
receptor pathway) (Wakisaka et al., 2010), and neuroprotection (suppressing the 
oxidative stress as a result of AT2 receptor pathway) in stroke (Iwai et al., 2004). 
Currently, angiotensin II receptor blockers and ACE inhibitors are used to prevent 
stroke in patients with and without history of stroke, as well as to lower blood 
pressure (Dahlof, 2009). 
1.2.6 Animal models 
Animal models have been selectively inbred over several generations to study 
human CVD, including HTN, in order to identify the genetics determinants and 
patho-physiological pathways is vital. This is due to (a) increased genetic 
homogeneity, (b) reduced environmental factors using standardised housing 
criteria, (c) production of specific inter-crosses between diseased and control 
animals for linkage analysis (Graham et al., 2005), (d) access to disease relevant 
tissues even at early age with diet induce disease (e) Most of human genes have 
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corresponding orthologues in mouse (Waterston et al., 2002) and rat genomes 
enhancing translation studies (Gibbs et al., 2004).  
1.2.6.1 Mouse 
The early availability and development of both genome and genetic 
manipulation (knock-out or knock-in gene of interests) in the mouse, made it the 
preferred animal model for molecular research. Although, genetic and non-
genetic mouse strains for human CVD are already in existence, due to the small 
animal body size and increase heart rate, mouse models are not as suitable as 
rats for the study human CVD (Rapp, 2000).  
1.2.6.2 Rat 
Using rats as an animal model for the study of human CVD has more advantages 
over mouse models due to the fact that (a) rats’ bigger body size allows for 
easier handling, surgery, and physiological measurements and (b) rats have 
longer life span, allowing for a better patho-physiological similarity to human 
CVD (Rapp, 2000). A number of inbred rat strains, brother and sister mating over 
20 generations to achieve homozygous (genetically identical) strain, have been 
selectively bred to display human CVD phenotypes. In 2008, the STAR consortium 
surveyed over 20,000 SNPs across 167 inbred laboratory rat strains (including our 
hypertensive and normotensive rat strains) facilitating the construction of high-
density genetic maps, characterising SNPs for disease gene mapping, and QTL 
identification (Saar et al., 2008). Most commonly used inbred hypertensive rat 
strains, including selectively inbred and/or induced by surgery or diet, were 
developed from either Wistar-related or Sprague-Dawley stocks and these have a 
common origin (Reviewed by McBride et al., 2004). Recently, a phylogenetic tree 
analysis was carried out on 28 laboratory rat strains, genome sequence, with a 
number of complex traits (including hypertensive and normotensive rat strains) 
to gain an insight into the pressures underlying selection for these phenotypes 
(Figure 1-4) (Atanur et al., 2013). This study includes divergent rat strains, for 
example Dahl salt-sensitive (SS/Jr) and resistant (SR/Jr ), as well as Sabra 
hypertension-prone (SBH/Ygl) and resistant (SBN/Ygl), in which sensitive and 
prone rat strains develop high blood pressure in response to high salt intake 
while resistant rat strains remain normotensive. Nevertheless, spontaneously 
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hypertensive rats (SHR) are a selectively inbred rat strain that develops high 
blood pressure without any provocative dietary and environmental factors. 
 
 
 
Figure  1-4 Phylogenetics tree of 28 rat strains for complex human disease. 
Phylogenetics tree of 28 laboratory rat strains for human complex disease including models for 
hypertension with their control strains (highlighted in blue), diabetes, and insulin resistance. The 
scale represents genetic distance based on rats whole genome sequence compared to Brown 
Norway (BN/Mcwi) as the reference strain (Modified figure from Atanur et al., 2013). 
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1.2.7 The Stroke-Prone Spontaneously Hypertensive Rat (SHRSP) 
The SHR rat was selectively developed from the Wistar-Kyoto (WKY) 
normotensive rat. Further inbreeding in SHR with high blood pressure (180-220 
mmHg) led to the development of the stroke-prone spontaneously hypertensive 
rats (SHRSP), a sub-strain of SHR with increased blood pressure (220-240 mmHg) 
and a greater propensity to cerebral stroke (approximately 80%) than SHR 
(approximately 10%) (Yamori & Okamoto, 1974; Okamoto et al., 1975). Moreover, 
the incidence of cerebral stroke in the SHRSP reaches 100% with high salt intake 
(Yamori et al., 1974). Further phenotype and end-organ damage assessment 
studies showed that the SHRSP displays other human CVD features as well, such 
as left ventricular hypertrophy (Clark et al., 1996), endothelial dysfunction (Kerr 
et al., 1999) and insulin resistance (James et al., 2001). As these patho-
physiolologal traits shared similarity with the human disease traits (Rapp, 2000), 
the SHRSP was considered an excellent model to study the development, 
prognosis and treatment of HTN, in addition, to gene-environment interaction. 
Nevertheless, human CVD, such as spontaneous heart failure, and 
atherosclerosis, have not been observed in the SHRSP.  
The University of Glasgow animal facilities have maintained SHRSP and WKY 
(normotensive reference strain) colonies since 1991. Both rat strains are known 
officially as SHRSPGla and WKYGla rat strains. The spontaneous onset hypertension 
state in the SHRSPGla is maintained by selective mating of a male with systolic 
pressure between 170-190 mmHg and a female with systolic pressure between 
130-150 mmHg at 12 weeks of age, compared to 130 mmHg in WKYGla rats (male 
and female) of the same age (Davidson et al., 1995; Graham et al., 2007). The 
blood pressure difference between SHRSPGla genders has been confirmed to be 
due to the genetics influence on chromosome Y (Negrin et al., 2001). 
A previous genome wide scan was carried out by our group, in order to identify 
QTLs underlying the SHRSPGla phenotype (Clark et al., 1996). The linkage analysis 
study start with cross between parental strains (SHRSPGla and WKYGla) to 
generated heterozygotic first generation (F1). The F1 offspring undergo brother-
sister mating to generate F2 progeny, which have random genetic compliment of 
the parental strains. The offspring’s of F2 are genotyped with microsatellite 
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markers spanning the genome and phenotyped for SHRSPGla traits. Both genotype 
and phenotype data are imported into a statistical software to calculate the 
probability of LOD of each trait set against the genomic positions. This approach 
identified a number of QTLs with LOD score higher than 3.0 for SHRSPGla; two 
QTLs on chromosome 2 for blood pressure (with and without salt diet), QTL on 
chromosome 3 for pulse pressure (with and without salt diet), QTL on 
chromosome 14 for LVMI (Figure 1-5a), and QTL for stroke on chromosome 5 
(Jeffs et al., 1997). The QTL regions identified were too large to carry out 
positional cloning, in order to identify trait controlling genes. Therefore, to 
validate and confine an implicated QTL, a substitution of small segments of a 
chromosome from one strain to another is used to fine-map the QTL region to 
identify genes that influence hypertension, cardiac hypertrophy and stroke 
(Rapp, 2000). Congenic strains were constructed using marker-assisted approach 
to confirm the existence of these QTLs so as to allow genetic dissection of the 
implicated regions (Graham et al., 2005). This is carried out by introgression of 
donar sequences from the WKYGla strain to the SHRSPGla background by 
backcrossing WKYGla strain to SHRSPGla with selective breeding of the genetically 
best animals from each generation to be maintained for backcrossing using 
microsatellite markers (Figure 1-6). The QTLs were validated when the 
phenotype of the congenic strains of chromosome 2, 3 and 14 were compared to 
the SHRSPGla, for blood pressure (McBride et al., 2003), pulse pressure and LVMI 
(Foote et al., 2011), respectively (Figure 1-5b). 
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Figure  1-5 The identification and validation of the SHRSPGla phenotype QTLs. 
a) Previous genome wide scan study between SHRSPGla and WKYGla identified SHRSPGla 
phenotype QTLs for blood pressure on chromosome 2 (two QTLs), pulse pressure on chromosome 
3, and LVMI on chromosome 14 rats with LOD score cut-off >3.0 (Clark et al., 1996). b) Phenotype 
validation on the constructed congenic strains: chromosome 2 congenic strain showed significant 
reduction systolic blood pressure (with and without salt diet) compared to the SHRSPGla, 
chromosome 3 congenic strain showed significant reduction in pulse pressure (with and without 
salt diet) compared to the SHRSPGla, and chromosome 14 congenic strain showed significant 
reduction in LVMI compared to the SHRSPGla at 16 weeks of age (Data courtesy of Glasgow 
University laboratory). 
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Figure  1-6 Congenic strain construction. 
Congenic strain constructed using marker assisted approach by introgressing the QTL of interested 
from the donor (WKYGla) rat strain into the genetic background of the recipient (SHRSPGla) strain by 
mating the two to generate the first generation. Then first backcross offsprings are genotyped with 
microsatellite markers spanning the entire genome including chromosome of interests in which 
additional markers are used. Selective breeding is used for the second backcross where only the 
rat males with the least heterozygous marker alleles on the chromosomal region of interest and the 
most homozygous for recipient alleles on remaining genome are used to mate with the recipient 
female rat strain. The backcrosses is repeated with the same criteria for selective breeding to 
produce a congenic strain with homozygousity in all background markers. Finally, QTL of interest is 
fixed to obtain homozygous by crossing appropriate males and females (Original figure, 
constructed from information within Graham et al., 2005). 
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1.2.7.1 Microarray Expression Analysis and Congenic Strains 
Microarray gene expression profiling is defined as the simultaneous measurement 
of thousands of genes expression levels within a given messenger RNA (mRNA) 
sample (from two or more experimental conditions) using DNA microarrays. Since 
the introduction of microarray technology, the advancements in clinical 
diagnostics (confirmation of genes or biomarkers) and medical research (study 
the mechanisms involved in complex disorders and the response of therapeutic 
drug or diet), have flourished. 
Microarray analyses are a multiplex technique that requires the use of specialist 
machines to analyse and detect the signals from the hybridization of 
oligonucleotides probes bound to the target and control DNA, detecting the 
variation in expression by measuring the difference in the intensity of the signal. 
Typically, microarray expression data include a number of variation sources, such 
as random error,introduced during the performance of the experiment and/or 
measurement error associated with acquisition of raw intensity data from 
microarray hybridized images (Tarca et al., 2006). As a result, normalisation 
method are used to reduce these systemic effects and maintain biological 
variability. 
The implementation of integrating gene expression profiling and congenic rat 
strains has been successful in isolating candidate genes for hypertension in QTL 
regions. Cd36 gene (thrombospondin receptor), which regulates fatty acid 
metabolism and ectopic accumulation of fat, was identified as a causative gene 
(mutated) for insulin resistance in the SHR using rat chromosome 4 congenic 
strains (with QTL from the normotensive BN rat) (Aitman et al., 1999). Srebf1 
(sterol regulatory element binding factor 1c isoform) was identified as causative 
gene (mutated) for hepatic steatosis (common metabolic disorder in 
hypertensive patients) in the SHR using rat chromosome 10 congenic strain (with 
QTL from the normotensive BN rat) (Pravenec et al., 2008b). 
Alternatively, other research groups integrated recombinant inbred (RI) rat 
strains and gene expression profiling as a strategy to identify candidate genes for 
hypertension. RI strains have been generated by mating two inbred strains 
(hypertensive and a control), followed by at least 20 generations of brother-
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sister interbreeding, so as to produce inbred strains in which each individual RI 
strain has unique parental strains genetic mixture. This approach led to the 
identification of Ogn (osteoglycin) as a candidate gene for cardiac hypertrophy 
of the left ventricle using BXH/HXB panel of rat RI strains, derived from SHR and 
BN strains (Petretto et al., 2008). 
 
1.2.7.2 Candidate Genes for Blood Pressure Regulation and Salt Sensitivity 
in SHRSPGla 
Our group carried out renal gene expression profiling between SHRSPGla, WKYGla 
and chromosome 2 congenic strains to identify differentially expressed genes 
mapping within the blood pressure QTL (positional candidate genes). Gstm1 
(glutathione S-transferase μ-type 1) which is involved in defence against 
oxidative stress found to be expressed in kidney at low level in the SHRSPGla 
when compared to chromosome 2 congenic and WKYGla strains at early age 
(McBride et al., 2003). A follow-up study identified sequence variants within 
Gstm1 promoter and coding regions (McBride et al., 2005). The reduction of 
renal and vascular expression level of Gstm1 in the SHRSPGla were not affected 
with anti-hypertensive drugs suggesting its involvement in hypertension 
pathogenesis is via oxidative stress pathway (Koh-Tan et al., 2009). Furthermore, 
Gstm1 transgenic SHRSPGla strain model, Gstm1 from WKYGla integrated into the 
SHRSPGla background, shows significant reduction in systolic pressure compared 
to SHRSPGla (Olson, 2014).  
Sphingosine-1-Phosphate Receptor 1 (S1pr1) and Vcam1 have been identified as 
candidate genes for salt-sensitive hypertension in the SHRSPGla. Sequence 
variants were identified in S1pr1 and Vcam1 and their expression levels were 
significantly differentially expressed between chromosome 2 congenic strains 
and the SHRSPGla in response to salt intake (Graham et al., 2007). S1pr1, also 
known as endothelial differentiation gene 1 (Edg1), is essential for the 
regulation and protection of vascular growth and development during 
embryogenesis via vascular endothelial cell growth factor (Chae et al., 2004; 
Gaengel et al., 2012). S1pr1 knock-out mice died due to vascular de-stabilisation 
(Garcia et al., 2001). S1pr1 is important inducer of pro-inflammatory signaling 
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pathway that may contribute to vascular inflammation in SHRSPGla (Yogi et al., 
2011). Vcam1 is also considered as pro-inflammatory marker, which is mainly 
expressed in endothelial cells. Meta-analysis studies on renal gene expression 
profiling from a number of hypertensive rat strains and their control (publically 
available), found variation in Vcam1 expression levels between all hypertension 
rats compared to all normotensive rats at established hypertension stage only 
(Marques et al., 2010). This may suggest that Vcam1 is involved in kidney 
inflammation. 
1.2.7.3 Systems Genetics Analysis 
Associating sequence variation within a positional gene identified by the 
integration of microarray expression analysis and congenic strains was used as 
strategy to identify causative genes for SHRSPGla phenotype. The recent 
availability of the SHRSPGla and WKYGla whole genome sequence (Atanur et al., 
2013) opened the door for other integrative approaches. For instance, 
integrating deleterious sequence variants from whole genome sequence with 
differentially expressed genes from gene expression profiling data can identify a 
genetic loci that control mRNA expression levels on functional tissues between 
SHRSPGla and WKYGla. This integration can be enhanced with addition of 
expression profiling of microRNAs (miRNA), short non-coding RNA sequence that 
regulate genes expression at post translation level, especially if a positional 
differentially expressed miRNA is affected by genetic variants and/or a 
positional differentially expressed gene with miRNA (that is also differentially 
expressed) binding region affected by a sequence variant. This integration can 
be further enriched with the addition of other 'omics' data, such as proteomics 
and metabolomics (intermediates and products of metabolism) to fully 
understand the genetic determinants of disease in the SHRSPGla (Figure 1-7). 
Nevertheless, the integrative 'omics' strategy varies among researchers; however, 
they are divided into two general approaches a) independent integration: to 
determine the results separately in each 'omics' then combine the results from 
each 'omic' into one interpretative model (simple and popular among 
researchers), b) dependent integration: combine all 'omics' data into one 
mathematical model (challenging requiring advanced bioinformatics analysis). 
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Integrative studies in human using functional sequence variants from whole 
genome population and GWAS studies are more likely to regulate gene expression 
(Nicolae et al., 2010; Lappalainen et al., 2013) in a tissue specific manner 
(Dimas et al., 2009). This makes the application of systems genetics analysis 
directly to humans challenging, due to obtaining samples of CVD functionally 
relevant tissues. Alternatively, animal models serve as invaluable source for 
systems genetics analysis, in which the prioritised genes and/or pathway can be 
translated to human. For example, Ogn that was identified from integrative 
approach in rat studies, then was validated in mouse by knock-out experiment, 
and afterwards, translated to human when its expression level in RI rat strains 
correlated with heart tissue from patients with aortic stenosis (Petretto et al., 
2008). 
 
 
Figure  1-7 Multiple 'omics' analysis in the SHRSPGla. 
Systems genetics analysis via integrative 'omics' data aims to give answers to A) what happen 
using genomics analysis (associate causative genetic variants to the SHRSPGla traits), B) what 
appears to be happening using transcriptomic analysis, C) what makes it happen using proteomics 
analysis and D) what has happened and is happening using metabolomics analysis. B,C and D is 
carried out by monitoring mRNA, microRNA, proteins and metabolites levels in a functionally 
relevant tissues to the SHRSPGla traits (when compared to a control). Molecular data of A, B, C and 
D that target different cellular information along with SHRSPGla traits can help to model biological 
networks which can be later translated to human study (original diagram compiled from information 
from MacLellan et al., 2012). 
 
1.2.7.4 Gene Expression analysis tools 
A number of bio-statistical methods were used to analyse the differentially 
expressed genes in the dataset, by Glasgow Cardiovascular Research Centre 
(GCRC) staff. Previously, our group used two classic approaches in analysing gene 
expression profiling from microarray experiments. In-house Rank Products 
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analysis (RP), was used by our group, which is a simple and rapid technique 
based on calculating rank products from replicate experiments. This method 
includes many advantages, and it is mainly reliable in small and highly noisy 
microarray data, uses biological reasoning; hence is very powerful in 
determining biological relevant expression changes, and needed few numbers of 
replica experiments to obtain reproducible results (Breitling et al., 2004). Rank 
product is a script that runs on R programming language (http://www.r-
project.org/), and is widely used for statistical software development and data 
analysis that needs prior knowledge of R language and there is no graphic user 
interface i.e not user friendly. Alternatively, since diseases are often caused by 
the disruption of a system, or network of genes, identifying only the individual 
differentially expressed genes from a tissue may not be sufficient to discover the 
underlying mechanisms of cardiovascular disease. To overcome this obstacle, our 
group used co-expression analysis, called meta-covariate (Hopcroft et al., 2010), 
in which a set/cluster of genes that expressed in coordinated fashion i.e 
“response- relevant” under controlled or uncontrolled perturbation in an 
experiment.  
Recently our group started to use Partek® Genomic Suit, a commercially 
statistical and data mining software that offers interactive data visualization of 
the results. Partek® supports a complete workflow for microarray analysis which 
measure changes in gene, exon and miRNA expression. In addition, to next 
generation sequencing that facilitate molecule quantitation analysis at the 
transcript level, alternative splicing, allele specific expression, and SNP 
discovery are also possible (http://www.partek.com/). Partek uses Analysis of 
variance (ANOVA), which is an ideal method for gene expression analysis; it can 
identify both sources of variation, characterize the signal to noise ratio in a 
system, and can include more than two factors (multi-way ANOVA) that may 
contribute to total experimental variation such as scanner, scan date, operator, 
etc. 
In simple differential expression analysis of large-scale gene expression survey, 
the analysis must be corrected for multi-testing. False Discovery Rate (FDR) is 
used by our group for the control of false positive in multi-tests that result in 
significant result (Benjamini & Hochberg, 1995; Pawitan et al., 2005).  
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1.2.7.5 Ingenuity Pathway Analysis (IPA) 
We also used IPA functional analysis for our gene expression profiling data, genes 
affected by genomics variants, as well as the integration between the two. IPA is 
a web-based software widely used for the analysis of microarray results with 
respect to biological pathway context and prediction of novel interactions 
between genes that appear to be differentially expressed. IPA reflects a 
multifaceted knowledge database, known as Ingenuity Pathway Knowledge Base 
(IPKB), and contains information on genes, proteins, chemicals, drugs, diseases, 
biological functions and pathways which have been extracted manually from 
different published journals. One of the advantage of IPA over other data mining 
tools is they have their own unique annotation for genes, in which all uploaded 
data including probe identifiers from all commercial gene expression arrays, 
Ensembl gene identifiers, and gene names map to their database giving them 
unique identifiers. This unique identifier can facilitate integration/comparison 
between genes within QTL regions, genes affected by genomics variants and with 
differentially expressed genes from different array platforms 
(http://www.ingenuity.com/). 
 
1.2.7.6 Gene Expression Validation 
A number of steps were used to increase the detection sensitivity of true 
significantly differentially expressed gene, such as normalisation of the data, 
and correcting for multi-testing. Nevertheless, large-scale gene expression 
survey has the disadvantages of identifying false-positive results (Larkin et al., 
2005). As a result, independent confirmation by quantitative Reverse 
Transcription - Polymerase Chain Reaction (qRT-PCR) is necessary. qRT-PCR 
permits accurate and sensitive measurement of gene expression level, which will 
be used to validate candidate gene expression. 
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1.2.7.7 Translation studied from rat to human and vice versa 
It is important to note that direct translation from rat to human is not always 
possible due to the difference of genetics between the two species. For 
example, when we tried to associate human orthologues of Gstm1 (candidate 
gene for HTN in SHRSPGla) (McBride et al., 2003; McBride et al., 2005) with 
hypertension in human via sequencing, genotyping and studies in three different 
independent cohorts, we failed to show significant results (Delles et al., 2008c). 
To our best knowledge, no successful translation of candidate genes for 
hypertension was made from rat to human. Nevertheless, human orthologues of 
Cd36, candidate gene for insulin resistance and blood pressure in the SHR) 
(Pravenec et al., 2008a) were successfully associated with insulin resistance in 
human populations via genetic CD36 renal deficiency (Miyaoka et al., 2001; 
Lepretre et al., 2004). In addition, epoxide hydrolase 2, cytoplasmic (Ephx2) 
candidate gene for heart failure in the spontaneously hypertensive heart failure 
rats (Monti et al., 2008) and Ogn candidate gene for left ventricular hypertrophy 
in the SHR (Petretto et al., 2008) both translated to human studies. 
Alternatively, other groups questioned the usefulness of identifying individual 
candidate genes for hypertension in hypertensive rats and should focus only on 
the pathogenesis roles of clusters, networks and pathways instead as human 
GWAS studies can directly identify candidate genes for hypertension (Nabika et 
al., 2012). This led to another translation direction of candidate gene for 
hypertension from human to rat. This translation approach was carried out by (a) 
integrative comparative genomics between human GWAS candidate genes for 
hypertension and hypertensive rat to explore the transcriptional mechanisms 
that mediates the outcome of the genes identified (Langley et al., 2013) (b) 
Applying Zinc-finger nuclease mediated mutagenesis to test the role of human 
GWAS candidate genes for hypertension in hypertensive rats (Jin et al., 2014) 
and to differentiate between multiple causative genes at a single GWAS locus 
(Flister et al., 2013). For example, Endres et al., 2014 showed evidence 
concluding that pleckstrin homology domain containing, family A member 7 
(Plekha7), using Zinc-finger nuclease technology, may affect the variation in 
blood pressure and cardiovascular functions by effecting vasculature via changes 
in intracellular calcium handling and of nitric oxide bioavailability in Dhal salt-
sensitive rat.  
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1.3 Aims 
The overall aim of this study is to investigate the genetic determinants of the 
SHRSPGla traits that will help in human translational studies for hypertension and 
vice versa.  
In chapter 3: Improving and implementing new gene expression analysis 
workflows that allows for (a) properly adjusting of batch bias transcriptomic 
data to improve the accuracy of identification positional candidate genes, (b) 
maximising the efficiency of identifying positional candidate genes in our 
integrative approach of gene expression profiling data with congenic strains, and 
(c) identifying candidate genes for the SHRSPGla phenotype via gene expression 
cluster analysis between SHRSPGla and WKYGla across multiple tissues at different 
hypertensive stages. 
In chapter 4: Identifying, annotating and validating the genomic variations 
between SHRSPGla and WKYGla whole genome sequence compared to BN reference 
assemblies and extracting and prioritising SHRSPGla unique sequence variants 
from 27 (non stroke-prone) rat genomes. 
In chapter 5: applying a multifaceted approach that includes and integrates 
systems genetics analysis from rat and human studies that allows for (a) 
investigation of different types of genomics variants that are likely to influence 
transcriptome data outcome between our rat strains, (b) customisation of 
commercial gene expression arrays to our rat strains to improving the accuracy 
of our analysis, (c) prioritisation of candidate genes for blood pressure, cardiac 
mass, and stroke in the SHRSPGla, and (d) prioritisation of CVD candidate genes 
and miRNAs for translation study from our rat strains to human and vice versa.  
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2 Methods 
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2.1 Materials 
2.1.1 Rat strains 
The standardised housing criteria for both SHRSPGla and WKYGla, which have been 
developed at University of Glasgow since 1991 and the construction of congenic 
rat strains using microsatellite marker-assisted, were previously described 
elsewhere (Graham et al., 2005). The nomenclature of these congenic rat strains 
consists first of the abbreviation of the background strain (SP used as a short for 
SHRSP), second by the donor strain, third the origin of the colony (Gla used as 
short for Glasgow) and a number which refers to the rat chromosome number 
that was introgressed from the donor strain. 
In this study a number of congenic rat strains were used for chromosome 2, 3 
and 14. Chromosome 2 congenic consists of SP.WKYGla2a using microsatellite 
markers D2Rat13 (located at 37,753,748 bp) and D2Rat157 (located at 
216,711,836 bp) with 179 Mbp transferred congenic interval and SP.WKYGla2c* 
using microsatellite markers D2Wox9 (located at 165,636,169 bp) and D2Mgh12 
(located at 210,636,169 bp) with 45 Mbp transferred congenic interval. 
Chromosome 3 congenic strains consists of SP.WKYGla3d using microsatellite 
markers D3Mgh16 (located at 6,373,335 bp) and D3Wox3 (located at 27,506,822 
bp) with 21 Mbp transferred congenic interval and SP.WKYGla3d using 
microsatellite markers D3Mgh16 (located at 6,373,335 bp) and rs197649383 
(located at 13,643,063 bp) with 7 Mbp transferred congenic interval. 
Chromosome 14 congenic strains consists of SP.WKYGla14a using microsatellite 
markers D14Rat54 (located at 5,116,492 bp) and D14Rat110 (located at 
107,119,581 bp) with 102 Mbp transferred congenic and WKY.SPGla14a using 
microsatellite markers D14Rat54 (located at 5,116,492 bp) and D14Got41 
(located at 34,375,297 bp) with 29 Mbp transferred congenic. Researchers at the 
British Heart Foundation - Glasgow Cardiovascular Research Centre (BHF/GCRC) 
had collected tissues from the above rat strains previous to this study. 
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2.1.2 Microarray gene expression profiling data 
All gene expression profiling data used in this study were carried out previously by BHF/GCRC staff, some published, however, their 
analysis in this study were improved, combined, integrated and extended to other genes expression analysis tools (Table 2-1). All gene 
expression profiling data in these rat strains were from male specimens. 
Table  2-1 Gene expression profiling data from different tissues, ages and platforms used in this study. 
 
() indicate the data was never published before or no gene expression data was carried out at this time point. 
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2.1.3 Genes annotation and functional analysis 
A number of resources used for gene expression probes where their database 
houses information for annotation, mapping genes to functional related 
physiological rat regions and provides biological interpretations for genes of 
interests. 
 
2.1.3.1 Affymetrix and Illumina 
Affymetrix Rat Gene Chip Array (http://www.affymetrix.com) probesets (group 
of oligomeric probes, each 25 bases in length, per gene or small group of highly 
similar genes) were annotated with annotation files version 33 released in 
February, 2013.. Whereas, Illumina RatRef-12v1 Expression BeadChip Array 
(http://www.illumina.com) probes (usually one specific 50 bases oligmer probe 
per gene attached to silica bead type that are randomly replicated on each 
array) were annotated with annotation file ratref-12_v1_0_r5_11222119_a 
released in January, 2010. The Affymetrix and Illumina arrays version that were 
used in this study between our rat strains are listed in Table 2-1.  
2.1.3.2 Ensembl 
Ensembl (http://www.Ensembl.org/) is a joint project between EMBL - EBI and 
the Wellcome Trust Sanger Institute which aims to maintain and update 
annotation of several species genomes. Ensembl offer automated genes 
prediction (these are donated with LOC symbol) which are later processed 
manually and released in the next Ensembl annotation version. Ensembl also host 
a data mining tool BioMart that allows the querying of large gene expression 
probes from Affymetrix and Illumina for genes symbols, position in the genome, 
and orthologous. As Affymetrix and Illumina gene expression annotation files 
update relies on Ensembl gene build annotation upgrade this study also utilised 
the Basic Local Alignment Search Tool (Blast) available on Ensembl to query 
prioritised probes (sequence) with predicted and/or no gene symbols to get the 
recent annotation. 
  57 
 
2.1.3.3 Rat Genome Database 
Rat Genome Database (RGD; http://rgd.mcw.edu/) offers tools for gene 
prediction which are incorporated into Ensembl genome annotation (these are 
donated with RGD symbol). RGD also hosts a traits and phenotypes database for 
several rat strains including QTL for several disease models. This study accessed 
blood pressure and stroke QTLs from RGD to prioritise candidate genes in the 
SHRSPGla.  
2.1.3.4 Ingenuity pathway analysis 
IPA software (http://www.ingenuity.com) was used to provide biological and 
functional interpretations for genes found to be differentially expressed and/or 
harbour genomic variants. The functional analysis starts with uploading the 
dataset which includes an identifier (this can be gene name and/or gene 
expression probe ID) with corresponding fold change or expression intensity. 
Each identifier in the dataset map to its corresponding gene in the IPKB, or else 
it is excluded from the analysis. IPA then generates networks based on the 
molecular relationships between genes, whether it is direct (gene to gene) or 
indirect (genes products), according to the published literature in IPKB (as of 
27/6/2014). In each network the genes associated with biological function, 
disease and/or canonical pathway were identified and a p value derived from 
Fisher's exact test to determine the probability that each biological function, 
disease and/or canonical pathway assigned to a given network is due to chance 
alone. Then networks were then scored for top biological functions, diseases and 
canonical pathways. In IPA, genes and/or gene products are shown as nodes 
(shape for each functional class) and the biological connectivity between two 
nodes are shown as edges (line supported by a literature reference) (Figure 2-1). 
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Figure  2-1 IPA network shapes and relationships. 
A diagram showing IPA different functional classes for molecules and relationships types (IPA, 
http://www.ingenuity.com). 
2.1.4 Gene expression analysis tools 
2.1.4.1 Partek 
Partek® Genomic suite software (http://www.partek.com/) was used in this 
study to analyse gene expression in pairwise comparison. Normalisation for all 
Affymetrix gene expression data were carried out in Partek® Genomic suite 
software using Robust Multi-array Average (RMA; Irizarry et al., 2003) and all 
Illumina gene expression data were quantile normalised in Illumina Genome 
Studio was imported to Partek®. 
2.1.4.1.1 Analysis of variance 
 
One-way ANOVA was used to analyse all gene expression data using the strains in 
rat and condition in human as factor in the ANOVA model. FDR of <0.05 was used 
a cut off to identify significant differentially expression genes. Furthermore, in 
batch biased gene expression data two-way ANOVA model was used for the 
analysis in which the batch and the rat strain used as factors. 
2.1.4.1.2 Batch effect removal tool 
 
Previously batch biased gene expression profiling of heart between data of 
SHRSPGla, WKYGla and chromosome 14 congenic rat strains at neonatal, 5 and 16 
weeks of age was analysed by BHF/GCRC staff using two-way ANOVA (batch and 
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strains as factors) in Partek® with a cut-off of FDR <0.05 (Crawford, 2011). The 
analysis of the data was extended to implement Partek® Batch effect removal 
tool after quantile normalisation in Genome Studio and analysed with the same 
two-way ANOVA model. Partek® 3D principle components analysis (PCA) was used 
to identify and compare batch effect from both analyses. In addition, the 
comparison of two analyses included differentially expressed genes focusing and 
prioritising on the least differentially expressed comparison WKYGla versus 
WKY.SP14aGla across different time points. 
2.1.4.2 BiolayoutExpress3D 
BioLayoutExpress3D is a tool used for visualisation and clustering of large network 
graphs of microarray gene expression profiling data (Freeman et al., 2007). 
Initially, pairwise transcript-to-transcript correlation matrix is calculated based 
on each gene/transcript expression intensity between our rat strains across 
different tissues and/or timepoints. Later, undirected networks with weighted 
edges are constructed based on a Pearson’s correlation threshold cut-off of r= 
0.75, where nodes represent transcripts and edges represent Pearson 
correlations above the threshold. Finally, network graphs are clustered using 
Markov Clustering algorithm (MCL).However, different cut-off values were used 
in the analysis presented in this thesis to generate network graphs due to the 
number of samples in the imported data and when no informative cluster with 
genes expression pattern of interests is found after applying Markov clustering 
algorithm on the network graphs. 
2.1.4.2.1  Cluster analysis between SHRSPGla and WKYGla and 2c congenic rat strains 
on renal transcriptomic data  
 
BioLayoutExpress3D cluster analysis carried out on previously generated data of 
SHRSPGla, WKYGla and chromosome 2 congenic SP.WKYGla2a rat strains at 16 and 
21 weeks of age with and without salt intake using a cut-off value of 0.85. Gene 
expression data were normalised with RMA in Partek® before being imported to 
BioLayoutExpress3D. 
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2.1.4.2.2 Cluster analysis between SHRSPGla and WKYGla across tissues at different 
ages 
 
Benefiting from the gene expression platform free feature in IPA, normalised 
Affymetrix and Illumina gene expression intensity data were uploaded to IPA 
separately. Common genes, which were used as identifiers, between all dataset 
across tissues at 5 and 16 weeks of age were chosen for BioLayoutExpress3D 
cluster analysis. At 21 weeks of age and salt challenged each Illumina gene 
expression data of a tissue was normalised separately and BioLayoutExpress3D 
cluster analysis was run across all tissues using Illumina probes as an identifier. 
Figure 2-2 shows flow diagram of the steps taken in the BioLayoutExpress3D 
analyses. 
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Figure  2-2 Flow diagram of the steps taken in the BioLayoutExpress
3D
 analyses. 
A flow diagram detailing how gene expression data from different tissues, platform age were normalised, processed and imported in BioLayoutExpress
3D
 for cluster 
analysis. 
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2.1.5 Whole genome Next generation sequencing of SHRSPGla 
and WKYGla rat strains 
2.1.5.1 Samples 
Both rat strains sequencing library preparations were processed on the Illumina 
platform (HiSeq 2000) by collaboration. The SHRSPGla was sequenced at Prof. 
Norbert Huebner’s laboratory, Max Delbrück Center for Molecular Medicine, 
Germany with read length 75 bp. Whereas, the WKYGla was sequenced at Prof. 
Tim Aitman’s laboratory, Imperial College, London, UK with read length 100 bp. 
2.1.5.2 Rat reference genome RGSC 3.4 
Training on handling SHRSPGla and WKYGla whole genome sequence data including 
mapping to Rat Genome Sequencing Consortium (RGSC) 3.4 rat reference 
genome, calling and annotating sequence variants and large deletion on SHRSPGla 
and WKYGla was offered at Tim Aitman’s laboratory. The calling and annotation of 
NGS small sequence variants, as well as the calling of raw large deletion analysis 
against BN RGSC 3.4 was executed by Mr Santosh Atanur from Tim Aitman’s 
laboratory. 
2.1.5.2.1 Mapping  
 
Raw paired-end reads, trimmed at the end of read of all the bases with quality 
less than 20, of SHRSPGla and WKYGla mapped to the draft reference genome of 
Brown Norway RGSC 3.4 (Gibbs et al., 2004) with Burrows wheeler aligner 
version 0.5.8c (Li & Durbin, 2009). Sequence Alignment Map data were then 
compiled and converted to a single compressed binary file, for each strain, using 
SAMtools (Li et al., 2009). Picard software (http://picard.sourceforge.net) was 
used to remove duplicate reads.  
2.1.5.2.2  Sequencing variants calling 
 
Genome Analysis Toolkit (GATK; McKenna et al., 2010; Depristo et al., 2011) 
version 1.0.6001 was used to reduce the rate of false positive results by (a) local 
realignment of a read that overlapped with an INDEL since there are mis-
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alignments around the location (b) recalibration of base quality since Illumina 
quality scores are biased toward high quality. GATK with multi sample feature 
were used to call filtered SNPs and INDELs (<50 bp) which are unique between 
our strains discarding common variants generated by each strain against rat 
reference genome RGSC 3.4.  
2.1.5.2.3 Variants effect predictor annotation Ensembl 69  
 
Variants effect predictor tool version 2.4 (McLaren et al., 2010) was used to 
annotate and functionally categorize the effect of small variants based on their 
location in a gene based on Ensembl 69 gene set. 
 
Figure  2-3 Ensembl 69 predicted sequence variants consequence types. 
A diagram showing the location of the types of consequences relative to the transcript structure 
(Modified figure from McLaren et al., 2010). 
2.1.5.2.4  Large deletion 
 
A custom tool described previously (Atanur et al., 2010) with algorithm to detect 
large deletions (>50 bp) was used by Imperial College staff to generate raw data 
(deleted regions and the number of reads implicated) for each strain 
independently. Deleted regions in SHRSPGla and WKYGla with > 4 reads was chosen 
as cut off and annotated with Ensembl BioMart version 69. 
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2.1.5.2.5  Copy number variation 
 
Copy number variations (CNV) were called with CNVnator version 0.2.7 (Abyzov 
et al., 2011) for each chromosome with bin size of 100 bp guided by rat 
reference genome RGSC 3.4 for each strain independently. Regions with CNV 
duplication and deletion were annotated with Ensembl BioMart version 69. 
2.1.5.3 Rat reference genome Rnor 5.0 
2.1.5.3.1 Mapping  
 
Raw paired-end reads, trimmed at the end of read of all the bases with quality 
less than 20, of SHRSPGla and WKYGla mapped to the new reference genome of 
Brown Norway Rnor 5.0 with improved Burrows wheeler aligner version 0.7.4 (Li 
& Durbin, 2009). Sequence alignment Map data were then compiled and 
converted to a single compressed binary file, for each strain, using SAMtools (Li 
et al., 2009). Picard software (http://picard.sourceforge.net/) was used to 
remove duplicate reads.  
2.1.5.3.2  Sequencing variants calling 
 
Genome Analysis Toolkit version 2.5-2 (GATK; McKenna et al., 2010; Despristo et 
al., 2011) was used to reduce the rate of false positive results by (a) local 
realignment of a read that overlapped with an INDEL since there are mis-
alignments around the location (b) recalibration of base quality since Illumina 
quality scores are biased toward high quality. GATK with multi sample feature 
were used to call filtered SNPs and INDELs (<50 bp) which are unique between 
our strains discarding common variants generated by each strain against rat 
reference genome Rnor 5.0. 
2.1.5.3.3 Variants effect predictor annotation Ensembl 71 
 
Variants effect predictor tool version 7.1 (McLaren et al., 2010), which offers 
more predicted consequence types than version 2.5 was used to annotate and 
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functionally categorize the effect of small variants based on their location in a 
gene based on Ensembl gene set 71. 
 
 
Figure  2-4 Ensembl 71 predicted sequence variants consequence types. 
A diagram showing the location of the types of consequences relative to the transcript structure 
(Modified figure from McLaren et al., 2010). 
 
2.1.5.4 Quality control 
Three different sequencing data were used as quality control for whole NGS of 
SHRSPGla and WKYGla. 
2.1.5.4.1 SureSelect 
 
SureSelect (Agilent Technologies, UK) targeted sequence capture data generated 
by Mr Santosh Atanur from Imperial College staff for SHRSPGla and WKYGla on 
chromosome 2 region (between 211,822,164-213,846,183 bp) was compared to 
the rat reference genome RGSC 3.4 (using the same pipeline in paragraph 
1.1.2.1). DNA used to generates targeted paired-end short reads (100 bp in 
length) constructed from libraries with 300-600 bp insert size that were 
sequenced on an Illumina HiSeq2000. The annotated sequence variants between 
SHRSPGla and WKYGla by Ensembl variants predictor (version 64) was provided in 
Excel sheet format in 2010 (Martin McBride, personal communication). The 
sequence capture array has high coverage (10,000x) and was used as quality 
control for NGS whole genome sequence data. 
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2.1.5.4.2  Sanger sequencing 
 
In addition, previously published data (McBride et al., 2005; Graham et al., 
2007) of 34 SNPs/INDEL of traditional capillary sequencing for genes on congenic 
region on chromosome 2 were compared to NGS data and sequence capture 
against rat reference genome RGSC 3.4 as quality control. 
 
2.1.5.4.3 STAR SNP database 
 
2,338 unique SNPs between SHRSPGla and WKYGla against rat reference genome 
RGSC 3.4 on all chromosomes were extracted from STAR Consortium data (Saar 
et al., 2008) and compared to NGS data against rat reference genome RGSC 3.4 
as quality control. 
2.1.5.5 Visualisation of variants 
2.1.5.5.1 Genome level 
 
NGS genomic variants were visualised on genome level by Circos (Krzywinski et 
al., 2009). 
2.1.5.5.2 Single nucleotide level 
 
NGS genomic variants were visualised on gene and single nucleotide level by 
Integrative Genomic Viewer (IGV; Robinson et al., 2011). 
 
 
2.1.5.6 SHRSPGla unique sequence variants 
2.1.5.6.1 SHRSPGla sequence variants compared to 27 whole genome sequenced rat 
strains 
 
SHRSPGla unique SNPs and INDELs were extracted from raw NGS data of 28 whole 
genome rat strains against rat reference genome RGSC 3.4 (Atanur et al., 2013). 
SHRSPGla unique sequence variants were then annotated with variants effect 
predictor annotation on Ensembl version 69 gene set (McLaren et al., 2010). 
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Moreover, SHRSPGla unique non-synonymous SNPs (Ensembl gene identifiers) were 
uploaded to IPA to carry out functional analysis. In addition, SHRSPGla and WKYGla 
QTLs for blood and pulse pressure, left ventricular mass index and stroke as well 
as rat strains blood pressure and stroke QTLs from RGD website were used to 
prioritise protein coding SHRSPGla unique sequence variants. Furthermore, 
predicted protein coding SHRSPGla unique sequence variants compared to the rat 
reference genome RGSC 3.4 were mapped to rat reference genome Rnor 5.0 and 
annotated with variants effect predictor annotation on Ensembl gene set 71 to 
prioritise variants with consistent and deleterious predicted consequences. 
2.1.5.6.2 SHRSP rat strains STAR SNP database 
 
SHRSPGla and another 4 SHRSP inbred rat strains SNPs against rat reference 
genome RGSC 3.4 were extracted from STAR Consortium data (Saar et al., 2008) 
to carry out a comparison analysis. 
2.1.6 Integrating transcriptomic and genomic data 
2.1.6.1 In rats 
2.1.6.1.1 Integration of transcriptomic data and genomic variants between SHRSPGla 
and WKYGla 
 
Small sequence variants and structural variants including large deletions and 
CNV were integrated with gene expression profiling data from heart and kidney. 
Illumina gene expression profiling of the heart at neonatal, 5 and 16 weeks of 
age were quantile normalised in Genome Studio and Affymetrix gene expression 
profiling of the kidney at 16 and 21 weeks of age were RMA normalised in 
Partek®. Both gene expression data were analysed by ANOVA in Partek® 
Genomics Suite using cut-off FDR <0.05. Ensembl gene identifier of genes 
affected by different types of genomic variants data and differentially expressed 
probes of the heart and kidney transcriptomic data were uploaded to IPA to carry 
out the integration step. 
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2.1.6.1.2 Improvement of microarray analysis by utilising integration of NGS 
sequence variants and gene expression data 
 
Affymetrix Chip Description File (CDF) was downloaded from 
http://brainarray.mbni.med.umich.edu/ and called default CDF in this study 
(Dai et al., 2005). The default CDF were filtered by Imperial College staff of 
probes that harbour a SNP within their target region and called custom CDF in 
this study. Both CDFs were used to analyse Affymetrix gene expression data of 
kidney at 21 weeks of age between SHRSPGla and chromosome 2 congenic 
SP.WKYGla2a where both were RMA normalised with the same ANOVA model in 
Partek® Genomics Suite using cut-off FDR <0.05. Both Affymetrix default and 
custom CDF analyses were compared to investigate the impact of SNPs on 
differentially expressed Affymetrix probes prioritising positional candidate 
genes.  
To further assess the impact of SNPs on differentially expressed probes, SNPs 
between SHRSPGla and WKYGla were examined in 24,000 Illumina probes (50 bp) 
target regions. The impacted Illumina probes were uploaded to IPA along with 
genes within the congenic strains on chromosome 2, 3 and 14 to check for 
positional candidate genes that may falsely identify as differentially expressed 
gene in Illumina analysis. 
2.1.6.1.3 “Swiss cheese” integrative and reductive model 
 
Significantly differentially expressed positional candidate genes identified by 
Partek® Genomics Suite with a cut-off of FDR <0.05 and 2 fold change in kidney 
and heart tissues that harbour protein coding sequence variants were prioritised. 
Affymetrix kidney gene expression data at 16 and 21 weeks of age were 
normalised with RMA and Illumina heart gene expression data at neonatal and 5 
and 16 weeks of age was quantile normalised in Genome Studio. IPA facilities the 
integration by uploading variants (Ensemble gene identifier), differentially 
expressed genes (probe identifier), genes within the congenic regions (Ensemble 
gene identifier) on chromosome 2, 3 and 14, as well as functional analysis on the 
result. 
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2.1.6.1.4 Integrating SHRSPGla unique small sequence variants compared to 27 
genome sequence rat strains with brain gene expression of SHRSPGla and 
WKYGla 
 
The isolated SHRSPGla unique sequence variants were integrated with those 
previously generated and analysed by BHF/GCRC staff for brain transcriptomic 
data between SHRSPGla and WKYGla at different time points (Bailey et al., 2014) 
and salt loaded using Rank Products (Breitling et al., 2004). The identified 
differentially expressed genes with FDR cut-off of <0.05 that harbour SHRSPGla 
unique sequence variants were checked whether they mapped to SHRSPGla and 
WKYGla QTLs for blood and pulse pressure, left ventricular mass index and stroke 
as well as rat strains stroke QTLs from RGD website were used to prioritise 
candidate genes for stroke in the SHRSPGla. 
2.1.6.2 In human to rat and vice versa 
Three different approaches were used to translate candidate genes and miRNA 
associated with hypertension from rat to human and vice versa. 
2.1.6.2.1 Human GWAS genes for blood pressure and hypertension integrated with 
SHRSPGla and WKYGla transcriptomic and genomic data 
 
Human candidate genes for blood pressure and hypertension were obtained from 
several GWAS studies (Levy et al., 2009; Newton-Cheh et al., 2009; 
Padmanabhan et al., 2010; Ehret et al., 2011; Johnson et al., 2011; Kato et al., 
2011; Wain et al., 2011; Salvi et al., 2012; Franceschini et al., 2013) and 
integrated with differentially expressed genes in heart and kidney and sequence 
variants between SHRSPGla and WKYGla. Human candidate genes for blood 
pressure and hypertension were checked for orthology in rat using 
EnsemblCompara (precomputed data: phylogeny based orthology and paralogy 
predictions) available at Ensembl BioMart website, and whether they map to 
QTLs for blood and pulse pressure, left ventricular mass index between SHRSPGla 
and WKYGla as well as other blood pressure QTL from other rat strains obtained 
from RGD website. Illumina gene expression profiling of the heart at neonatal, 5 
and 16 weeks of age were quantile normalised in Genome Studio and Affymetrix 
gene expression profiling of the kidney at 16 and 21 weeks of age and were RMA 
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normalised in Partek®. Both gene expression data were analysed by ANOVA in 
Partek® Genomics Suite using cut-off FDR <0.05.  
Affymetrix and Illumina probes targeted regions of prioritised candidate genes 
were checked for sequence variants between SHRSPGla and WKYGla. Furthermore, 
prioritised candidate genes were checked for differential spliced exons events 
from previously published Affymetrix Exon array data on heart at 5 and 16 weeks 
of age between SHRSPGla and WKYGla (Crawford, 2011).  
2.1.6.2.2 Integrating renal miRNA sequencing data from human and rat 
 
Small RNA molecule NGS in human between hypertensive and control kidney 
(cortex and medulla) and in rat between SHRSPGla and WKYGla and chromosome 2 
congenic SP.WKYGla2c* kidney at 16 weeks of age both with no replica was 
executed by Glasgow Polyomics Facility (Glasgow, UK) using Illumina Solexa 
sequencing technology. Short Solex read were processed in statistical computing 
software called R Console (http://www.r-project.org) using the Kraken suite 
components (Davis et al., 2013). Reaper tool was used to trim the smallRNA kit '3 
adapter, PolyA, PolyN, low scoring and complexity tracts and obtain clean. Tally 
another tool from Kraken suite components were used to collapse redundant into 
unique reads with their depth information. Unique clean reads of human and rat 
Solexa reads were later mapped against miRBase (version 20) using Krakenbot 
Mapping Tool available on (http://wwwdev.ebi.ac.uk/enright-srv/krakenbot/). 
DEseq statistical package (Anders & Huber, 2010) was used to identify 
differential expression in simple pairwise approach for human study between 
hypertensive and control and for rat study between SHRSPGla, WKYGla and 
SP.WKYGla2c* using adjusted p value of <0.05 as cut-off. 
Positional targeted genes of differentially expressed miRNA in rat kidney study 
between SP.WKYGla2c and SHRSPGla were integrated with sequence variants within 
3' UTR and kidney gene expression profiling at 16 and 21 weeks of age between 
SHRSPGla and WKYGla to prioritise candidate miRNA for the SHRSPGla phenotype. 
Affymetrix kidney gene expression profiling at 16 and 21 weeks of age were RMA 
normalised in Partek®. Both gene expression data were analysed by ANOVA in 
Partek® Genomics Suite using cut-off FDR <0.05. 
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2.1.6.2.3 Integrating heart gene expression data from human and rat 
 
In the rat study, whole heart gene expression profiling on Illumina platform of 
SHRSPGla and WKYGla at neonatal, 5 and 16 weeks were used for the analysis. 
Moreover, in the human study, left ventricular gene expression data of heart 
failure were used for the analysis. The first, Heart data 1, was between normal 
and post-ischemic heart failure (Greco et al., 2012). The second, Heart failure 
data 2, was between normal and heart failure that arises from familial, 
idiopathic dilated, ischemic, viral, hypertrophic cardiomyopathies (Schinke et 
al., 2004). Both rat and human gene expression data were RMA normalised and 
analysed by Partek® Genomic suite where a FDR of <0.05 and a fold change of 
1.5 were used as cut-off.  
2.1.7 Gene expression validation 
Reagents and laboratory equipments used in this study were of the highest 
available grade. Hazardous chemicals were handled in accordance with Control 
of Substances Hazardous to Health regulations with laboratory coat and latex 
gloves were worn while conducting laboratory experiments. In addition, 
nuclease-free reagents and consumables were used in gene expression 
validation. 
2.1.7.1 Validation in rat 
2.1.7.1.1 Quantification of nucleic acids 
 
Total RNA (DNase free) that were generated previously by BHF/GCRC staff was 
accurately quantified by measuring 1.5 μL of RNA of each sample on a Nanodrop 
(ND-1000) spectrophotometer (Thermo Scientific, U.K.). Absorbance at 260 nm 
was used for quantification of nucleic acids, an optical density of 1 
corresponding to 40ng/μL RNA. Absorbance ratios (260 nm/280 nm) was used as 
an indicator for sample purity in which a ratio of 2 for RNA was considered pure 
and free from protein contamination. 
2.1.7.1.2 Complementary deoxyribonucleic acid (cDNA) synthesis 
 
cDNA was synthesised using Taqman reverse transcription reagents (Applied 
Biosystems, USA) on PTC-225 Peltier Thermal Cycler (MJ Research) in 96 well 
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plates using the following conditions: 25°C for 10min, followed by 48°C for 
30min, then 95°C for 5min, finally 4°C forever. Reverse transcription reaction 
consists of 10X Reaction Buffer 2.0μL, MgCl2 (25mM) 4.4μL, dNTPs (2.5mM ea.) 
4.0μL, Primers (50μM) 1.0μL, RNase Inhibitor (20U/μl) 0.4μL, Multiscribe reverse 
transcriptase (50U/μl) 0.5μL and 1μg of RNA template and adjusted with water 
(RNase-free) to final reaction volume of 20 μL per well.  
 
2.1.7.1.3 Quantitative real-time polymerase chain reaction QRTPCR 
 
All Real-time PCR data performed in this study was carried out on an ABI PRISM 
7900HT Sequence Detection system with Taqman Gene Expression Assays from 
(Applied Biosystems, USA) in 384 well plates. The Taqman Gene Expression 
Assays used are Atp11b (Rn01493364_m1, labelled FAM), Pik3r1 
(Rn00564547_m1, labelled FAM), Fubp3 (Rn01436208_m1, labelled FAM), Ugt2b7 
(Rn00821928_m1, labelled FAM), Afm (Rn00597217_m1, labelled FAM), Gucy1a3 
(Rn00367252, labelled FAM), Gucy1b3 (Rn00562775, labelled FAM), Gpr98 
(Rn01757838_m1, labelled FAM), Smoc2 (Rn01455681_m1, labelled FAM), Lamc2 
(Rn01759129_m1, labelled FAM), β-actin (4352340E, labelled VIC) and B2m 
(Rn00560865_m1, labelled FAM).  
In Kidney, validation reactions consisted of 2.5 μL Taqman Expression PCR Master 
Mix, 1X (gene of interest) FAM labelled, 1x β-actin (housekeeping gene) VIC 
labelled and 2 μL of cDNA in a final volume of 5μL in duplex. Whereas, singleplex 
reactions was used for validation in heart which consists of 2.5 μL Taqman 
Expression PCR Master Mix, 1X (gene of interest or B2m a housekeeping gene) 
FAM labelled, 1x water (RNase-free) and 2 μL of cDNA in a final volume of 5μL. 
Both were run on the same temperature cycling conditions; 50°C for 2min, then 
95°C for 10min, then 40 cycles of 95°C for 0.15 seconds then 60°C for 1min. 
qRT-PCR results were analysed using the relative quantification expression 
method of comparative Ct system (2
-ΔΔCt) (Livak & Schmittgen, 2001) with β-actin 
(for kidney tissue) and B2m (for heart tissue) utilised as endogenous controls. 
This allows for the standardisation of the cDNA amounts added to the reaction, 
thus acting as a normaliser to correct for sampling discrepancies.  
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During the extension phase of the PCR reaction the fluorescence released from 
the qRT-PCR probe is directly proportional to the amount of product generated 
in each cycle that is detected and measured by ABI PRISM 7900HT thermo cycler. 
During exponential phase of amplification in PCR reaction, a threshold of 
fluorescence is set automatically by Applied Biosystems Sequence Detection 
Software. The fluorescence signal detected at a cycle number that is above this 
threshold is called the cycle threshold (Ct). Genes of interest were normalised to 
β-actin (for kidney tissue) and B2m (for heart tissue) gene expression that 
calculated by the ΔCt using the following equation:  
ΔCt = Ct (gene of interest) - Ct (housekeeping gene).  
The relative quantity value (RQ) was then calculated: 
 RQ = 2-ΔΔCt 
Data was analysed in at least triplicate for each rat. The comparison between 
the congenic and parental strains for qRT-PCR was carried out by 2 sample 
Student’s t-test.  
qRT-PCR results of Osteopontin (Spp1) on heart at neonatal and 5 weeks of age 
and Dnm1, Rabgap1 and Tor1b on kidney at 21 weeks of age and salt challenged 
in our rat strains was carried out by BHF/GCRC staff.  
2.1.7.2 Validation in human 
To validate the potential candidate genes, heart failure hearts from Paul 
Barton’s lab at Imperial College, London were used. These heart failure types 
includes dilated cardiomyopathy at different recovery and unstable stages as 
well as controls. The validation of Smoc2 and lamc2 was carried out in London by 
a colleague. 
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3 Gene expression analysis in the SHRSPGla and 
WKYGla rat strains 
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3.1 Introduction 
A number of experiments have been conducted across different strains, tissues, 
time points and conditions to identify candidate genes for the SHRSPGla 
phenotype. However, it should be noted that there are many factors that make 
the integration of these experiments challenging. These include the use of 
different microarray platforms and statistical analysis tools, as well as changes 
in the state of annotation over time. 
Affymetrix released a number of rat gene chip expression arrays over the years 
in which each upgraded version provides more probes that mapped to newly 
discovered genes in fewer or single array. Affymetrix continues releasing updates 
for genes annotation for all their rat arrays with every rat genome upgrade.  
Illumina released one rat gene expression array before the release of a rat 
genome and has no plans to update the array genes annotation. However, a 
computational biology group from Cambridge University released a re-annotation 
of Illumina probe sequences (Barbosa-Morais et al., 2010). Illumina 50 bp oligo-
nucleotide probe increases hybridisation efficiency and specificity to its target 
compared to Affymetrix 25 bp oligo-nucleotide length probe (Chou et al., 2004). 
Illumina 12 samples format in single array at an economical price compared to 
Affymetrix allowed for large gene expression studies. 
Large gene expression studies usually suffer from systemic error or batch effect 
when analysing samples from multiple batches, having potentially an impact on 
the results. Principal component analysis (PCA), a mathematical algorithm used 
to scale down a high dimensional data while maintaining most variability in the 
data (Ringner, 2008), is used to identify non-biological biases such as batch 
effects. 
Partek® genomic suite, commercial software, offers two strategies to adjust for 
batch effect. First method to correct for batch effect is by accounting for batch 
bias as factor in ANOVA model and the second is by removing the batch bias by 
Partek® effect removal tool. However, no comparison study between the two 
batch bias adjusting methods has been carried out in our transcriptomic bias 
data. 
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There is no gold standard method to analyse gene expression data; therefore, 
our group implemented different statistical tests and clustering methods on our 
transcriptomic data. Renal expression datasets from SHRSPGla, WKYGla and 
chromosomal 2 congenic (SP.WKYGla2a) rat strains, which were with and without 
salt challenge, were analysed a Bayesian meta-covariate cluster method and 
conventional pairwise approach by Rank Products. Previously in our laboratory, 
Bayesian meta-covariate tool identified a cluster of 13 genes (Hopcroft et al., 
2010) of which most were not identified in Rank Products analysis (Graham et 
al., 2007). Functional analysis by IPA showed that genes involved in 
transcriptional activation and circadian rhythm may contribute in the protection 
against hypertension in response to high salt intake (Hopcroft et al., 2010). 
Nevertheless, the meta-covariate clustering method used is very intensive 
computationally and requires the use of specialist expertise that has not since 
been available. 
BioLayoutExpress3D application is a visualization and clustering tool for gene 
expression data that produces clusters (groupings) of genes based on pattern of 
expression (Freeman et al., 2007). BioLayoutExpress3D software can be run on 
most personal computers and only requires a common identifier of genes and 
normalised expression intensity for the analysis. This allows for a network 
analysis on gene expression from different platforms and across multiple tissues 
(Kapetanovic et al., 2013).  
Over the years our group has built a library of gene expression profiling data 
between SHRSPGla and WKYGla, documenting early and advanced phases of 
hypertension. Additionally, this library also includes chromosome 2, 3 and 14 
congenic and sub-congenic rat strains, allowing for the prioritisation of 
positional candidate genes for SHRSPGla phenotype (Figure 3-1; Table 3-1). 
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3.2 Aims 
This chapters specific aims are: 
 Improve and implement new gene expression analysis workflows to identify 
candidate genes in the SHRSPGla 
o Compare two strategies to adjust for batch biased heart gene expression 
data between SHRSPGla, WKYGla and chromosome 14 congenic strains using 
Partek® genomic suit 
o Combined expression chip platforms approach to identify renal positional 
candidate genes between SHRSPGla, WKYGla and chromosome 3 congenic 
strains 
o Run BioLayoutExpress3D cluster analysis to identify renal positional 
candidate between SHRSPGla, WKYGla and chromosome 2 congenic strains 
 Run cluster analysis by BioLayoutExpress3D between SHRSPGla and WKYGla 
across tissues at pre-hypertensive, hypertensive and severely hypertensive 
phases
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Figure  3-1 SHRSPGla, WKYGla and chromosome 2, 3 and 14 sub-congenic strains phenotype. 
Schematic showing the position of microsatellite markers used in constructing chromosome a1) 2, b1) 3 and c1) 14 sub-congenic strains. a2) Systolic blood pressure 
among SHRSPGla, WKYGla and chromosome 2 sub-congenic strains. b2) Pulse pressure among SHRSPGla, WKYGla and chromosome 3 sub-congenic strains. c2) Left 
ventricular mass index among SHRSPGla, WKYGla and chromosome 14 sub-congenic strains. *P<0.05 
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Table  3-1 Summary of all gene expression profiling from different platforms of SHRSPGla, WKYGla and congenic strains. 
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3.3 Results 
3.3.1 Improving and implementing new gene expression analysis 
workflows to identify candidate genes in the SHRSPGla 
 
3.3.1.1 Partek® effect removal analysis on batch biased heart gene 
expression data between SHRSPGla, WKYGla and chromosome 14 
congenic strains 
PCA analysis was carried out on heart gene expression data between SHRSPGla, 
WKYGla, chromosome 14 congenics (SP.WKYGla14a called F for short and 
WKY.SPGla14a called D for short) across neonatal, 5 and 16 weeks of age. 
Overlaying the PCA plot with sentrix barcode (batches) and sample group used 
(Figure 3-2 A1&A2) shows that the age of rat strains divided the data into three 
sections, which is an excepted effect. However, batch bias is another effect 
observed in which each clustered at specific position regardless of sample group. 
After the batch bias was removed with Partek® effect removal tool, PCA plot 
overlaid with batches and sample group used (Figure 3-2 B1&B2) revealed a 
better sample group clustering and no batch biases compared to the PCA plot 
without batch effect removed (Figure 3-2 A1&A2).  
To assess the improvement of Partek® effect removal tool, we compared WKYGla 
versus WKY.SPGla14a comparison at neonatal, 5 and 16 weeks with batch effect 
accounted for as factor in an ANOVA model against batch effect is removed by 
Partek® effect removal tool same with a cut-off of FDR <0.05 using Partek® 
Genomic suite software. The overall results show that Partek® batch removed 
analysis identified more significant genes including positional candidate genes 
than batch as factor analysis (Figure 3-2 A3&B3). Osteopontin (Spp1), a 
significantly differentially expressed positional gene, was identified by batch 
removed analysis at two time points and at 1 time point by batch as factor 
analysis. Previous qRT-PCR validation work by a colleague in our group on Spp1 
showed that the change in expression between WKYGla and WKY.SPGla14a at the 
same two time points identified by batch removal analysis (Figure 3-3). 
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Figure  3-2 Partek® effect removal analysis on batch biased heart gene expression data 
between SHRSPGla, WKYGla and chromosome 14 congenic strains. 
PCA analysis on heart data from SHRSPGla, WKYGla and chromosome 14 congenic strains at three 
different time points which are randomised across 4 array chips. A1: PCA plot with sentrix barcode 
(batch) shows that there is a minor chip bias in which each chip are clustered at specific location 
such as 4630616012 chip represented by red colour are at the top, 4630616034 chip represented 
in blue is at the bottom and the other chips are in the middle. This means a sample may show a 
bias, depending on the chip it is hybridized to. A2: PCA mapping of the sample groups (each strain 
at each time point) confirms the bias caused by chip location of each sample. A3: Venn diagram of 
WKYGla versus WKY.SPGla14a (D) shows few significant differentially expressed genes in (black) 
especially positional candidate (blue) at different time points for example Spp1 only significant at 
neonatal. B1: After removing the batch effect, overlaying the PCA plot with the sentrix barcode 
does not indicates chip bias where each chip is not clustered at specific position. B2: This is 
confirmed when the PCA plot overlaid with sample groups that shows a better groups clustering 
compared to the PCA plot with sample groups before removing the batch effect (A2). B3: Venn 
diagram of WKYGla versus WKY.SPGla14a (D) shows more significant genes in all time points for 
instance spp1 is significant at neonatal and 5 weeks of age.  
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Figure  3-3 qRT-PCR of Spp1 in heart between WKYGla and WKY.SPGla14a. 
Spp1 significantly differentially expressed between WKYGla and WKY.SPGla14a (D) in heart at 
neonatal and 5 weeks of age. *P<0.05. Data courtesy of Ms. Wendy Beattie. 
 
In order to further investigate which type of batch bias corrections is more 
appropriate for our data, we compared the Partek® effect removal or Batch as 
factor in an ANOVA model. We looked at top diseases that could be related to 
WKY.SPGla14a phenotype from genes identified in each method using IPA. At 
neonatal and 5 weeks of age, Partek® batch removal analysis identified more 
cardiovascular and inflammatory disease genes than accounting for batch bias as 
factor in an ANOVA model analysis. However, at the age of 16 weeks both 
analyses identified same disease names and gene numbers (Figure 3-4). 
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Figure  3-4 IPA top diseases analysis from two batch bias correction methods between 
WKYGla and WKY.SPGla14a in heart. 
Partek® batch removal analysis between WKYGla and WKY.SPGla14a in heart at neonatal and 5 
weeks of age implicated more cardiovascular and inflammatory disease genes than accounting for 
batch bias as factor in an ANOVA model analysis. At 16 weeks of age, both analyses have the 
same top disease name and genes number. 
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3.3.1.2 Combined expression chip platforms approach to identify renal 
positional candidate genes between SHRSPGla, WKYGla and 
chromosome 3 congenic strains 
Partek® ANOVA analysis in the Illumina BeadChip expression data between 
SHRSPGla, WKYGla, and chromosome 3 congenic strains identified positional 
candidate differentially expressed genes mapped to the congenic interval 
common between SP.WKYGla3d and SP.WKYGla3f (Figure 3-5). These genes are 
dynamin1 (Dnm1) and torsin family 1 member B (Tor1b) (Table 3-2). Partek® 
ANOVA analysis in the Affymetrix GeneChip expression data between SHRSPGla 
and WKYGla identified between GTPase activating protein 1 (Rabgap1) as the only 
gene significantly differentially expressed mapped to the unique SP.WKYGla3d 
congenic interval when compared to SP.WKYGla3f (Table 3-3). The Illumina RatRef 
Beadchip RatRef-12v1 does not contain a probe that targets the Rabgap1 gene.  
qRT-PCR validation was carried out by our group for the prioritised genes; Dnm1, 
Tor1b and Rabgap1 from the microarray expression profiling data (Figure 3-6). 
Expression of Dnm1 mRNA level was significantly higher in WKYGla, SP.WKYGla3d 
and SP.WKYGla3f kidneys compared to SHRSPGla at 21-weeks salt-challenge. 
Expression of Tor1b mRNA level was significantly lower in WKYGla, SP.WKYGla3d 
and SP.WKYGla3f compared to SHRSPGla at 21-weeks salt-challenge. Expression of 
Rabgap1 mRNA level was significantly higher in WKYGla and SP.WKYGla3d 
compared to SP.WKYGla3f and SHRSPGla at 21-weeks salt-challenge. 
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Figure  3-5 Significant Illumina probes between parental and chromosome 3 congenic 
strains in kidney at 21 weeks old of age salt. 
Partek® ANOVA analysis between SHRSPGla, WKYGla, SP.WKYGla3d and SP.WKYGla3f in kidney at 
21 weeks of age salt challenge. Two genes were in-common between WKYGla versus SHRSPGla, 
SP.WKYGla3d versus SHRSPGla and SP.WKYGla3f versus SHRSPGla comparisons. 
 
Table  3-2 Illumina results for positional candidate genes which are in common between 
SP.WKYGla3d and SP.WKYGla3f congenic intervals. 
 
 
Table  3-3 Affymetrix results for a positional candidate gene which is unique to the 
SP.WKYGla3d congenic strain interval. 
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Figure  3-6 qRT-PCR of Dnm1, Tor1b and Rabgap1 in kidney between SHRSPGla, WKYGla and chromosome 3 congenic strains at 21 weeks of age salt-
challenge. 
qRT-PCR validated microarray gene profiling expressing results for the prioritised positional candidate genes Dnm1, Tor1b and Rabgap1 between SHRSPGla, WKYGla, 
SP.WKYGla3d and SP.WKYGla3f in kidney at 21 weeks of age salt challenge. *P<0.05. Data courtesy of Mr Ting Wang and Ms. Wendy Beattie.
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3.3.1.3 BioLayoutExpress3D cluster analysis to identify renal positional 
candidate between SHRSPGla, WKYGla and chromosome 2 congenic 
strains  
BioLayoutExpress3D cluster analysis on SHRSPGla and WKYGla and chromosome 2 
congenic SP.WKYGla2a kidney resulted in 1 cluster (109) of 6 genes in which their 
pattern of expression in WKYGla is the same in SP.WKYGla2a strain at 16 and 21 
weeks of age with and without salt treatment (Figure 3-7a). Four of 6 genes in 
the cluster 109 mapped to the SP.WKYGla2a congenic interval (Figure 3-7b).  
IPA functional and pathway analysis implicated Gstm1, Gstm7 and Pik3r1 with 
pathological functions and a canonical pathway that are directly related to the 
SHRSPGla phenotype (Figure 3-8).  
Positional candidate genes, Atp11b and Pik3r1, were prioritised for qRT-PCR 
validation between SHRSPGla, WKYGla and SP.WKYGla2a at 21 weeks of age with 
and without salt treatment. As there is no longer SP.WKYGla2a kidney available at 
16 weeks of age, SP.WKYGla2c* congenic strain was chosen instead at this time 
point with parental strains.  
qRT-PCR results at 16 weeks of age of Atp11b and Pik3r1 (Figure 3-9) revealed 
that their mRNA level is significantly differentially expressed between SHRSPGla 
and WKYGla and is not between SHRSPGla and SP.WKYGla2c* strain which is 
expected as Atp11b and Pik3r1 does not mapped to their congenic interval. At 21 
weeks of age, Pik3r1 mRNA level is significantly differentially expressed between 
SHRSPGla and WKYGla, and SHRSPGla and SP.WKYGla2a and Atp11b mRNA level is 
only significantly differentially expressed between SHRSPGla and WKYGla. 
However, at 21 weeks of age salt challenge both mRNA level is significantly 
differentially expressed between SHRSPGla and WKYGla, and SHRSPGla and 
SP.WKYGla2a. 
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Figure  3-7 BioLayoutExpress
3D
 Cluster 109. 
a&b: A cluster (109) of 6 genes including 4 are mapped to the congenic interval SP.WKYGla2a in 
which their expression pattern in WKYGla is the same in SP.WKYGla2a in relation to SHRSPGla 
expression pattern. 
 
 
Figure  3-8 IPA biological and pathway analysis on cluster 109. 
Pathological function of hypertrophy of the heart and spontaneously hypertensive both observed in 
SHRSPGla phenotype. All of the three genes implicated in oxidative stress response pathway. 
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Figure  3-9 qRT-PCR validation of BioLayoutExpress
3D
 Cluster 109. 
At 16 weeks, Atp11b and Pik3r1 are significantly differently expressed between SHRSPGla and 
WKYGla. At 21 weeks, Atp11b and Pik3r1 are significantly differently expressed between SHRSPGla 
and WKYGla; however, only Pik3r1 is significantly differently expressed between SHRSPGla and 
SP.WKYGla2a. At 21 weeks of salt challenge, Atp11b and Pik3r1 are significantly differently 
expressed between SHRSPGla and WKYGla, and SHRSPGla and SP.WKYGla2a. *P<0.05 
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3.3.2 BioLayoutExpress3D cluster analysis on gene expression 
data across multiple tissues and ages between SHRSPGla 
and WKYGla 
Utilising IPA probe annotation of different experimental gene expression 
platforms, we were able to run cluster analysis on common genes from multiple 
tissues gene expression data between SHRSPGla and WKYGla from different gene 
expression platforms. 
 
3.3.2.1 BioLayoutExpress3D cluster analysis on kidney, heart and brain gene 
expression data between SHRSPGla and WKYGla at 5 weeks of age 
BioLayoutExpress3D cluster analysis on kidney, heart and brain gene expression of 
SHRSPGla and WKYGla at 5 weeks of age identified one cluster (108) of genes 
where their expression intensity pattern is different between SHRSPGla and 
WKYGla (Figure 3-10). 
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Figure  3-10 BioLayoutExpress
3D
 Cluster 108. 
a&b: A cluster (108) of 2 genes in which their expression pattern in SHRSPGla is different than 
WKYGla and consistent across kidney, heart, brain (frontal and mid-coronal) gene expression data 
at 5 weeks of age. 
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3.3.2.2 BioLayoutExpress3D cluster analysis on kidney, heart, aorta and 
brain gene expression data between SHRSPGla and WKYGla at 16 
weeks of age 
BioLayoutExpress3D cluster analysis on kidney, heart, aorta and brain gene 
expression of SHRSPGla and WKYGla at 16 weeks of age identified one cluster (53) 
of genes were their expression intensity pattern is different between SHRSPGla 
and WKYGla (Figure 3-11). 
 
Figure  3-11 BioLayoutExpress
3D
 Cluster 53. 
a&b: A cluster (53) of 5 genes in which their expression pattern in SHRSPGla is different than 
WKYGla and consistent across kidney, heart, aorta and brain (frontal and mid-coronal) gene 
expression data at 16 weeks of age. 
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3.3.2.3 BioLayoutExpress3D cluster analysis on kidney, heart and brain gene 
expression between SHRSPGla and WKYGla at 21 weeks of age and 
salt challenge 
BioLayoutExpress3D cluster analysis on kidney, heart, and brain gene expression 
of SHRSPGla and WKYGla at 21 weeks of age salt challenge identified 4 clusters 
(48, 104, 300, 410) of genes were their expression intensity pattern is different 
between SHRSPGla and WKYGla (Figure 3-12, 3-13, 3-14, 3-15). 
 
Figure  3-12 BioLayoutExpress
3D
 Cluster 48. 
a&b: A cluster (48) of 11 genes in which their expression pattern in SHRSPGla is different than 
WKYGla and consistent across kidney, heart, brain (frontal and mid-coronal) gene expression data 
at 21 weeks of age salt challenge.  
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Figure  3-13 BioLayoutExpress
3D
 Cluster 104. 
a&b: A cluster (104) of 7 genes in which their expression pattern in SHRSPGla is different than 
WKYGla and consistent across kidney, heart, brain (frontal and mid-coronal) gene expression data 
at 21 weeks of age salt challenge. 
  
95 
 
 
 
Figure  3-14 BioLayoutExpress
3D
 Cluster 300. 
a&b: A cluster (300) of 5 genes in which their expression pattern in SHRSPGla is different than 
WKYGla and consistent across kidney, heart, brain (frontal and mid-coronal) gene expression data 
at 21 weeks of age salt-challenged. 
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Figure  3-15 BioLayoutExpress
3D
 Cluster 410. 
a&b: A cluster (410) of 3 genes in which their expression pattern in SHRSPGla is different than 
WKYGla and consistent across kidney, heart, brain (frontal and mid-coronal) gene expression data 
at 21 weeks of age salt challenge. 
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3.3.2.4 Functional and validation analysis on BioLayoutExpress3D clusters 
across multiple tissues and ages between SHRSPGla and WKYGla 
Functional analysis on BioLayoutExpress3D clusters with genes differentially 
expressed between SHRSPGla and WKYGla across tissues at 5, 16 and 21 weeks of 
age salt-challenged (Figure 3-16) all implicated genes associated with molecular 
transport and cardiovascular system function. Nevertheless, clusters with genes 
at the hypertensive and severely hypertensive phases implicated genes 
associated nervous system function and inflammatory response.  
Atp11b was prioritised for qRT-PCR validation in heart as it has been identified 
in BioLayoutExpress3D clusters across tissues at pre-hypertensive, hypertensive 
and severely hypertensive phases. qRT-PCR results showed that Atp11b mRNA 
level in heart is significantly differentially expressed between SHRSPGla and 
WKYGla at neonatal, 5 and 16 weeks of age (Figure 3-17). 
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Figure  3-16 Functional analysis on BioLayoutExpress
3D
 clusters with genes differentially expressed between SHRSPGla and WKYGla across tissues and 
ages. 
IPA functional analysis on BioLayoutExpress
3D
 clusters across tissues and ages implicated genes with cardiovascular system function at a) 5, b) 16 and c) 21 weeks of 
age and salt challenge. IPA also implicated genes with nervous system function and inflammatory disease at 16 and 21 weeks of age and salt challenge. 
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Figure  3-17 qRT-PCR of Atp11b in heart at neonatal, 5 and 16 weeks of age between SHRSPGla and WKYGla. 
Atp11b mRNA level is significantly differentially expressed between SHRSPGla and WKYGla in heart at neonatal, 5 and 16 weeks of age. *P<0.05 
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3.4 Discussion 
This chapter has investigated a number of gene expression analysis workflows to 
identify candidate genes for the SHRSPGla phenotype. 
 
The implementation of Partek® effect removal tool for batch bias in 
transcriptomic data analysis, identified more significant differentially expressed 
genes including positional candidate genes for LVMI between WKYGla and 
WKY.SPGla14a when compared accounting for batch bias as factor in ANOVA 
model. Partek® batch effect removal analysis also enhanced the IPA functional 
analysis by identifying more cardiac function genes which are related to the 
WKY.SPGla14a phenotype. qRT-PCR validation of positional candidate gene Spp1 
for LVMI (paper in preparation) between WKYGla and WKY.SPGla14a at two time 
points suggests that using Partek® batch removal analysis gives better prediction 
of candidate genes compared to our regular analysis in which we could missed 
positional candidate genes for LVMI if we used one time point. 
 
Improving a biased transcriptomic data is not the only strategy to identify 
potentially missed candidate genes for SHRSPGla phenotype. The combination of 
Affymetrix and Illumina gene expression platform increased the efficiency of 
identification of renal positional candidate genes for pulse pressure where some 
could be missed if we relied only on one experimental platform.  
 
The identified positional candidate Dnm1 and Tor1b mapping to the congenic 
interval common between SP.WKYGla3d and SP.WKYGla3f and Rabgap1 mapping to 
the congenic interval unique to SP.WKYGla3d all not associated with essential 
hypertension before. Dnm1 encodes Dynamin 1 protein that is essential for the 
formation of vesicles via clathrin-mediated endocytosis that regulates kidney 
filtration barrier maintenance (Soda et al., 2012), synaptic transmission 
(Ferguson et al., 2007) and mitochondrial fission (Lefevre et al., 2012). Hyndman 
et al., 2011 showed that Dynamin isoforms (Dnm1, Dnm2 and Dnm3) interact 
with nitric oxide synthase (NOS) isoform in rat kidney and the inhibition of Dnm2 
led to increased NO production which is essential for the regulation of blood 
flow and pressure. Tor1b encodes Torsin B protein, which is found in the nuclear 
membrane and cytoplasmic endoplasmic reticulum, plays a role in synaptic 
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transmission (Kakazu et al., 2012). A mutation in Tor1b has been associated with 
torsion dystonia, a neurological condition in which muscles contracts 
involuntarily (Kamm et al., 2006). Rabgap1 encodes for a protein that belongs to 
the Rab GTPase family, which they regulates a number of intracellular vesicle 
trafficking steps (Nagai et al., 2013). 
 
BioLayoutExpress3D cluster analysis between SHRSPGla, WKYGla and chromosome 2 
congenic SP.WKYGla2a in kidney at 16 and 21 weeks of age with and without salt 
challenge, identified a cluster (109) with new positional candidate genes that 
were not identified previous with our Rank Products (Graham et al., 2007) and 
meta-covariate cluster analysis (Hopcroft et al., 2010) on the same rat strains at 
21 weeks of age and salt challenge. In addition, cluster (109) identified Gstm1, a 
previously validated functional and positional candidate gene for hypertension in 
the SHRSPGla (McBride et al., 2005) providing proof of concept for our 
BioLayoutExpress3D cluster analysis. Functional analysis of IPA on cluster 109 
implicated some genes with pathological functions such as heart hypertrophy 
and spontaneous hypertension and oxidative stress canonical pathway were both 
phenotypes are observed in the SHRSPGla were it is also a model for oxidative 
stress. The prioritised positional candidate genes Pik3r1 and Atp11b for 
validation have biological functions that can be a causative for the SHRSPGla 
phenotype. Pik3r1 plays an important role in the metabolic actions of insulin, 
and a mutation in this gene has been associated with insulin resistance 
(Malodobra et al., 2011). Moreover, Atp11b transports ions across membranes 
and is part of a subfamily of P-type ATPases that transport ions such as H(+), 
Na(+), K(+), or Ca(+) (Apell, 2004) and are important in regulation of blood 
pressure. qRT-PCR results confirm that Pik3r1 and Atp11b mRNA levels are 
significantly differentially expressed between parental strains and SP.WKYGla2a 
and SHRSPGla at 21 weeks old and salt challenge. Furthermore, qRT-PCR results 
shows no change of mRNA levels of Pik3r1 and Atp11b at 16 weeks of age 
between SHRSPGla and an improved blood pressure congenic strain SP.WKYGla2c* 
(both genes do not map to SP.WKYGla2c* congenic interval) which may suggest 
these genes are not related to inflammatory and stress response. Unlike Pik3r1, 
Atp11b mRNA level does not show significant change between SP.WKYGla2a and 
SHRSPGla at 21 weeks of age which may imply that Atp11b is salt response 
candidate gene in the SHRSPGla. However, the latter cannot be ruled out without 
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further qRT-PCR validation carried out between SP.WKYGla2a and SHRSPGla in 
kidney at 16 weeks of age as well as earlier time points. 
 
The success of the identification and validation of differentially expressed genes 
with BioLayoutExpress3D encouraged us to carry out more complex cluster 
analysis on multiple and available functionally related tissues to SHRSPGla at 
different hypertensive phases. BioLayoutExpress3D cluster analysis identified 
clusters of genes with differentially expressed pattern between SHRSPGla and 
WKYGla that is consistent across tissues at all hypertensive phases. IPA functional 
analysis on these clusters implicated genes related to cardiovascular system 
function and molecular transport from all hypertensive phases and nervous 
system function, organismal injury and abnormalities and inflammatory response 
at hypertensive and severely hypertensive phases were all captured SHRSPGla 
phenotype.  
 
BioLayoutExpress3D cluster analysis across tissues identified a cluster of genes in 
which their pattern of expression is high in WKYGla compared to SHRSPGla at all 
hypertensive phases in which Atp11b was common in all these clusters. This may 
suggest that Atp11b is driving disease as it is differentially expressed from an 
early age on a number of tissues that can regulate and influence blood pressure. 
The latter is confirmed by qRT-PCR results of Atp11b, which shows that it is 
significantly differentially expressed between SHRSPGla and WKYGla in kidney and 
heart at different time of age. At severely hypertensive phase 3 clusters 
identified by BioLayoutExpress3D in which their genes expression pattern is high 
in SHRSPGla compared WKYGla. One of these genes in these clusters is Gucy1a3, 
that has been shown to cause heart hypertrophy by preventing the pulmonary 
vasodilator response to NO in mice knockout experiment (Vermeersch et al., 
2007) and it has been associated with blood pressure in Genome wide association 
study in human (Ehret et al., 2011). 
 
BioLayoutExpress3D cluster analysis is fast to carry out in and all the presented 
data takes less than an hour for each, whereas in our meta-covariate cluster 
analysis it took months to get results for only small set of data (Hopcroft et al., 
2010). However, BioLayoutExpress3D is not efficient in finding clusters with gene 
expression pattern related to the user criteria. As a result, the user has to 
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browse hundreds of possible clusters expression patterns in order to find one of 
interests. Moreover, our BioLayoutExpress3D cluster analysis across tissues at 5 
and 16 weeks of age was limited to genes that were common between gene 
expression platforms from different versions of Affymetrix chips and Illumina 
platform. However, the BioLayoutExpress3D cluster analysis across tissues at 21 
weeks of age and salt challenge used one gene expression platform (Illumina), 
which may reduce the chances of missing genes that contribute to the SHRSPGla 
phenotype. Like all clustering methods, follow-up experiments are using qRT-
PCR is necessary to differentiate between the highlighted clusters (i.e genes) if 
they are truly useful or just spurious. 
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4 Whole Genome Next Generation Sequencing of 
SHRSPGla and WKYGla Rat Strains 
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4.1 Introduction 
Currently, the term Next generation sequencing (NGS) used to described 
sequencing technologies that reads DNA templates in a massively parallel 
manner which generates short reads (35-500 bp) randomly along the whole 
genome compared to the very low throughput of Sanger sequencing (Zhang et 
al., 2011). NGS of the whole genome or a targeted region is more efficient in 
terms of cost, time and effort when compared to traditional Sanger sequencing. 
NGS can detect structural variations, such as large deletions, as well as CNV, in 
addition to the detection of high-throughput SNPs and INDELs (Metzker, 2010). 
The application of NGS for the analysis of human (Ahn et al., 2009), mouse 
(Keane et al., 2011; Yalcin et al., 2011) and rat (Atanur et al., 2010; Atanur et 
al., 2013; Guo et al., 2013) in research has been successful and recently been 
used as a genetic diagnostic tool (Shanks et al., 2013). A number of platforms 
offer NGS, most of which are based on common principles; enrichment of the 
genome, template library preparation, sequencing and imaging (Figure 4-1), 
however, they differ in sequencing technology (Metzker, 2010). Illumina NGS 
templates can be short paired-end (PE) reads (two ends of the same DNA 
fragment) or long mate pair reads, with each variation having its advantages. We 
used the PE template since it is standard for most platforms (Van Heesch et al., 
2013) and therefore will be more informative when compared to other 
sequenced rat strains so as to isolate genomic variants for a phenotype and/or 
phylogenetic analysis (Atanur et al., 2013). In order to do this, NGS of rat strains 
reads should to be aligned to an accurate reference genome sequences instead 
of de novo assembly.  
Brown Norway (BNSsNHsd/Mcwi) rat strain is the reference genome; it has been used 
widely as control strain for a number of fields and studies as well as it is the 
founder of RI rat strains. Baylor College of Medicine and Celera genomics 
constructed the initial draft genome of BN Rat Genome Sequencing Consortium 
(RGSC) 3.1 with a combination of Whole Genome Shotgun (WGS) sequencing with 
a bacterial artificial chromosome (BAC) refined by DNA fingerprints, genetics 
markers and syntenic regions (Worthey et al., 2010). Further improvements of 
Atlas assembler version, targeted problematic regions and draft sequence of Y 
chromosome led to the release of draft sequence RGSC 3.4, however, the Y 
chromosome was not included (Gibbs et al., 2004). Both RGSC 3.1 and 3.4 
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suffered from significant gaps (Worthey et al., 2010). Recently, RGSC released an 
upgraded version of the assembly Rnor 5.0 with  
 
 
Figure  4-1 Overview of NGS Illumina Technology 
1) Sample preparation begins with sequencing library by adapters ligate at opposite ends of DNA 
fragment and the use of Illumina flow cell. 2a) Primers on flow cell capture the adapters of DNA 
fragment and immobilised the template on flow cell surface then bridge amplification is performed. 
2b) the amplification form dense DNA clusters on flow cell channel. 2c) Denaturation of the bridges 
leaves one strand anchored to the flow cell surface ready for sequencing. 3a) Universal 
sequencing primer anneal to the DNA fragment adapter and first base extension is performed with 
reverse termination of four deoxynucleotides carrying different flurophores and a blocking group to 
terminate the extension of DNA polymerase after incorporating 1 identified nucleotide by capturing 
the image of the laser activated fluorescence. 3b) The latter step is repeated after washing down 
the unincorporated nucleotides and cleavage step removes both the blocking group and the 
fluorescent dyes. 3c) The resulting images are used to generate base calls of each DNA cluster 
sequence (Original diagram compiled from information on Metzker, 2010).  
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improvement in the total length and gaps before scientific publication. To 
present day, Y chromosome sequence is not included in any BN assembly 
versions. This might be due to the fact that BN Y chromosome, includes 
polymorphism, is significantly larger than other rat strains (Kren et al., 2001). 
No and/or low coverage (average number of times a nucleotide base is read) of 
quantity and quality of reads are likely to lead to missed sequence variants or 
sequencing error. Hence, assessing average coverage and NGS sequence variants 
with variants from other sequencing methods as a means of quality control, is 
very important. Moreover, mapping the NGS reads to a newer assembly will 
improve sequencing coverage and thus, increase accuracy of detection genomic 
variants. 
The rate of BN assembly updates compared to the mouse and human reference 
assemblies is slow and does not meet standards of a finished level genome 
(Worthey et al., 2010). As a result, Guo et al., 2013 constructed genomes draft 
of their own a rat strains via de novo assembly aided by BN reference genome 
and GapCloser tool achieving larger genomes than the BN, and eventually 
leading to the detection of novel genomic variants. Nevertheless, these novel 
variants will not have functional significance since functional annotation of 
sequence variants is assessed by BN reference genome.  
Annotation tools such as Ensembl variant effect predictor (McLaren et al., 2010) 
of sequence variants, are essential for identifying disease causative genes. 
Consequence effect of sequence variants can be categorised into protein coding 
and non-coding sequences, a change in these classes can induce a phenotype. 
Predicted evolutionary conserved protein coding consequences, such as non-
synonymous, stop gain and/or loss, and frameshift variants, are usually 
prioritised according to which change is more likely to influence protein function 
(Cooper & Shendure, 2011). Predicted non coding consequences are also 
important since they can alter gene expression. For instance, upstream and 5’-
UTR variants can disturb the transcription factor binding site or epigenetic 
regulation and 3’-UTR consequence can disturb miRNA binding regions causing 
mRNA destabilisation followed by degradation, and/or by mRNA translational 
repression (Boffa et al., 2008; Guo et al., 2013). On the other hand, variants in 
intronic and intergenic are usually given a lower priority. Recently, Encyclopedia 
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of DNA Elements (ENCODE) project suggested that such regions are functional 
(Ian et al., 2012); however, some evolutionary biologists disagree (Graur et al., 
2013). The release of the BN reference genome Rnor 5.0 led to a major upgrade 
in Ensemble variant effect predictor version 71 classification of consequences 
and offered new prediction tools such as Sorting Intolerant From Tolerant (SIFT) 
algorithm to assess likely damaging non-synonymous SNPs by using conserved 
homology sequence (Kumar et al., 2009). 
The first whole genome inbred rat strain sequenced by NGS is the spontaneously 
hypertensive rat (SHROlaIpcv) which was compared to BN reference RGSC 3.4 
(Atanur et al., 2010). Atanur et al., 2010 identified in the SHROlaIpcv more than 3 
million SNPs with high level of sensitivity and specificity validation at low (10x) 
coverage. The SHROlaIpcv whole genome had another NGS update which improved 
the coverage to 23x and led to the identification of new sequence variants that 
might be causative for the SHROlaIpcv phenotype (Simonis et al., 2012). Atanur et 
al., 2010 success in carrying out NGS, encouraged other groups, including ours, 
to collaborate and sequence a number of rat strains in order to identify genetic 
determinants which underlie human complex diseases and to carry out 
phylogenetic analysis (Atanur et al., 2013). Nevertheless, sequencing SHRSPGla on 
its own against BN reference will generate a large number of genomic variants. 
Moreover, preliminary analysis between SHRSPGla and WKYGla sequence variants 
from targeted sequencing (sequence capture) and STAR project consortium 
sequencing data (Saar et al., 2008) estimated that over 40% of SHRSPGla 
sequence capture SNPs would not be informative as they are common with 
WKYGla. As a result, sequencing WKYGla is necessary to prioritise genomic 
variants. In addition, SHRSPGla and WKYGla with the publically available sequence 
of SHROlaIpcv will further prioritise candidate genes for hypertension; common 
variants between SHROlaIpcv and SHRSPGla, and stroke; unique SHRSPGla variants. 
The latter can be further prioritised with other strains of SHR along other 
hypertensive rats that were sequenced in the phylogenetic study of 28 rat 
genomes (Atanur et al., 2013) and non-synonymous SNPs of SHRSPIzm compared to 
SHRIzm against BN reference RGSC 3.4 at two QTLs on chromosome 1 and 18 for 
stroke latency (Gandolgor et al., 2013). Nevertheless, SHRSPGla was the only rat 
strain in that study with unique phenotypes of severe hypertension and stroke 
prone (Atanur et al., 2013). 
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4.2 Aims 
 
This chapter specific aims are:.  
 
 Identification and annotation of genomics variants between SHRSPGla and 
WKYGla genome sequences compared the BN reference assemblies and 
isolating variants at congenic intervals for blood pressure on chromosome 
2 QTL, pulse pressure on chromosome 3 QTL, LVH on chromosome 14 QTL.  
 
 Estimate genomic variants’ distribution and frequencies between SHRSPGla 
and WKYGla compared to the reference BN RGSC 3.4. 
 
 Provide independent validation of genome sequencing of SHRSPGla and 
WKYGla using sequence variants from STAR project consortium SNP 
genotyping data, sequence capture and Sanger sequencing. 
 
 Identify a strategy that allows for comparison, at the nucleotide level, 
between the closely related SHROlaIpcv and SHRSPGla strains. 
 
 Identify SHRSPGla unique and deleterious protein coding sequence variants 
against to 27 rat strains genome compared to BN reference genome RGSC 
3.4 and prioritising common SHRSPIzm variants. 
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4.3 Results 
4.3.1 Sequence variants between SHRSPGla and WKYGla compared 
to BN reference RGSC 3.4 
4.3.1.1 Variants calling between SHRSPGla and WKYGla 
When both strains were compared to the BN reference RGSC 3.4 genome, a high 
proportion of the SNPs and INDELs common between the SHRSPGla and WKYGla. 
Furthermore, the total number of unique genomic sequence variants in the 
SHRSPGla were less than WKYGla when compared to the BN reference RGSC 3.4 
genome (Figure 4-2a). Heterozygous sequence variants were detected in our 
inbred rat strains (Figure 4-2b). 
 
Figure  4-2 SHRSPGla and WKYGla genomic sequence variants compared to BN reference 
genome RGSC 3.4. 
a) Venn diagrams showings all SNPs and INDELs, for each rat strain compared to BN assembly 
RGSC 3.4. Common variants (intersect) were filtered out from the analysis to focus on unique 
variants between SHRSPGla and WKYGla resulted in 1,163,332 SNPs and 213,130 INDELs. b) 
Venn diagrams showing only heterozygous SNPs and INDELs for SHRSPGla and WKYGla. 
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4.3.1.2 Distribution and density of sequence variants 
Circos plots with the genomics sequence variants (first two tracks) distribution 
and density over 100 kb window across the BN genome RGSC 3.4. It was observed 
that genomic variants were not uniform; for instance, in chromosome 1 there 
were certain areas with high cluster of SNPs and others without. The same was 
observed in the INDEL track, which additionally seemed to be correlated with 
the SNPs track (Figure 4-3). 
 
 
Figure  4-3 SHRSPGla and WKYGla genomic variants and their density distribution across BN 
reference genome RGSC 3.4. 
A circos plot showing the unique sequence variants density distribution between SHRSPGla and 
WKYGla over 100 kb window across rat genome RGSC 3.4. The distribution of SNPs and INDELs 
was not uniform and correlated at 27x SHRSPGla and 26x WKYGla median coverage.  
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4.3.1.3 Small INDEL size distributions 
As demonstrated in Figure 4-4A, size distribution of small insertions that were, 
unique to SHRSPGla versus WKYGla when compared to BN reference RGSC 3.4, 
revealed that 1 bp was the highest in genome wide and in variants that affect 
protein function. However, 3 bp was also high; nevertheless, this could be biased 
for the reading frame. Moreover, as depicted in Figure 4-4B, in small deletions, 
unique to WKYGla versus SHRSPGla when compared to BN reference RGSC 3.4, 1 bp 
size distribution was the highest, and in variants that have an effect on protein 
function, 3 bp. 
 
 
Figure  4-4 Small insertions and deletions size distribution comparison. 
A) Distribution of small insertions sizes shown as a percent of total for all (blue) insertions and for 
predicted insertions that have an effect on proteins function (red). B: Distribution of small deletions 
sizes shown as a percentage of total for all (blue) deletions and for predicted deletions that have an 
effect on proteins function (red). 
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4.3.1.4 Variants effect predictor annotation Ensembl 69 
Table 4-1 shows the predicted effect of sequence variants unique to SHRSPGla 
versus WKYGla when compared to BN reference genome RGSC 3.4 (Figure 4-2a) by 
Ensembl variants effect predictor tool (version 69). Predicted consequences from 
SNPs and INDELs suggested that there were more intergenic and intronic variants 
compared to exonic variants, in both SNPs and INDELs. Protein coding sequence 
variants were then prioritised according to which ones were more likely to have 
an effect on protein function. 
Table  4-1 Predicted consequence of all SHRSPGla versus WKYGla sequence variants 
compared to BN reference genome RGSC 3.4. 
 
 
The numbers generated in this table are based on the predicted sequence variants location within 
a gene relative to the transcript structure by Ensembl annotation.  
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4.3.1.5 IPA results for all unique SHRSPGla versus WKYGla NGS variants 
Biological interpretation of unique SNPs and INDELs between SHRSPGla and WKYGla 
when compared to BN reference genome RGSC 3.4, implicated networks, 
diseases and canonical pathways that regulate cardiovascular disease (Table 4-
2). 
 
Table  4-2 IPA results for all unique SHRSPGla versus WKYGla sequence variants compared to 
BN reference genome RGSC 3.4. 
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4.3.1.6 Variants effect predictor annotation on SHRSPGla and WKYGla QTLs 
Table 4-3 shows extracted protein coding sequence variants in addition to other 
sequence variations in genes within SHRSPGla and WKYGla validated QTLs regions 
on chromosome 2 (1,000,000bp-225,000,000bp), 3 (1,000,000bp-36,000,000bp), 
and 14 (5,000,000bp-112,194,335bp) from the the whole annotated sequence 
variants between SHRSPGla versus WKYGla in Table 4-1 as they are more likely to 
be the causative of the SHRSPGla phenotype. 
Table  4-3 Predicted consequences of SHRSPGla versus WKYGla sequence variants compared 
to BN reference genome RGSC 3.4 on QTL regions at chromosomes 2, 3 and 14. 
 
 
The numbers generated in this table are based on the predicted sequence variants location within 
a gene relative to the transcript structure by Ensembl annotation.  
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4.3.2 Mapping SHRSPGla and WKYGla NGS reads to BN new 
assembly Rnor 5.0 
Table 4-4 demonstrate an improved of mapping and average coverage of NGS 
reads of SHRSPGla and WKYGla with the BN new reference Rnor 5.0 when 
compared to the BN reference genome RGSC 3.4. In addition, there were many 
improvements in the BN new reference genome Rnor 5.0 in base pairs 
(66,296,177) and total length (145,534,490) compared to the BN reference RGSC 
3.4. 
 
Table  4-4 Mapping and coverage results of SHRSPGla and WKYGla reads when compared to 
BN difference assemblies. 
 
 
*Gb of bases mapped and average coverage was calculated after removing clonal reads. 
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4.3.3 Sequence variants between SHRSPGla and WKYGla compared 
to BN new reference genome Rnor 5.0 
4.3.3.1 Variants calling between SHRSPGla and WKYGla 
When SHRSPGla and WKYGla strains were compared to the BN new reference Rnor 
5.0, a high proportion of the SNPs and INDELs were common between our rat 
strains. Furthermore, the total number of unique genomic variants with BN new 
reference genome Rnor 5.0 was more than the BN reference genome RGSC 3.4. 
However, in both, the unique variants in SHRSPGla were less than WKYGla (Figure 
4-5).  
 
 
Figure  4-5 Variants calling between SHRSPGla and WKYGla against BN new assembly Rnor 
5.0. 
Venn diagrams showing intersections of SNPs and INDELs that common and unique to each strain 
when compared to the BN new reference genome Rnor 5.0 as well as the total unique variants 
between SHRSPGla and WKYGla. 
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4.3.3.2 Ensembl Variants effect predictor annotation 71 
Table 4-5 shows the predicted effect of sequence variants which are unique to 
WKYGla versus SHRSPGla when compared to BN new reference genome Rnor 5.0 
(Figure 4-5) by Ensembl variants effect predictor tool (version 71). Furthermore, 
predicted consequences suggested that there were more intergenic and intronic 
variants compared to exonic variants. In additionally, the new Ensembl variants 
annotation 71 added new and more refined predicted consequences compared to 
Ensembl variants predictor annotator 69. 
Table  4-5 Variants Ensembl effect predictor of SHRSPGla and WKYGla total unique sequence 
variants. 
The numbers generated in this table are based on the predicted sequence variants location within 
a gene relative to the transcript structure by Ensembl annotation. 
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4.3.3.3 Improvements of BN new assembly on selected genes of interest  
Figure 4-6 Shows examples of improvements of BN new reference Rnor 5.0 
compared to BN reference genome RGSC 3.4 were observed in the Spp1 and 
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 5 
(Hsd3b5) genes. Spp1 annotation and Hsd3b5 missing sequences are improved in 
the BN new reference genome Rnor 5.0 when compared to BN reference genome 
RGSC 3.4.  
 
 
 
Figure  4-6 Improvements of BN new reference sequence compared to the old reference 
visualised by IGV. 
A) Spp1 gene sequence in BN reference genome RGSC 3.4 was incomplete when compared to 
the new BN reference genome Rnor 5.0. The new Spp1 regions harbour potential functional 
sequence variants such as A1 SNP‎at‎3’‎UTR‎region‎and‎A2 upstream insertion when viewed with 
IGV. B) The interogenic gap of hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 5 (Hsd3b5) on the BN reference genome RGSC 3.4 was closed in the new reference 
Rnor 5.0 thus new regions to look for sequence variants were revealed. 
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4.3.4 Quality control of NGS data 
4.3.4.1 Quality control comparing NGS data with sequence capture data  
As a quality control, a region on chromosome 2 (211,822,164-213,846,183 bp) 
was sequenced by both Illumina NGS whole genome and Agilent SureSelect 
sequence capture between SHRSPGla and WKYGla compared to BN reference 
genome RGSC 3.4 was used. Figure 4-7, presents 75% of SNPs that were common 
between both Illumina NGS whole genome and Agilent SureSelect sequence 
capture, as well as the ones that were unique to each method. NGS data 
detected more unique SNPs than sequence capture, which might be due to the 
presence of gaps (Figure 4-7a). Sequence capture detected SNPs which were not 
captured by NGS data; this could be due to a low number of reads for variants 
calling parameters (Figure 4-7b). 
 
 
Figure  4-7 Quality control: NGS data versus Sequence Capture. 
Venn diagram showing SNPs that were common and unique to each of the sequencing method. a) 
IGV shows an example of a SNP that is detected in the NGS analysis but not in the sequence 
capture analysis due to SureSelect design, which covers exonic regions more than intergenic 
regions. b) IGV shows an example of a SNP that was detected by sequence capture but not in the 
NGS analysis due to the low number of reads in the WKYGla genome at the SHRSPGla SNP position 
in which it was excluded from the analysis. 
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4.3.4.2 Quality control comparing NGS data with STAR sequence data 
Unique SNPs from NGS data and STAR project consortium sequencing data of 
SHRSPGla and WKYGla compared to BN reference RGSC 3.4 was also used as quality 
control. NGS data captured 98% of STAR data and 1.7% SNPs that were unique to 
STAR data (Figure 4-8a). Nevertheless, only 42.5% (17 SNPs) (Figure 4-8b2) of the 
1.7% unique SNPs to STAR data were true positive SNPs that were missed by NGS 
analysis. This is due to the fact that since half of the unique STAR data SNPs are 
either not properly annotated (Figure 4-8b1) or does not map to the BN 
reference genome RGSC 3.4 (i.e not comparable) (Figure 4-8b3).  
 
 
Figure  4-8 Quality control: NGS data versus STAR data. 
a) Venn diagram showing SNPs that were common and unique to each of the sequencing method. 
The NGS data captured most of the STAR SNPs. b) not all the SNPs that are unique to STAR data 
are true and/or comparable SNPs. b1) IGV shows 1of out 5 STAR unique SNPs that were 
incorrectly called by 1 bp. b2) IGV shows one of out 17 STAR unique SNPs which was missed by 
NGS data due to insufficient reads for variant calling parameters. b3) 18 STAR unique SNPs were 
not mapped to the BN reference genome RGSC 3.4 and thus, were incomparable SNPs to NGS 
data. 
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4.3.4.3 Quality control comparing NGS data, sequence capture with Sanger 
sequencing 
When comparing 34 SNPs/INDELs from Sanger sequencing on a region 
chromosome 2 to both NGS data and sequence capture unique sequence from 
SHRSPGla and WKYGla compared to BN reference RGSC 3.4. Both were able to 
detect most of the variants, however, NGS data missed 4 SNPs and 1 INDEL, while 
sequence capture data missed only 3 SNPs (Figure 4-9). 
 
 
Figure  4-9 Quality control: NGS data and sequence capture compared to Sanger sequencing 
data. 
a,b) Venn diagram showing SNPs and INDELs of Sanger sequencing that were common and 
unique to NGS data and sequence capture. c) Sanger sequence SNP (complementary) visualised 
by IGV, were captured by sequence capture analysis but missed by NGS analysis due to the low 
number of reads in the WKYGla genome at the SHRSPGla SNP position in which it was excluded 
from the analysis. (Capillary image courtesy of Ms. Wendy Beattie) 
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4.3.5 Structural variations between SHRSPGla and WKYGla 
Structural variations analysis on NGS data of SHRSPGla and WKYGla detected large 
deletion (more than 45 bp) and CNV when compared to the BN reference 
genome RGSC 3.4.  
4.3.5.1 Large deletion 
Figure 4-10a demonstrates that the number of large deletions implicated present 
in the WKYGla was higher compared to SHRSPGla. Additionally, results of mapping 
deleted regions in SHRSPGla and WKYGla to genes via Ensembl BioMart (version 69) 
are shown in Figure 4-10b. 
 
 
Figure  4-10 Large deletions analysis in SHRSPGla and WKYGla. 
a) Large deletion analysis between the SHRSPGla and WKYGla revealed that there were more 
deletions in the WKYGla. b) Venn diagrams showings deleted and/partial deleted genes that are in-
common and unique to each rat strain compared to BN reference genome RGSC 3.4. 
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4.3.5.1.1 Large deletion size distributions 
 
Figure 4-11 demonstrate large deletions at chromosomes and size distribution in 
the SHRSPGla. Analysis revealed that SHRSPGla had a high proportion of large 
deletion across rat chromosomes, when corrected to their length, were located 
on chromosomes 1 and 2 (Figure 4-11a). Moreover, high proportion of large 
deletion size distribution in the SHRSPGla was between 100-250 bp and larger 
than 10 kb (Figure 4-11b). 
 
 
Figure  4-11 Large deletion distributions in size and across rat genome. 
a) Distribution of large deletion in the SHRSPGla across rat genome in which high proportion of 
deletion were in chromosomes 1 and 2. b) Distribution of sizes of large deletions in the SHRSPGla 
were between 100-250 bp and larger than 10 kb. 
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4.3.5.2 Copy number variation 
CNV analysis in SHRSPGla and WKYGla when compared to the BN reference genome 
RGSC 3.4 showed that there were more copy number duplications in the SHRSPGla 
than WKYGla (Figure 4-12a). In addition, the copy number deletions in the WKYGla 
were more compared to the SHRSPGla (Figure 4-12b). When the CNV regions of 
duplication and deletion annotated were by using Ensembl BioMart (version 69), 
we refined only what was unique to each rat strain for duplication (Figure 4-12c) 
and deletion (Figure 4-12d), and therefore, of interest.  
 
 
Figure  4-12 CNV analysis in SHRSPGla and WKYGla. 
a) Copy number variants of duplication in SHRSPGla were more when compared to WKYGla. b) 
Copy number variants of deletion in WKYGla were more when compared SHRSPGla. c) Venn 
diagram showed what was common and what was unique of CNV of duplication to each rat strain. 
d) Venn diagram showed what was common and what was unique of CNV of deletion to each rat 
strain. 
 
  
126 
 
4.3.6  NGS whole genome sequence of WKYGla, SHRSPGla, and 
SHROlaIpcv 
When comparing the NGS whole genome SNPs across all three rat strains 
compared to BN reference genome RGSC 3.4, the intersection that was common 
among them had the highest number of SNPs, around 2.5 million (Figure 4-13). 
Such an observation, was expected, given the fact strains’ were relative similar 
compared to BN reference genome RGSC 3.4. Prioritising intersections of what 
was common between SHRSPGla and SHROlalpcv and what was unique to SHRSPGla 
was of interest since they could harbour causative variants for spontaneous 
hypertension and stroke proneness, respectively.  
 
 
Figure  4-13 SNPs calling between SHRSPGla, WKYGla and SHROlaIpcv against BN assembly 
RGSC 3.4. 
Venn diagram of SNPs across the three rat strains showing different intersection of what was 
common and what was unique among the three rat strains. 
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4.3.7 SHRSPGla unique sequence variants compared to 27 NGS rat 
genomes 
SHRSPGla NGS sequence variants compared to NGS whole genome of 27 rat strains 
against BN reference genome RGSC 3.4 resulted in SNPs 23,621 INDELs 3,532 
unique to the SHRSPGla. 
4.3.7.1 SHRSPGla unique variants effect predictor annotation Ensembl 69 
Table 4-6 shows annotated sequence variants unique to the SHRSPGla when 
compared to NGS 27 rat against BN reference RGSC 3.4. Predicted consequences 
from SNPs and INDELs showed that there were more intergenic and intronic 
variants compared to exonic variants in both SNPs and INDELs. Protein coding 
sequence variants from SNPs and INDELs were prioritised as these were more 
likely to have an effect on protein function. 
Table  4-6 Variants Ensembl effect predictor of SHRSPGla unique sequence variants 
compared to 27 NGS rat genomes. 
 
The numbers generated in this table are based on the predicted sequence variants 
location within a gene relative to the transcript structure by Ensembl annotation. 
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4.3.7.2 SHRSPGla unique SNPs compared to 27 NGS rat genomes 
Subsequently, we prioritised protein coding SHRSPGla unique SNPs compared to 27 
NGS rat genomes specifically the 103 non-synonymous and 3 stop gain SNPs as 
they were likely to have a deleterious effect on protein function. IPA analysis on 
the 88 genes with non-synonymous mutations Figure 4-14 in which (only 67 genes 
were mapped to IPA) implicated functional networks (Figure 4-14a), disease 
(Figure 4-14b), and pathways (Figure 4-14c), that regulate cardiovascular 
disease. SHRSPGla and WKYGla QTL regions for blood pressure, left ventricular 
index, and stroke (chromosome 5: 62,555,131 bp-148,718,705 bp) as well as 
other QTLs for blood pressure and stroke from other rat strains on RGD were 
used to prioritise candidate genes. Furthermore, the consistent consequence 
prediction in the BN new reference genome Rnor 5.0 and SIFT predication score 
(for non-synonymous) were also used to prioritised SHRSPGla unique non-
synonymous (Table 4-7) and stop gained (Table 4-8) SNPs. 
 
Figure  4-14 IPA analysis of SHRSPGla unique non-synonymous SNPs. 
The 67 genes with non-synonymous SNPs implicated a) top networks such as haematological 
functions and tissue morphology, b) top disease such as cardiovascular and c) top canonical 
pathways hypoxia signalling in cardiovascular system all of which can regulate of the 
cardiovascular disease. 
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Continued 
Table  4-7 SHRSPGla unique non-synonymous SNPs compared to 27 NGS rat genomes. 
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Continued 
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SIFT (Sorting Intolerant from Tolerant) algorithm predicts and score the effect of coding variants on protein function result of a non-synonymous SNP based on 
sequence homology and the physical properties of amino acids.  
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Table  4-8 SHRSPGla unique stop gain SNPs compared to 27 NGA rat genomes. 
 
 
4.3.7.3 SHRSPGla unique INDELs compared to 27 NGS rat genomes 
We prioritised protein coding SHRSPGla unique INDELs compared to 27 NGS rat 
genomes specifically the 4 non-synonymous and 3 frame shift INDELs as they 
were likely to have a deleterious effect on protein function. SHRSPGla and WKYGla 
QTL regions for blood pressure, left ventricular index, and stroke as well as 
other QTLs for blood pressure and stroke from other rat strains were used to 
prioritise candidate genes. In addition, the consistent consequence prediction in 
the BN new reference genome Rnor 5.0 were also used to prioritised SHRSPGla 
unique non-synonymous (Table 4-9) and frame shift (Table 4-10) INDELs. 
 
Table  4-9 SHRSPGla unique non-synonymous INDELs compared to 27 NGS rat genomes. 
 
 
 
Table  4-10 SHRSPGla unique frame shift INDELs compared to 27 NGS rat genomes. 
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4.3.8 SHRSP rat strains STAR SNPs analysis 
Five SHRSP rat stains SNPs from STAR data were compared to each other against 
BN reference genome RGSC 3.4. Figure 4-15 shows that a high proportion of SNPs 
were common among SHRSP rat strains 
 
 
 
Figure  4-15 STAR data analysis among SHRSP rat strains. 
Venn diagram of 5 SHRSP rat strains STAR data SNPs in which it shows high proportion of SNPs 
were common between all SHRSP rat strains. 
  
134 
 
4.4 Discussion  
Even though the BN and WKYGla are normotensive rats and the SHRSP derived 
from the WKY strain, the WKYGla strain has more genomic variants compared to 
reference BN than to SHRSPGla. Nevertheless, another WKY strain (WKYNHsd), also 
has more genomic variants than SHRSPGla and WKYGla when compared to BN 
reference genome (Atanur et al., 2013). This suggests that the two WKY strains 
are genetically different from BN reference genome than the SHRSPGla; 
nonetheless, these genomics differences do not have an effect on blood pressure 
regulation. Nevertheless, a large number of sequence variants is common 
between SHRSPGla and WKYGla. This observation is further validated by 
phylogenetic analyses performed by Atanur et al., 2013 in which both strains 
belong to the same subtree that derived from Japanese Wistar strains, models 
for hypertension. In addition, density distribution analysis of genomic variants 
revealed regions on all rat chromosomes with either low clusters or no SNPs and 
INDELs, which also suggesting that these regions are shared by descent. 
Moreover, the non uniform peak pattern of SNPs and INDEL tracks across the 
genome suggests that they are likely to be correlated, a phenomenon observed 
also in another Japanese Wister derived strain SHROlalpcv (Atanur et al., 2010). 
SHRSPGla and WKYGla are inbred rat strains over several generations and they are 
expected to be homozygous at every locus in the genome. However, a 
percentage of 3.04 SNPs and 3.09 INDELs in WKYGla and 3.09 SNPs and 9.25 
INDELs in SHRSPGla were detected in heterozygous state. Possible explanations of 
heterozygous sequence variants are combinations of 1) biological true positive 
due to de novo mutations and incomplete inbreeding 2) technical false positive 
due to sequencing errors, mapping errors in problematic regions that suffer from 
CNV and highly repetitive sequence (Atanur et al., 2010; Simonis et al., 2012; 
Atanur et al., 2013). Guo et al., 2013 Sanger sequenced 45 NGS heterozygous 
SNPs and found that 6 were true positive while 39 were false positive, suggesting 
that caution should be taken into account when analysing NGS heterozygous 
sequence variants.  
Functional annotation by Ensembl variants effect predictor showed that 
sequence variants of SHRSPGla and WKYGla are higher in intergenic and intronic 
regions compared to the exonic region the same is observed in SHROlalpcv (Atanur 
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et al., 2010), Dark Agouti (DA) and Fischer (F344) rat strains (Guo et al., 2013). 
This is most likely to the evolutionary pressure on protein coding genes, 
something that could explain the selective sizes of INDEL that are biased (triplet) 
towards the reading frame. 
The functional implication of biological and canonical pathways’ results from IPA 
of all SHRSPGla and WKYGla NGS sequence variants captured some of the SHRSPGla 
phenotypes. Isolating validated QTLs regions implicated protein coding variants 
and these are also likely to be causative for SHRSPGla phenotypes. 
The new BN assembly Rnor 5.0 improved in both base pairs sequence and total 
length when compared to the BN assembly RGSC 3.4. When our NGS short reads 
mapped to both BN old and new assemblies, there were additional bases mapped 
with the new BN reference 1.71 Gb for WKYGla and 1.34 Gb for SHRSPGla. There 
was also an improvement of at least 0.50x of average coverage in both SHRSPGla 
and WKYGla. Moreover, from variant sequences that are unique between SHRSPGla 
and WKYGla total 1,295,337 SNPs and 382,972 INDELs in the new BN assembly 
Rnor 5.0; this is more than the 1,163,332 SNPs and 213,130 INDELs with BN 
assembly RGSC 3.4. Variant effect predictor annotation 71 was also improved to 
give more defined consequences of sequence variants when compared to the 
previous version 69. The improvement of the reference genome was reflected in 
our genes of interest. For example in Spp1, new regions show sequence variants 
of interest and in Hsd3b5 sequence gap was closed with BN new assembly Rnor 
5.0. 
The quality control results between the NGS and sequence capture when 
compared to RGSC 3.4 showed that 75% of the SNPs are common. This might be 
due to the design of the sequence capture bait in a way that maximizes the 
coverage area by focusing more on the exonic regions over intragenic regions 
resulting in more unique SNPs to the NGS analysis. In addition, sequence capture 
has unique SNPs because the NGS reads in one of the strain is not sufficient to be 
identified as a SNP, this is likely to be due to sequence capture much deeper 
coverage. The quality assessment of STAR Consortium data of true and 
comparable SNPs against NGS variants of SHRSPGla and WKYGla compared to RGSC 
3.4 confirmed that 99.3% of these SNPs are true positive (Saar et al., 2008). Both 
NGS data and sequence capture performed well in detecting Sanger sequencing 
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variants between the SHRSPGla and WKYGla; however, sequence capture detected 
more variants than NGS data which might be due to its higher coverage resulting 
in higher sensitivity and specificity. Some unique NGS SNPs and INDELs between 
SHRSPGla and WKYGla might not be called due to not fulfilling the sequence 
variants calling cut-off. Using IGV to manually browse reads across genes of 
interest can identify such variants which should be further validated by Sanger 
sequencing. 
The frequencies of large deletions are much more common in the WKYGla when 
compared to SHRSPGla against BN reference genome RGSC 3.4 this is the same 
with WKYNCrl and WKYNHsd (Atanur et al., 2013). For the purpose of this study, 
unique large deletions in the SHRSPGla were prioritised. The large deletions in 
SHRSPGla, which are more common in 100-200kb, would either result in partial 
and/or complete deleted 478 genes. The read length of paired-end whole-
genome which is 75 bp in SHRSPGla and 100 bp in WKYGla with libraries of 
different insert size can have an impact on the accuracy of the identified 
structural variations. Guo et al., 2013 estimated that the accuracy of detected 
structural variant of one insert size library had 45-50% sensitivity. As a result, 
having multiple insert sizes of both small and large can increase the sensitivity 
of the detected structural variants (Atanur et al., 2010). Several groups have 
reported CNV can correlate with gene expression levels in mouse (Yalcin et al., 
2011), rats (Guryev et al., 2008; Charchar et al., 2010; Simonis et al., 2012) and 
humans (Stranger et al., 2007) such integration can used as a reductive approach 
to prioritise causative candidate genes for SHRSPGla phenotype. 
When comparing SNPs from SHRSPGla, WKYGla and SHROlaIpcv against the BN 
reference assembly RGSC 3.4, the intersection that is shared by all, has the 
highest proportion of SNPs which fits the WKY clade and supports that these 
strains are similar evolutionary and genetically. Additionally, the SNPs in the 
common shared intersection between the SHRSPGla and SHROlaIpcv can be 
prioritised as potentially hypertensive causal SNPs. Furthermore, SNPs that are 
unique to SHRSPGla might be the causative of stroke-prone phenotype, 
nevertheless, another reductive strategy is needed to work with sensible 
variants number.  
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To further enrich for causative sequence variants of stroke-prone phenotype 
sequence variants, SHRSPGla were compared to 27 rat genomes against BN 
reference genomes RGSC 3.4. To assess whether the protein coding sequence 
variants that are unique to the SHRSPGla contribute to the SHRSPGla 
cardiovascular phenotypes, we used our validated QTL regions on chromosome 2, 
3 and 14 as well as QTL 5 for stroke to identify positional and functional 
candidate gene or genes. Consistency of sequence variants consequence 
prediction in the BN new reference genome Rnor 5.0 and SIFT deleterious 
predication non-synonymous SNPs were also prioritised. Moreover, we 
investigated whether the implicated gene encompassed a rat cardiovascular QTL 
and identified the most relevant citation that describes the implicated function.  
SHRSPGla unique non-synonymous SNPs with predicted deleterious effect on 
protein function implicated dentin matrix acidic phosphoprotein 1 (Dmp1) and 
solute carrier family 10, member 6 (Slc10a6) within our congenic regions on 
chromosome 14, and olfactory receptors 847 (Olr847) 852 (Olr852) within our 
stroke QTL. Dmp1 is a protein important in the mineralization of tissues; 
mutations within this gene in humans or complete genetic ablation in knock-out 
mouse resulted in hypophosphatemic rickets (low levels of phosphate in the 
blood) and elevated levels of fibroblast growth factor 23 (Rangiani et al., 2012) 
which induced left ventricular hypertrophy (Faul et al., 2011). Slc10a6 has no 
known function that can cause LVH; nonetheless, it has been implicated with 
insulin resistance in a genome wide association study (Chen et al., 2012). The 
olfactory receptor genes which are responsible for detection of odour, form the 
largest gene family. However, we did not find a study implicating these genes in 
stroke. ATP-binding cassette, subfamily A (ABC1), member 1 (Abca1) was 
candidate gene to have a damaging effect on non-synonymous SNP at the border 
line score that mapped to our stroke QTL. Abca1 protein functions as cholesterol 
efflux pump, and the mouse knock-out model had higher instance of developing 
left and right ventricular hypertrophy (Christiansen-Weber et al., 2000), while 
mutations within Abca1 increased the risk of stroke (Pasdar et al., 2007) 
We extended the stroke candidate genes analysis in the SHRSPGla to include 
deleterious non-synonymous SNPs within stroke QTLs of other SHRSP rat strains 
in which we identified two genes. One of these genes was the Ets2 repressor 
factor (Erf), a member of the EST family that regulates cell proliferation and 
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differentiation. Mutations in Erf have been associated with premature closure of 
the lambdoid cranial sutures (craniosynostosis) (Twigg et al., 2013), and knock-
out mouse model developed hypoplasia of forebrain and anaemia (Papadaki et 
al., 2007) which increases significantly the risk for stroke (Maguire et al., 2007). 
Another implicated gene is Ras and Rab interactor-like (Rinl); however, this gene 
it does not have a relevant function to stroke. Nevertheless, it was recently 
published that NGS non-synonymous SNPs of SHRSPizm within its stroke QTL 
(Gandolgor et al., 2013) and two of these SNPs are common with deleterious 
SNPs that are unique to the SHRSPGla. These SNPs are mapped to Rinl and MHC I 
like leukocyte 1 (Mill1) which have been predicted to be involved in nutrient 
metabolism (Rabinovich et al., 2008). Another interesting non-synonymous SNP 
in a gene that does lie within stroke QTLs but function for stroke is plasminogen 
(Plg). Plg protein has an important role in dissolving blood clots and inhibiting 
angiogenesis; defects in this gene are likely to cause hypertension (Levi et al., 
2001) and/or stroke (Su et al., 2008) 
SHRSPGla unique stop gain SNP implicated stromal interaction molecule 1 (Stim1) 
within other SHRSP stroke QTL and one for blood pressure. STIM1 protein 
mediates store operated calcium channels which plays an important role in 
arterial thrombosis and ischemic brain infarction (Varga-Szabo et al., 2008). 
Recently, Stim1 was identified as candidate gene for stroke in the SHRSPIzm strain 
which harbour the same stop gain SNP identified by our analysis (Ferdaus et al., 
2014). 
SHRSPGla unique non-synonymous INDELs implicated coiled-coil domain 
containing 97 (Ccdc97) and predicted gene Loc30401 within QTL stroke of other 
SHRSP strains; however, no relevant function was found. Finally, frame shift 
INDELs that are unique to SHRSPGla implicated ATPase, class VI, type 11B 
(ATP11b) within our QTL for blood pressure. ATP11b is involved in the transport 
of aminophospholipid and ions across membranes, a function that can be 
important in the regulation of blood pressure. 
STAR Consortium SNPs of the five SHRSP rat strains against BN RGSC 3.4 analysis 
shows that high proportion of SNPs are common; suggesting close phylogenetic 
proximity between these SHRSP rat strains. As we prioritised SHRSPGla unique non 
synonymous SNPs that are common with SHRSPizm, we can extend this to other 
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SHRSP rat strains to further prioritised sequence variants on whole genome level. 
Furthermore, over 600 inbred strains on Rat genome Database and in the near 
future these strains will be sequenced and comparing these with SHRSPGla unique 
sequence variants will further prioritise candidate genes for SHRSPGla phenotype.  
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5 Integration of transcriptomic and genomic 
variants to prioritise candidate genes in Rat and 
translation to Human
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5.1 Introduction 
Single dimension -omic data have proven beneficial in the identification of 
candidate genes, however, they may lead to complex, less reliable, and/or 
misleading biological interpretation when compared to more integrated 
approaches. It is a common belief that the overall surveillance of multiple 
biological systems, through the integration of genomic, transcriptomic and 
proteomic data, can facilitate a better biological interpretation which will 
eventually lead to the identification of prioritised candidate genes for the 
SHRSPGla phenotype from an improved analysis to translate in human and vice 
versa.  
The integration of different types of genomic variants and transcriptomic across 
tissues and time points at QTLs and genome level is helpful to understand, study 
and elucidate the genetic architecture of complex disease including 
hypertension in SHRSPGla. This posed a challenging task before the availability of 
NGS of SHRSPGla and WKYGla genomes.  
The identification of NGS sequence variants in our strains is beneficial for 
designing PCR assays primers and private microarray probes. The latter can be 
extended to public microarray probes by the identification of sequence variants 
within probes' target region which may alter probe hybridisation affinities 
leading to false results (Benovoy et al., 2008). Therefore, research groups such 
as Tim Aitman's, customised their public microarray gene expression chip to be 
unique to their rat strains, and the affected probes were masked/filtered to 
improve the analysis (Maratou et al., 2011). Although this issue can be solved by 
mRNA profiling using NGS on our rat strains, over the years we have compiled a 
transcriptomic library cataloguing thousands of differentially expressed genes 
between SHRSPGla and WKYGla across tissues, times points and their response to 
salt using Affymetrix and Illumina chips. 
Reductive methods have been proposed to identify and prioritise candidate 
genes from high-throughput transcriptomic data (Lombard et al., 2007) and 
genomics data (Jaffe et al., 2011) separately but not for integrating the two 
omics fields. Hence, we are proposing the Swiss cheese model as an integrative 
and reductive method to identify candidate genes for SHRSPGla phenotype 
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(Figure 5-1). The model consists of an integrational approach for prioritising 
predicted protein coding sequence variants with positional and functional renal 
and cardiac differentially expressed genes that could potentially contribute to 
blood pressure regulation and cardiac mass in the SHRSPGla. 
 
 
Figure  5-1 Swiss Cheese model: reductive and integrative method. 
The pipeline starts with high number of unique genomic variants that are more likely to cause 
loss/gain of protein function. Then the resulted candidate genes should be significant differently 
expressed, using cut-offs of p-value < 0.05 and fold change > 2-fold, across time points and tissues 
within our QTLs. Functional and biologically relevance of the resulted candidate genes will be 
assessed and validate. If the genes passed all these criteria then the genes will be qualified to be 
candidate for SHRSPGla phenotype. 
 
There is no one perfect integrative method for transcriptomic and genomics 
data. Thus, utilising publicly availably related -omics data can be used as 
reductive and integrative method. Knowing that the SHRSPGla have exceptionally 
higher blood pressure and cerebral stroke compared to the 27 rats that were 
sequenced in Atanur et al., 2013 including SHR strains. The integration of 
isolated SHRSPGla unique sequence variants with transcriptomic brain data across 
frontal and mid-coronal sections and age between SHRSPGla and WKYGla (Bailey et 
al., 2014) can serve as another integrative approach to isolate candidate genes 
causing hypertension and stroke in the SHRSPGla. 
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Clinician and geneticist may argue whether the SHRSP still useful model to 
identify candidate genes for hypertension when GWAS in human genome can 
directly accomplish this (Nabika et al., 2012). However, implicating human GWAS 
candidate genes in the SHRSPGla at functional related regions, with sequence 
variations which are differentially expressed across tissues and age can further 
prioritise a more promising candidate genes for blood pressure and hypertension 
which are conserved between rat and human. 
Recently, the role of miRNA targeting the renin-angiotensin-aldosterone system, 
vascular smooth muscle cells as well as endothelial and renal cells in human and 
rat for hypertension was studied (Batkai & Thum, 2012).Expression profiling of 
renal miRNA and mRNA between hypertensive human patients and control were 
integrated to identify and demonstrated that miRNAs can regulate renin 
expression (Marques et al., 2011). The identification of differentially expressed 
mir-181a miRNA and its targeted renin gene as candidate for hypertension in 
human (Marques et al., 2011) were translated with the same level of expressions 
in BPH/2J genetically hypertensive mice confirming their contribution in 
hypertension (Jackson et al., 2013). 
The availability of human hypertensive expression profiling of renal miRNA and 
mRNA data (Marques et al., 2011) is a rare valuable translational opportunity to 
integrate with SHRSPGla and WKYGla renal miRNA and mRNA to prioritise and 
translate conserved candidate miRNA and mRNA for hypertension. Even though 
human renal (medulla and cortex section) expression profiling for mRNA and 
miRNA expression profiling analysis in Marques et al., 2011 were corrected for 
ethnicity, age, weight, however, the p-value cut-off used in all comparisons was 
not consistent, and all above 0.1 as oppose to the standard < 0.05. It is unclear 
why the authors did so; however, previously Marques et al., 2010 published a 
meta analysis on all public transcriptomic data of hypertensive rats where some 
of the identified genes were later validate candidate genes for hypertension in 
human (Marques et al., 2011). 
Human tissue availability for hypertension studies is severely restricted, making 
it hard to obtain samples for our renal and cardiac translation. Thus, cardiac 
transcriptomic data for heart failure is the next best data available to integrate 
with our rat strains data in order to prioritise and translate cardiac candidate 
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genes. However, our rat strains do not have a heart failure phenotype at the 
ages measured; nevertheless, given the fact the genes differently expressed 
consistently from early time till the hypertrophy phenotype established, this 
might lead eventually to heart failure at older age. 
 
5.2 Aims 
This chapter specific aims are: 
o To integrate cardiac and renal transcriptomic data with genomics variants 
between SHRSPGla and WKYGla and examine which types of genomic 
variants are likely to alter transcriptomic output at genome wide and 
congenic regions. 
o To assess the improvements of gene expression analysis utilising SHRSPGla 
and WKYGla sequence variants to customising public gene expression chips  
o To apply our reductive and integrative Swiss cheese model to prioritise 
candidate genes that control blood pressure in the SHRSPGla. 
o To isolate blood pressure and stroke candidate genes in SHRSP by the 
integration of SHRSPGla unique sequence variants compared to 27 rat 
genomes and brain gene expression data.  
o To assess how informative the SHRSPGla compared to human GWAS 
candidate genes for blood pressure and hypertension.  
o To translate renal and cardiac candidate genes and miRNA from our rat 
strains and human and vice versa. 
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5.3 Results 
5.3.1 Prioritising rat candidate genes 
A number of integrative approaches were used to prioritise candidate genes for 
the SHRSPGla. 
 
5.3.1.1 Integration of rat transcriptomic data and genomic variants between 
SHRSPGla and WKYGla  
The integration of transcriptomic data and different types of genomic variants 
data between SHRSPGla and WKYGla were combined using IPA to investigate a 
potential direct relation. Significantly differentially expressed genes in the heart 
of neonates (486 genes), at 5 weeks (182 genes) and at 16 weeks of age (330 
genes), as well as in the kidney at 16 weeks of age (482 genes) and at 21 weeks 
of age (1,172 genes) were combined with different types of genomic variants. 
 
5.3.1.1.1 Integration of transcriptomic data and small sequence variants between 
SHRSPGla and WKYGla 
 
Affected genes with small sequence variants that mapped to IPA for SNP and 
INDEL, in coding and non-coding regions, were compared to renal and cardiac 
transcriptomic data at different time points. Overlapping genes were assessed 
for implication in our congenic regions (Figure 5-2). The highest proportion of 
overlapping genes in both tissues was affected by non-coding variants, especially 
upstream, downstream, in intronic and splice sites – this included genes within 
our congenic regions and the proportion affected by coding variants especially 
stop lost/gained, frameshift and essential site splice. 
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Figure  5-2 Integration of transcriptomic data and small sequence variants. 
Top left; affected genes with small sequence variants (SNPs and INDELs) in coding and non coding regions with different predictive consequences between SHRSPGla 
and WKYGla. Top right; gene expression data of SHRSPGla and WKYGla from kidney and heart at different time points. Bottom circles; genes common between 
transcriptomic data and small single genomic variants as well as genes mapped to our congenic regions. 
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5.3.1.1.2 Integration of transcriptomic data and structural variants 
 
To investigate other types of genomic variants that were likely to alter gene 
expression levels, we combined transcriptomic data with structural variants 
between SHRSPGla and WKYGla using IPA. 
 
5.3.1.1.2.1 Integration of transcriptomic data and large deletions 
 
Subsequently, we combined partially and/or fully deleted genes that were 
unique to SHRSPGla (273 genes) and WKYGla (1,583 genes), with transcriptomic 
data from SHRSPGla and WKYGla, using IPA (Figure 5-3). The highest proportion of 
overlapping genes was observed between large deletions unique to WKYGla 
(including genes within our congenic regions) and large deletions unique to 
SHRSPGla.  
 
5.3.1.1.2.2 Integration of transcriptomic data and copy number variations 
 
We decided to combine CNV with transcriptomic data from SHRSPGla and WKYGla 
using IPA (Figure 5-4, Figure 5-5). Genes affected by CNV duplications in SHRSPGla 
(Figure 5-5) and CNV deletions in WKYGla (Figure 5-4) had the highest proportion 
of significantly differentially expressed genes in both tissues at different time 
points, including genes mapped to our congenic regions. Furthermore, structural 
variations of copy number overlapped more with genes that present with 
changes in expression levels, including genes mapping to our congenic regions 
rather than large deletions. 
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Figure  5-3 Integration of transcriptomic data and large deletions. 
Left; Venn diagram of large deletions, showing genes unique and common between the SHRSPGla and WKYGla. Right; significantly differentially expressed genes from 
kidney and heart at different time points between SHRSPGla and WKYGla. Top and bottom circles; overlapping genes as well as genes implicated in our congenic 
regions.
149 
 
 
 
 
Figure  5-4 Integration of transcriptomic data and CNV of deletion. 
Combining CNV of deletions with transcriptomic data between SHRSPGla and WKYGla revealed that more significantly differentially expressed genes overlapped with 
CNV of deletions unique to WKYGla, including genes within our congenic regions than SHRSPGla.  
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Figure  5-5 Integration of transcriptomic data and CNV of duplication. 
Combining CNV of duplications with transcriptomic data between SHRSPGla and WKYGla showed more significantly differentially expressed genes overlapped with CNV 
deletions unique to SHRSPGla including genes within our congenic regions than WKYGla.
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5.3.1.2 Improvement of microarray analysis by utilising NGS sequence 
variants. 
5.3.1.2.1 Utilising NGS data to improve rat Affymetrix microarray analysis 
 
We then assessed the potential of optimisation of the Affymetrix microarray by 
removing probes whose targeted regions harboured SNPs, and therefore, could 
lead to false results. Significantly differentially expressed genes of chromosomes 
2 congenic strain (SP.WKYGla2a) versus SHRSPGla at 21 weeks of age in kidney 
identified using custom Affymetrix chip description file (CDF) unique to our 
strains were compared to default (BrainArray) Affymetrix CDF. The overall result 
revealed a 23% difference between the two Affymetrix CDF. Moreover, additional 
positional candidates were identified from the custom CDF when the results 
were filtered with regards to the SP.WKYGla2a congenic interval (Figure 5-6).  
 
 
 
 
 
Figure  5-6 Integration of transcriptomic data with sequence variants to improve microarray 
analysis. 
Affymetrix CDF unique to our strains analysis had an impact on overall results when compared to 
the default (BrainArray) Affymetrix CDF analysis between chromosome 2 congenic strain and 
SHRSPGla at 21 weeks of age in kidney including positional candidate genes. The two different 
CDF analysis were conducted on Partek® Genomic Suite using a cut-off of FDR <0.05. 
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5.3.1.2.2 Integrating Illumina rat expression BeadChip probes with NGS SNPs 
 
We assessed the optimisation of microarray analysis of our rat strains on Illumina 
platform. 633 probes out of 24,000 total probes/array, whose targeted regions 
harbour SNPs, were identified and integrated with our QTL/congenic regions on 
chromosome 2, 3 and 14. Genes mapped to affected Illumina rat probes' within 
our congenic regions were identified by using IPA, which should be removed to 
customised Illumina rat BeadChip to our rat strains (Figure 5-7). 
 
 
 
 
Figure  5-7 Utilising NGS data to identify affected probes on rat Illumina BeadChip. 
Affected Illumina rat probes (663 probes), that mapped to 302 genes in IPA, were integrated with 
our congenic regions of chromosome 2 (25 genes), 3 (8 genes) and 14 (9 genes).  
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5.3.1.2.2.1 qRT-PCR validation of genes whose probes’ region harbour SNPs 
 
In order to investigate the microarray analysis of our rat strains on the Illumina 
platform, we validated our results by performing qRT-PCR analysis. qRT-PCR 
analysis was performed on genes in which their Illumina rat probes' region 
contained SNPs within our congenic regions that should be removed to avoid 
false positive results. Our data demonstrated that the expression of Gstm1, 
previously identified as functional and positional candidate gene in the SHRSPGla, 
mRNA levels was significantly elevated in the 21 weeks of age kidney of WKYGla 
when compared to SHRSPGla (Figure 5-8), although this could have been done at 
other age of animals (McBride et al., 2003; McBride et al.,2005). Similarly, we 
observed a significant increase at the protein tyrosine phosphatase, non-
receptor type 13 (Ptpn13), potential positional candidate gene for LVF which 
maps to LVMI QTL on chromosome 14, mRNA expression in the 16 week heart at 
16 weeks of WKYGla compared to SHRSPGla. Statistical analysis was performed by 
using the Student’s t-test.  
 
 
 
Figure  5-8 qRT-PCR validation of genes whose probes’ region harbour SNPs 
a) Gstm1 is significantly elevated in WKYGla when compared to SHRSPGla at 21 weeks of age in 
kidney. b) Ptpn13 is significantly elevated in WKYGla when compared to SHRSPGla at 16 weeks of 
age in heart. *P<0.05. 
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5.3.1.3 Application of "Swiss cheese" integrative and reductive model in our 
rat strains 
5.3.1.3.1  "Swiss cheese" candidate genes for the SHRSPGla phenotype 
 
Protein coding variants; 769 non-synonymous coding, 5 stop gained, 24 frame 
shift coding variants within chromosome 2, 3, and 14 congenic regions were 
associated with significantly differently expressed positional candidate genes; 
Gstm1, Fubp3, Ugt2b7, and Afm in kidney and Atp6ap1l and Gpr98 in heart 
(Table 5-1). 
 
Table  5-1 Integrative and reductive “Swiss cheese” model candidate genes. 
 
 
 
5.3.1.3.1.1 NGS variants in prioritised "Swiss cheese" candidate genes  
 
The "Swiss cheese" model candidate genes - Fubp3, Ugt2b7, Afm, and Gpr98 - 
were prioritised for further analysis. These genes also harboured sequence 
variants in important non coding protein regions which could also contribute to 
the differential gene expression levels between SHRSPGla and WKYGla (Table 5-2, 
Table 5-3, Table 5-4, and Table 5-5). 
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Table  5-2 Fubp3 variants between SHRSPGla and WKYGla compared to BN RGSC 3.4 
assembly. 
 
 
 
Table  5-3 Ugt2b7 variants between SHRSPGla and WKYGla compared to BN RGSC 3.4 
assembly. 
 
 
 
Table  5-4 Afm variants between SHRSPGla and WKYGla compared to BN RGSC 3.4 assembly. 
 
 
 
Table  5-5 Gpr98 variants between SHRSPGla and WKYGla compared to BN RGSC 3.4 
assembly. 
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5.3.1.3.1.2 Validation of prioritised “Swiss cheese” candidate genes by using qRT-PCR 
 
The “Swiss cheese” model prioritised candidate genes Ugt2b7 and Afm, were 
further validated by qRT-PCR. Ugt2b7 and Afm mRNA level expression in kidney 
at 21 weeks of age and Ugt2b7 at 16 weeks of age were significantly elevated in 
WKYGla when compared to SHRSPGla. However, the expression of Fubp3 mRNA 
levels in kidney at 16 and 21 weeks of age showed no significant changes 
between SHRSPGla and WKYGla (Figure 5-9), nevertheless, the trend of fold 
change supports the microarray results (data not shown). Furthermore, Gpr98 
mRNA levels were not detectable in the hearts of neonates, or at 5 and 16 weeks 
of age using qRT-PCR in both SHRSPGla and WKYGla. Statistical analysis was 
performed by using the Student’s t-test.  
 
 
Figure  5-9 qRT-PCR of Swiss cheese candidate genes in kidney at 16 and 21 weeks of age of 
SHRSPGla and WKYGla strains. 
At 21 weeks of age a) the expression pattern of Fubp3 shows no significant change between 
SHRSPGla and WKYGla. However, mRNA levels in b) Ugt2b7 and c) Afm is significantly elevated in 
WKYGla when compared to SHRSPGla. At 21 weeks of age d) Fubp3 shows no significant change 
between our rat strains, however, e) Ugt2b7 is significantly elevated in WKYGla when compared to 
SHRSPGla. *P<0.05. 
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5.3.1.3.1.3 Troubleshooting Gpr98 experimental data result 
 
Further investigation of the Gpr98 qRT-PCR results was carried out by using the 
Ensembl gene annotation versions 69 and 71 and visualising the mapped NGS 
reads in Gpr98. Ensembl annotation version 69 of BN RGSC 3.4 assembly assigned 
the Ensembl gene id for Gpr98 as ENSRNOG00000016306; this has been changed 
in Ensembl annotation version 71 for new BN Rnor 5.0 to novel gene and Gpr98 
has been assigned a different Ensembl id (ENSRNOG00000046496). The 
discrepancy between the Gpr98 Ensembl ids may have affected the probe 
design, and this could explain why the qRT-PCR result did not validate. 
Additionally, an explanation regarding the qRT-PCR result in SHRSPGla, could be 
the large deletion of 2,199 bp in the SHRSPGla (Figure 5-10). 
 
Figure  5-10 Trouble shooting of Gpr98 experimental data. 
a) Ensembl gene id for Gpr98 in a1) BN RGSC 3.4 assembly differ than Ensemble gene id in a2) 
BN Rnor 5.0. b) NGS unmapped (white gap) reads (represented in grey) of Gpr98 indicating large 
deletion in SHRSPGla when visualised by IGV, but, that is not the case in the WKYGla. 
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5.3.1.4 Integrating SHRSPGla unique small sequence variants with brain gene expression between SHRSPGla and WKYGla. 
In order to prioritise stroke candidate genes in SHRSPGla, we integrated unique small sequence variants to the SHRSPGla when compared 
to 27 rat strains genome (Atanur et al., 2013) with previously published transcriptomic data of SHRSPGla and WKYGla frontal and mid-
coronal brain sections at different time points (Bailey et al., 2014) and salt loaded analysed with Rank Products (Breitling et al., 2004) 
and FDR cut-off of <0.05. SHRSPGla and WKYGla QTL regions for blood pressure, left ventricular index, and stroke as well as stroke QTLs 
from other rat strains on RGD were used to prioritise stroke candidate genes in the SHRSPGla (Table 5-6). 
Table  5-6 Integrating SHRSPGla unique variants compared 27 genome sequence rat strains with brain gene expression of SHRSPGla and WKYGla. 
 
Continued 
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Continued 
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(wk) short for weeks of age and (salt) short for salt loaded. 
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5.3.2 Prioritising human candidate genes 
5.3.2.1 Translation of candidate genes/miRNA from human to rat and vice versa 
5.3.2.1.1 Human GWAS genes for blood pressure and hypertension integrated with SHRSPGla and WKYGla transcriptomic and genomic data 
 
Subsequently, we attempted to translate human GWAS candidate genes for blood pressure and hypertension to our rat strains. We 
assessed whether a total of 72 genes map to rat genome, blood pressure QTLs, harbour functional small sequence variants and if they 
are significantly differentially expressed between SHRSPGla and WKYGla in kidney and heart tissues (Table 5-7). 
Table  5-7 Human GWAS of blood pressure and hypertension candidate genes integrated with SHRSPGla and WKYGla transcriptomic and genomic data. 
 
Continued 
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Continued 
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Symbol () indicates genes/probes map to the genome, symbol () indicates gene and/or probe does not map to the genome, (wk) 
short for weeks of age and (neo) short for Neonates. Human GWAS genes for blood pressure and hypertension obtained from a number of 
studies (Levy et al., 20091; Newton-Cheh et al., 20092; Padmanabhan et al., 20103; Ehret et al., 20114; Johnson et al., 20115; Kato et 
al., 20116; Wain et al., 20117; Salvi et al., 20128; Franceschini et al., 20139).
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5.3.2.1.1.1 qRT-PCR analysis of genes common between integrating human GWAS genes 
blood pressure and hypertension SHRSPGla and WKYGla transcriptomic and 
genomic data 
 
Human GWAS genes for blood pressure and hypertension Gucy1a3 and Gucy1b3 
were prioritised for qRT-PCR validation. Gucy1a3 and Gucy1b3 mapped to the rat 
genome and to the QTL for blood pressure in SHRSPGla and WKYGla strains while 
harbouring small genomic variants and differentially expressing in relevant 
tissues to hypertension. qRT-PCR of Gucy1a3 and Gucy1b3 showed no significant 
changes in mRNA level between SHRSPGla and WKYGla in heart at 5 and 16 weeks 
of age (Figure 5-11). 
 
Figure  5-11 qRT-PCR of translated candidate genes for blood pressure from human GWAS 
to our rat strains. 
At 5 weeks of age the mRNA expression level of a) Gucy1b3 b) Gucy1a3 in heart shows no 
significant change between SHRSPGla and WKYGla. At 16 weeks of age the mRNA expression level 
of c) Gucy1b3 d) Gucy1a3 in heart shows no significant change between SHRSPGla and WKYGla. 
*P<0.05. 
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5.3.2.1.1.2 Troubleshooting Gucy1a3 and Gucy1b3 experimental data 
 
To investigate why the experimental data of qRT-PCR of Gucy1a3 and Gucy1b3 
did not match with the microarray results between SHRSPGla and WKYGla in heart 
at 5 and 16 weeks of age, we followed the subsequent strategy. We identified 
variants of SHRSPGla and WKYGla within significant Affymetrix and Illumina probes' 
targeting regions as they could lead to false results (Table 5-8). Gucy1a3 
significant probes; in kidney only at 21 weeks of age with Affymetrix and in heart 
at all time points with Illumina. Both of these significant probes' target region, 
from two platforms, are affected by harboured sequence variants; however, 
each was affected by a different SNP. Gucy1b3 significant probe in heart at 5 and 
16 weeks of age with Illumina platform was not affected by variants within its 
targeted region. 
Table  5-8 Troubleshooting Gucy1a3 and Gucy1b3 microarray probes' target region 
 
 
In addition, to further investigate why the experimental data of qRT-PCR of 
Gucy1a3 and Gucy1b3 did not match the microarray results between SHRSPGla 
and WKYGla in heart at 5 and 16 weeks of age, we looked for evidence of 
alternate splicing of Gucy1a3 and Gucy1b3 using rat Affymetrix Exon ST array in 
heart at 5 and 16 weeks of age (previously generated data by our group) (Figure 
5-12). Gucy1a3 microarray transcript cluster probe ID (7210088) signal intensity, 
which is a relative measure of expression of the transcript is significantly higher 
level in SHRSPGla than WKYGla at the last exon (exon 9)/3' UTR in heart at 5 and 
16 weeks of age (Figure 5-12A1-A2). Taqman gene expression probe 
(Rn00367252) for Gucy1a3 gene span over exons 6 and 7 (Figure 5-12A3) which 
may not detect the alternative splicing at exon 9/3' UTR between SHRSPGla and 
WKYGla in heart at 5 and 16 weeks of age. There is no evidence of alternative 
splicing for Gucy1b3 signal intensity between SHRSPGla than WKYGla in heart at 5 
and 16 weeks of age (Figure 5-12B1-B2). However, overall probes signal intensity 
of Gucy1b3 gene is higher in the WKYGla than SHRSPGla in heart at 5 and 16 weeks 
of age. Gucy1b3 Taqman gene expression probe (Rn00562775) map to span over 
166 
 
 
exons 3 and 4 which has the little change of signal intensity between SHRSPGla 
than WKYGla in heart at both time point (Figure 5-12B3) 
 
 
Figure  5-12 Troubleshooting Gucy1a3 and Gucy1b3 using rat Affymetrix Exon ST array. 
a) Gucy1a3 signal intensity from the exon array between SHRSPGla and WKYGla in heart shows 
evidence of alternative splicing at a1) 5 weeks of age and a2) 16 weeks of age in which a3) 
Gucy1a3 Taqman gene expression probe does not span over the affected exon. b) Gucy1b3 signal 
intensity from the exon array between SHRSPGla and WKYGla in heart shows no evidence of 
alternative splicing but an overall change at b1) 5 weeks of age and b2) 16 weeks of age in which 
b3) Gucy1b3 Taqman gene expression probe spans over the least signal intensity difference 
between SHRSPGla and WKYGla at exon 3 and 4. 
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5.3.2.1.2 Integrating renal miRNA sequencing data from human and rat to prioritise 
hypertension candidate miRNA 
 
 
In order to translate differentially expressed renal miRNA between human to our 
rat, we integrated miRNA NGS renal data from normotensive and hypertensive 
subjects. The samples were derived from medulla and cortex sections and a 
whole kidney from WKYGla, chromosome 2 congenic (SP.WKYGla2c*, we call it 2c* 
for short) and SHRSPGla rat strains. Our data suggested that there was no 
common differential expression of miRNA between normotensive and 
hypertensive from human and rat analysis (Table 5-9-Table 5-13). 
In human study, normotensive and hypertensive subjects have no common 
differentially expressed miRNA between renal sections; medulla and cortex 
(Table 5-9, Table 5-10). In our rat study, there was common differentially 
expressed miRNA in whole kidney between WKYGla versus SHRSPGla, 2c* versus 
SHRSPGla, and WKYGla versus 2c* strains (Table 5-11- Table 5-13).  
We searched for sequence variants within miRNAs, and then investigated miRNAs 
mapping to our congenic region to prioritise candidate miRNA for hypertension in 
our rat strains. In all rat comparisons, all miRNAs did not harbour sequence 
variants and none of them mapped to chromosome 2 (Table 5-11, Table 5-12, 
Table 5-13). 
We then investigated whether the identified differentially expressed miRNA 
targets positional genes mapped to chromosome 2. Significantly differentially 
expressed miRNAs between 2c* vers SHRSPGla were prioritised by integrating 
miRanda (Betel et al., 2008) predicted target genes mapped to chromosome 2 
congenic region (422 genes); these included genes with 3' UTR harbour sequence 
variants unique to SHRSPGla (928 genes), and renal gene expression at 16 and 21 
weeks of age of SHRSPGla and WKYGla (Table 5-14). 14 targeted positional 
candidate genes by differentially expressed miRNA between 2c* and SHRSPGla in 
which their 3 'UTR region harbour variants unique to SHRSPGla. Three of the 14 
positional genes have variants on or close to the predicted miRNA binding site 
and 3 genes implicated in renal gene expression data. Gucy1a3 and Gstm1 3' UTR 
along with 2c* versus SHRSPGla significant renal miRNA binding sites and sequence 
variants from SHRSPGla and WKYGla is showing in Figure 5-13 and Figure 5-14.  
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Table  5-9 Differentially expressed miRNA in human renal medulla between normotensive 
and hypertensive subjects. 
The fold change value is in log2 fold change. 
 
Table  5-10 Differentially expressed in human renal cortex between normotensive and 
hypertensive subjects. 
The fold change value is in log2 fold change. 
 
Table  5-11 Differentially expressed miRNA in rat kidney between SHRSPGla and WKYGla. 
The fold change value is in log2 fold change. 
 
Table  5-12 Differentially expressed miRNA in rat kidney between 2c* and SHRSPGla. 
The fold change value is in log2 fold change. 
 
Table  5-13 Differentially expressed miRNA in rat kidney between WKYGla and 2c* 
The fold change value is in log2 fold change. 
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Table  5-14 Positional targeted genes of differentially expressed miRNA in rat kidney between 2c* and SHRSPGla. 
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Figure  5-13 Predicted target sequence for miRNA binding site and small sequence variants between SHRSPGla and WKYGla within the 3' UTR of Gucy1a3 
mRNA. miRanda predicted binding sites are scored for likelihood of mRNA downregulation using mirSVR for differentially expressed miRNA in kidney between 2c* and 
SHRSPGla within Gucy1a3 3'UTR along with sequence variants between SHRSPGla and WKYGla  
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Figure  5-14 Predicted target sequence for miRNA binding site and small sequence variants between SHRSPGla and WKYGla within the 3' UTR of Gstm1 
mRNA. 
miRanda predicted binding sites are scored for likelihood of mRNA downregulation using mirSVR for differentially expressed miRNA in kidney between 2c* and 
SHRSPGla within Gstm1 3'UTR along with sequence variants between SHRSPGla and WKYGla. 
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5.3.2.1.3 Integrating heart gene expression data from human and rat to prioritise 
cardiac candidate genes 
 
In order to translate cardiac candidate genes between human heart failure to 
our rat strains, we integrated differentially expressed genes from SHRSPGla and 
WKYGla whole heart across 3 time points with differently expressed genes of two 
human heart failure data (Schinke et al., 2004; Greco et al., 2012).from left 
ventricular of the heart (Figure 5-15). 
 
Figure  5-15 Translation of cardiac candidate genes from rat to human. 
A) Cardiac SHRSPGla and WKYGla common differentially expressed genes in all time points 
overlapped with human heart failure 1 (Greco et al., 2012) resulted in common genes; Smoc2 and 
Lamc2 in which the fold change direction is the same in rat and human. B) Cardiac SHRSPGla and 
WKYGla common differentially expressed genes in all time points overlapped with human heart 
failure 2 (Schinke et al., 2004) in which only Smoc2 was in-common and the fold change direction 
is the same in rat and human. Human and rat data analysis were conducted on Partek® Genomic 
Suite using a cut-off of FDR <0.05 and fold change of 1.5. 
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5.3.2.1.3.1 Genomic variants of the translated cardiac candidate genes in human and 
rat. 
Functional sequence variants of common genes between human and rat heart 
data were identified and isolated for Smoc2 and Lamc2 from SHRSPGla and WKYGla 
NGS variants compared to BN RGCS 3.4 (Table 5-15 and Table 5-16). 
 
Table  5-15 SPARC related modular calcium binding 2 (Smoc2) SHRSPGla and WKYGla 
variants compared to BN assembly RGSC 3.4. 
 
 
 
Table  5-16 Laminin, gamma 2 (Lamc2) SHRSPGla and WKYGla variants compared to BN 
assembly RGSC 3.4. 
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5.3.2.1.4.1  qRT-PCR of the translated cardiac candidate genes in human and rat. 
 
Subsequently, we decided to further validate by qRT-PCR the potential cardiac 
candidate genes from human heart failure and our rats, Smoc2 and Lamc2. A 
collaborator at Paul Barton’s laboratory in Imperial College carried out these 
experiments.  
Samples were obtained from different dilated cardiomyopathy (DCM) heart 
failure stages; first ‘stable’ end-stage heart failure DCM (HSC), second ‘unstable’ 
end-stage HF – Left Ventricular Assist Device (IMP) that either on a recovery 
which had the device explanted (IMP-recovery) or non-recovery (IMP-non-
recovery) and donor left ventricular controls (DVL). qRT-PCR of Smoc2 and 
Lamc2 were conducted on SHRSPGla and WKYGla whole heart at neonates, 5and 16 
weeks of age. Figure 5-16 demonstrates that the qRT-PCR validation analysis of 
rat to human translated cardiac genes revealed that Smoc2 is differentially 
expressed in human and rat hearts, whereas Lamc2 only significant in rats. 
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Figure  5-16 qRT-PCR analysis of translated cardiac candidate genes in rat and human. 
a1) Smoc2 was significantly differentially expressed between all the stages of dilated 
cardiomyopathy heart failure and control. a2) Lamc2 was not significant between all stages of 
dilated cardiomyopathy heart failure and control. b1) Smoc2 was significantly differentially 
expressed in heart between SHRSPGla and WKYGla at neonates and 16 weeks of age but not 5 
weeks of age. b2) Lamc2 was significantly differentially expressed in heart between SHRSPGla and 
WKYGla at all time points. *P<0.05. 
 
5.3.2.1.4.2 Troubleshooting Smoc2 experimental data in rat 
 
Smoc2 qRT-PCR results of rat and human were significantly differentially 
expressed, however, rat fold change directions in microarray (Figure 5-17) is 
different than qRT-pCR (Figure 5-16). Figure 5-17 also shows the difference in 
signal intensity between SHRSPGla and WKYGla significant but also very subtle.  
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Figure  5-17 Microarray signal intensities of Smoc2 on SHRSPGla and WKYGla rat strains at 
neonates, 5 and 16 weeks of age. 
Graph showing low microarray signal intensities of Smoc2 between SHRSPGla and WKYGla whole 
heart at neonates, 5 and 16 weeks of age from Illumina BeadChip array. Smoc2 was significantly 
differentially expressed in heart between SHRSPGla and WKYGla at all time points.*P<0.05. 
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5.4 Discussion 
Herein we have investigated the types of genomic variants that are likely to 
have an influence on the transcriptomic output between SHRSPGla and WKYGla. 
The overall results show that all types of genomics variations can correlate with 
transcriptomic data; however, CNV of duplication unique to the SHRSPGla have 
the largest portion of differentially expressed renal and cardiac genes compared 
to small sequence variation (SNPs and INDELs) and large deletion. These data are 
further supported by observations of Simonis et al., 2012 when different types of 
NGS genomic variants integrated with NGS RNA sequencing (RNA-Seq) on liver 
between SHROlaIpcv and a BN derived strain with polydactyly-luxate BNLx/Cub that 
showed gene duplications unique to SHROlaIpcv which were highly correlating with 
transcriptomic output compared to other types of genomic variants.  
 
Small sequence variations in non-coding regions are highly correlating with the 
overall transcriptomic output at congenic strains regions on chromosome 2, 3 
and 14 when compared to other types of genomic variants. Furthermore, at the 
whole genome level, small sequence variations in non coding regions, which is an 
important part that can regulate gene expression, is more likely to influence 
cardiac and renal gene expression compared to small sequence variations in 
coding region. These results may change and/or improve once the recent 
findings of Encyclopedia of DNA Elements (ENCODE) project which shows 80% of 
the human genome have biochemical functions and annotate regulatory 
elements for gene expression (Dunham et al., 2012) identified in the rat.  
 
In our analysis we observed an overall change in results between Affymetrix 
custom microarray unique to our strains and default Affymetrix, when comparing 
chromosome 2 congenic strain (SP.WKYGla2a) to SHRSPGla gene expression in 
kidney at 21 weeks of age. Additional unique positional candidate genes were 
identified using with the custom Affymetrix analysis. Nevertheless, removing the 
affected probes may have left some genes’ expression levels undetected, 
explaining, thus, the unique positional candidate genes identified by default 
Affymetrix analysis only. Additionally, Illumina rat chip affected probes mapped 
to Gstm1 and Ptpn13 are shown by qRT-PCR to be differentially expressed 
between SHRSPGla and WKYGla. Our results coincide with what is reported in 
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Schurmann et al., 2012, that the majority of sequence variants within probes' 
target region had no significant effect on hybridization efficiency. As a result, 
relying only on the custom microarray chip unique to our rat strains put the 
analysis at risk of missing true positive differentially expressed genes. 
 
Gstm1 has been previous identified as functional and positional gene for 
hypertension in the SHRSPGla kidney (McBride et al., 2005). Nevertheless, it has 
been identified by our reductive and integrative a Swiss cheese model. 
Furthermore, UDP glucuronosyltransferase 2 family, polypeptide B7 (Ugt2b7) and 
afamin (Afm) both map to congenic region of chromosome 14 and they are 
differentially expressed between SHRSPGla and WKYGla in kidney. There is no 
direct link for Ugt2b7 and Afm to hypertension. However, Ugt2b7 is involved in 
metabolic pathways for glucuronidation and conjugation that detoxify and 
eliminate variety of endogenous compounds such as steroid hormones (including 
estrogen) and xenobiotics drugs such as Carvedilo, a therapeutic agent used to 
treat hypertension (Cheng et al., 1998; Holthe et al., 2003; Ohno et al., 2004). 
Afm is vitamin E binding protein and also regulates the transport of vitamin E, 
playing an important role in lowering blood pressure as it is promoting the 
production of nitric oxide resulting in vasodilatation (Boshtam et al., 2002; 
Jerkovic et al., 2005). As a result, functional sequence variants in Ugt2b7 and 
Afm may affect their biological functions and result in hypertension.  
 
The 39 stroke candidate genes identified by the integration of SHRSPGla unique 
sequence variants compared to 27 rat strains genome with frontal and mid-
coronal brain gene profiling at different time points (Bailey et al., 2014) with 
salt loaded were not prioritised previously in Bailey et al., 2014 as stroke 
candidate genes. Given the number of time points of brain sections, including 
salt loaded, genes that were differentially expressed at more than one time 
point and/or brain section used to as filtering criteria in which 16 candidate 
genes were prioritised for stroke. Six of these genes that were mapped to RGD 
stroke QTLs; ribosomal protein S16 (Rps16), zinc finger protein 566 (Znf566), 
transcription factor 4 (Tcf4), sorting nexin 10 (Snx10), IQ motif and ubiquitin 
domain containing (Iqub), apolipoprotein C-I (Apoc1). Three out of the 16 
candidate genes for stroke mapped to QTLs between SHRSPGla and WKYGla for 
blood pressure; ATPase, class VI, type 11B (Atp11b), transcription termination 
179 
 
 
factor, RNA polymerase I (Ttf1) and for left ventricular mass index; predicted 
gene Loc360919. Snx10 has a role in regulation of osteoclast (Zhu et al., 2012) 
and when mutated lead to ostepetrosis (Pangrazio et al., 2013). Apoc1 is 
involved in the regulation of lipid transport and associated with Alzheimer’s 
disease (Zhou et al., 2014) and a mutated Ttf1 has been associated with brain-
lung-thyroid syndrome (Shetty et al., 2014). Atp11b, which is involved in ion 
transport, is the only gene with 28 bp deletion causing a frameshift. Apart from 
these genes with biological function, the rest of the identified genes mapped to 
QTLs of our interests are with uncertain function. This is in line with the few 
identified GWAS candidate genes for stroke in human in which genes have no 
biological functions related to stroke (Traylor et al., 2012) and none were 
implicated in our analysis. 
The integration of human GWAS studies for blood pressure and hypertension with 
our cardiac and renal transcriptomic data and sequence variants between from 
SHRSPGla and WKYGla was used as a strategic approach to get insights into their 
genetics mechanisms and translate candidate genes from human to rat. We have 
shown most human GWAS genes for hypertension were conserved and mapped to 
BP QTLs in rat. Moreover, half of these genes harbour sequence variants but few 
are differentially expressed in heart and kidney between SHRSPGla and WKYGla. 
Gucy1a3-Gucy1b3 were identified when we considered our congenic regions, 
sequence variants, transcriptomic data between SHRSPGla and WKYGla are 
associated with human GWAS candidate genes for hypertension. Both Gucy1a3-
Gucy1b3 serve as nitric oxide receptors (Saino et al., 2004), and both can 
facilitate communication between heart and kidney to regulate blood volume 
and Na+ balance (Garbers et al., 2006). qRT-PCR validation of the prioritised 
genes in heart did not match our microarray gene expression result. The 
identification of two significantly differentially expressed probes affected for 
Gucy1a3 by two different SNPs from two microarray gene expression in heart and 
kidney might explain the qRT-PCR results (although we tested Gucy1a3 in heart 
only), however, we have shown that having a SNP within probes' target region 
does not necessary lead to false positive result. Moreover, the alternative 
splicing of Gucy1a3 in heart from Exon array results showed that the Taqman 
probe used for testing might provide a better explanation for the qRT-PCR 
results as it does not cover the alternative spliced exon.  
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The integration of renal next generation data to translate differentially 
expressed miRNA between hypertensive and normotensive subjects from human 
to rat was not successful. This might be due to functional differences in kidney 
sections between cortex and medulla used in human compared to the whole 
kidney used in rat. Other reasons that might contribute to this are; the miRBase 
(version 20) total number of miRNA identified in human (1872) is about the triple 
compared to in rat (449) (Griffiths-Jones et al., 2008) and only one replica was 
used for each subject. Therefore, human and rat data were analysed separately. 
In human miRNA study, normotensive and hypertensive subjects have did not 
have common differentially expressed miRNA between renal medulla and cortex 
which, is consistent with their differences in anatomical boundaries and 
biological functions (Marques et al., 2011). None of the identified renal miRNA 
differentially expressed between hypertensive and control in our human study 
were in common with human hypertensive renal miRNA identified in Marques et 
al., 2011. Nevertheless, both hsa-mir-216a and -217 identified in human cortex 
together been associated with hepatocellular carcinoma recurrence and 
metastases (Xia et al., 2013) and are potential biomarkers for chronic kidney 
disease (Szeto et al., 2012). Furthermore, miR-217 act as an endogenous 
inhibitor of silent information regulator 1 promoting endothelial cell senescence 
which can cause endothelial dysfunction (Menghini et al., 2009). Additionally, 
hsa-mir-129-2-3p identified in human medulla has been suggested to regulate 
glycerol levels (Raitoharju et al., 2014), which can function as vasodilator to 
improve blood flow (Maruhashi et al., 2013). 
Low number of replica did not seem to have an impact on identifying common 
differentially expressed miRNA WKYGla versus SHRSPGla, 2c* versus SHRSPGla and 
WKYGla versus 2c* comparisons. However, none of the identified differentially 
expressed miRNA in all rat strains comparisons harboured sequence variants and 
none were mapped to chromosome 2 including 2c* versus SHRSPGla comparison. 
Therefore, we considered miRNA targeting genes and prioritised 2c* versus 
SHRSPGla comparison to identify positional genes with sequence variants in their 
3 'UTR that may affect cardiac and/or renal genes expression between SHRSPGla 
and WKYGla. Sorting nexin family member 27 (Snx27) has role in glucose and ion 
transport (Steinberg et al., 2013) and it is targeted by most of the miRNA 
identified which might be due its large 3' UTR size. The difference in mRNA level 
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of Gstm1 between SHRSPGla and WKYGla was reflected at the protein level 
(McBride et al., 2005), however, this change was not associated with miRNAs 
(rno-mir148b-3p and rno-mir-672) that targets small size 3' UTR. The 
identification of sequence variants next to the binding site of rno-mir-7a-5p, 
rno-mir-322-3p and rno-mir-30c-2-3p that target Gucy1a3 3'UTR might increase 
the chance of affect their binding affinity (Preskill & Weidhaas, 2013) and have 
an impact on mRNA degradation and translation (Valencia-Sanchez et al., 2006). 
The current miRNA study needs further work on laboratory validation of 
implicated miRNAs, mRNAs, sequence variants and proteins. 
When considering translation of cardiac differentially expressed genes common 
between our rat strains and two human heart failure data. We found Smoc2 and 
Lamc2 were common between our rat strains and human ischemic heart failure 
data 1 (Greco et al., 2012) where fold change direction is the same in rat and 
human. Smoc2 was the only common gene between our rat strains and human 
heart failure data 2 (Schinke et al., 2004), which arose from different aetiologies 
of cardiomyopathies. Sequence variants from SHRSPGla and WKYGla were 
implicated in both genes that may affect their function. When validating using 
qRT-PCR with human heart failure samples from Imperial College, Smoc2 was 
significantly differentially expressed between controls and all different stages of 
dilated cardiomyopathy heart failure. Low signal intensities between SHRSPGla 
and WKYGla and sequence variants in the Smoc2 3'UTR might contribute to the 
discrepancies in fold change results obtained from microarray and qRT-PCR in 
rat. Nevertheless, Lamc2 did not validate in dilated cardiomyopathy heart 
failure, which might suggest that it may be specific for ischemic heart failure. 
Also the samples used for validation are small subset of a larger study and a 
bigger sample can be used in the future for Lamc2. 
 
When considering the biology of these genes and how they can be functionally 
related to heart failure, there is evidence that Smoc2 plays role in 
Embryogenesis (angiogenesis) and wound healing (Rocnik et al., 2006). A 
mutated Lamc2 can cause abnormal morphology of tissue (Meng et al., 2003) 
that is localised to its epithelial cells. This suggests that these genes may play a 
role in cardiac stress and wound healing. 
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6 General Discussion 
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HTN is a major risk factor for premature CVD such as renal disease, coronary 
heart disease and cerebrovascular disease, and it has been estimated that it will 
have affected 29% of the population worldwide by 2025 (Kearney et al., 2005). 
Blood pressure regulation is influenced by the interaction of multiple genes as 
well as environmental factors, such as high salt diet. These factors complicate 
the elucidation of the genetic basis of HTN, as well as prevention and treatment 
of high blood pressure. Human GWAS has identified a number of candidate genes 
for blood pressure and hypertension (Levy et al., 2009; Newton-Cheh et al., 
2009; Padmanabhan et al., 2010; Ehret et al., 2011; Johnson et al., 2011; Kato 
et al., 2011; Wain et al., 2011; Salvi et al., 2012; Franceschini et al., 2013). 
Nevertheless, the effect of the associated SNPs on blood pressure is small and 
represents a modest fraction of the heritability estimated from family and twin 
studies (Feinleib et al., 1977; Mongeau et al., 1986; Staessen et al., 2003). 
Furthermore, the associated SNPs GWAS studied are usually located next to 
several genes that need further investigation to identify the causative genes and 
alleles. The use of rats that have been selectively bred to provide animal models 
for HTN offer more control over genetics background and environmental factors; 
this includes the production of specific inter-crosses between diseased and 
control rat for linkage analysis (Graham et al., 2005). The SHRSPGla is an 
excellent model for human cardiovascular diseases as it mimics a number of 
human cardiovascular disease features, including high blood pressure, 
endothelial dysfunction and left ventricular hypertrophy. Previous work in our 
laboratory identified a number of QTLs between SHRSPGla and WKYGla (control) 
(Clark et al., 1996) and consequently congenic strains were constructed on 
chromosomes 2, 3 and 14 for blood pressure, pulse pressure and left ventricular 
hypertrophy, respectively (Graham et al., 2005). 
 
The experiments presented in this project applied a wide range of systems 
genetic analysis to investigate the genetic determinants of the SHRSPGla traits 
that will help in human translational studies and vice versa. This was achieved 
by (1) implementing new gene expression analysis workflows that allow for (a) 
integrative analysis of gene expression profiling data and congenic strains, and 
(b) to run gene expression cluster analysis between SHRSPGla and WKYGla across 
tissues at different hypertensive stages, (2) identifying, annotating, and 
validating the genomic variations between SHRSPGla and WKYGla whole genomes 
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and extracting SHRSPGla unique sequence variants from 28 (non stroke-prone) rat 
genomes, (3) applying a multifaceted approach that includes and integrates 
systems genetics analysis from rat and human studies. 
 
The availability of large transcriptomic data from functional tissues relevant to 
CVD and genome sequences of SHRSPGla and WKYGla as well as other rat strains 
(Atanur et al., 2013) have accelerated our systems genetics analysis and 
translational studies between rat and human.  
 
Previously, a number of research groups attempted to translate human GWAS 
candidate genes for blood pressure and hypertension to their hypertensive rats 
so as to (a) to prioritise and confirm human candidate genes for hypertension 
(Endres et al., 2014; Jin et al., 2014) even at a single GWAS locus using zinc-
finger nuclease technology (Flister et al., 2013), and (b) to explore the 
regulatory mechanisms that mediate the outcome of genes identified using 
transcriptomic data from their hypertensive rat strain (Langley et al., 2013).  
 
In this study, we followed a different strategy but with the same objectives 
(Langley et al., 2013; Endres et al., 2014; Jin et al., 2014) for a translation study 
from human GWAS candidate genes for blood pressure and hypertension to the 
SHRSPGla (from "human to rat") using sequence variants, mRNA (renal and 
cardiac) and miRNA (renal) expression profiling data, and blood pressure QTLs 
between SHRSPGla and WKYGla. Findings from our human to rat translation study 
showed that human GWAS candidate genes for blood pressure are mainly 
conserved in rat and mapped to QTL regions for blood pressure, half of these 
genes harbour sequence variants, and few are differentially expressed in tissues 
between SHRSPGla and WKYGla. Due to time limitations we could not prove the 
involvement of these genes in our rat strains; nevertheless, our strategy could 
be used to prioritise human candidate genes for hypertension even at a single 
GWAS locus, in a cluster with correlated genes across functional tissues relevant 
to CVD and with detailed troubleshooting, that are likely be missed by other 
translation studies. For example, Gucy1a3-Gucy1b3 (human GWAS candidate 
genes for blood pressure) encode α and β sub-units of a heterodimeric protein, 
soluble guanylate cyclase, that function as nitric oxide receptor and a mouse 
knock-out of these subunits resulted in hypertension (Friebe et al., 2007). 
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Gucy1a3-Gucy1b3 were prioritised as translational candidate genes for 
hypertension since both map to a congenic interval (SP.WKYGla2c*) for blood 
pressure, are differentially expressed in heart and/or kidney and harbour 
functional sequence variants between SHRSPGla and WKYGla. Furthermore, 
BioLayoutExpress3D analysis across multiple tissues at severely hypertensive 
stage identified Gucy1a3 in a cluster of genes (total 8) that share common 
differentially expression pattern between SHRSPGla and WKYGla. This cluster of 
genes might contribute to a network or pathway that underlies the SHRSPGla 
phenotype which is considered an ideal translation approach (Delles et al., 2010; 
Pravenec et al., 2014) giving an insights into the pathogenesis and possible 
therapeutic targets for human hypertension. Validation by qRT-PCR results for 
Gucy1a3 and Gucy1b3 in heart did not match the microarray expression results. 
For Gucy1a3, this can be due to (a) sequence variants identified in probe–target 
sequences that may alter probe hybridization affinities causing false positive 
result, and (b) evidence from Exon array heart data (Crawford, 2011) showing 
that the Taqman probe used is inappropriate. Moreover, differentially expressed 
miRNA in kidney between SP.WKYGla2c* and SHRSPGla which target Gucy1a3’s 
3'UTR that may suggest a change at post-transcription and/or post-translation 
level.  
 
Alternatively, in the opposite direction of translation, from "rat to human", only 
a few groups have been able to successful translate their prioritised findings in 
hypertensive rats to human. Examples include one research group using specific 
spontaneously hypertensive heart failure rats to identify and translate Ephx2 as 
a heart failure susceptibility gene (Monti et al., 2008), while another group used 
recombinant inbred rat strains panel produced over years from SHR and BN rat 
strains to identify and validate Ogn as a left ventricular hypertrophy 
susceptibility gene (Petretto et al., 2008). 
 
In this study, we carried out a different strategy for translation from rat to 
human, using cardiac gene expression data at neonatal, 5 and 16 weeks of age, 
sequence variants between SHRSPGla and WKYGla integrated with two human gene 
expression data of heart failure from public repository data (Schinke et al., 
2004; Greco et al., 2012). This approach identified two commonly differentially 
expressed genes with the same fold-change direction in both rat and human 
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data. These are the Smoc2 and Lamc2 genes, and they are both involved in 
wound healing (Rocnik et al., 2006; Adair-Kirk et al., 2012). qRT-PCR results in 
rats confirmed the differential expression significance of Smoc2 and Lamc2. 
Nevertheless, Smoc2 qRT-PCR fold change direction in our rat study did not 
match the microarray expression data; the low expression level and/or influence 
of sequence variants identified within its 3' UTR may contribute to this. On the 
other hand, qRT-PCR in human dilated cardiomyopathy heart failure tissues 
validated Smoc2 differential expression from two microarray gene expression 
data of heart failure. This may suggest that Smoc2 plays a cross-species role in 
cardiac stress and wound healing.  
 
Previously, our group’s integrative approach of renal microarray gene expression 
profiling and chromosome 2 congenic strains led to the identification of a 
number of positional candidate genes. Gstm1 was identified as a positional and 
functional candidate gene for blood pressure using SP.WKYGla2c* (congenic 
interval does not contain salt-sensitivity QTL) (McBride et al., 2003). Similarly, 
S1pr1 and Vcam1 were identified as positional candidate genes for salt-
sensitivity hypertension using SP.WKYGla2a (congenic interval contain salt-
sensitivity QTL) (Graham et al., 2007). 
 
The success of our integrative approach of microarray gene expression profiling 
data with congenic strains usually focuses on single gene/genetic variants. This 
workflow puts the analysis at risk of missing potential positional candidate genes 
due to the limitation of the chip used. In addition, we wanted to move away 
from simple differential expression analysis to cluster analysis and integrate the 
results with sequence variants to allow findings to be interpreted in context of 
causative networks and pathways.  
 
In the current study, we improved our workflow for the integrative approach of 
gene expression profiling data with congenic strains. This was carried out by 
combining two renal gene expression profiling datasets during salt challenged 
between SHRSPGla and WKYGla from two microarray platforms as well as 
chromosome 3 sub-congenic strains from Illumina maximised the identification 
efficiency of positional candidate genes. This approach identified Dnm1 and 
Tor1b as novel candidate genes for blood pressure, localised within the common 
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congenic interval shared by SP.WKYGla3d and SP.WKYGla3f strains, and Rabgap1 as 
a novel candidate gene for salt-induced pulse pressure variability and renal 
pathology, located within the region unique to the SP.WKYGla3d strain. This 
workflow shed the light on failed integrative studies of microarray gene 
expression profiling and congenic strain to identify positional candidate genes, 
suggesting that it might be due to the limited efficiency of the gene array used 
(Moujahidine et al., 2004). 
 
Moving beyond simple differential expression analysis, cluster analysis was 
carried out by using the BioLayoutExpress3D tool on multiple functional 
cardiovascular relevant tissues to SHRSPGla traits at different hypertensive 
stages. Functional analysis on the identified clusters at pre-hypertensive, 
hypertensive and severely hypertensive stages between SHRSPGla and WKYGla 
implicated genes with a cardiovascular system and nervous system function, and 
genes involved in molecular transport, and inflammatory response. The latter 
was unique to the hypertensive and severely hypertensive stages. Atp11b, a P-
type ATPase membrane protein critical for ion transport (Halleck et al., 2002) 
and mediator of platinum chemotherapy resistance in ovarian cancer (Moreno-
Smith et al., 2013), was a common gene in all the identified clusters at different 
hypertensive stages. This may suggest that Atp11b is the disease-driving gene 
since it is differentially expressed from an early age in all relevant tissues and 
has a predicted frameshift mutation caused by a deletion of 28bp. qRT-PCR on 
heart and kidney between SHRSPGla and WKYGla at different time points validated 
the cluster analysis results. In addition, Atp11b was identified as a novel 
positional candidate gene for salt-induced blood pressure variability in another 
renal gene expression cluster analysis between WKYGla, SHRSPGla and SP.WKYGla2a 
congenic strains that was not identified previously using other gene expression 
analysis tools (Graham et al., 2007; Hopcroft et al., 2010). qRT-PCR showed that 
Atp11b, which is located within the congenic interval of SP.WKYGla2a strain, is 
significantly differentially expressed between SHRSPGla and SP.WKYGla2a congenic 
strains at the severely hypertensive stage and under salt challenged. Although a 
similar strategy was used on hypertensive mouse multiple tissues to identify 
potential pharmacological targets of hypertension (Puig et al., 2010). 
Nevertheless, their cluster analysis was at only one hypertensive stage, when it 
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is difficult to differentiate between cause and effect genes, especially in the 
absence of sequence variants. 
 
High-throughput NGS identified several genomic variants, including 1,163,332 
SNPs and 213,130 INDEL between SHRSPGla and WKYGla with uneven distribution 
across all BN reference genome RGSC 3.4 chromosomes including our QTLs 
regions on chromosome 2, 3 and 14. The release of new BN reference genome 
Rnor 5.0 improved our NGS coverage and genomic variants’ analysis. However, 
the overwhelming number of genomics variants makes it extremely difficult to 
find the SHRSPGla causal trait variants. Results from integrating genomic and 
transcriptomic data between SHRSPGla and WKYGla revealed that they are likely 
to be correlated, this coincides with findings from other NGS analysis in rat 
(Simonis et al., 2012) and human studies (Dimas et al., 2009; Nicolae et al., 
2010; Lappalainen et al., 2013). In addition, the small sequence variants that 
are likely to influence the gene expression between our rats were higher in non-
coding regions compared to coding regions which is notable in the light of the 
recent ENCODE findings that non-coding regions are functional (Ian et al., 2012). 
Nevertheless, integrating genomics and transcriptomics data can be used as a 
reductive approach especially when focusing on protein coding variants within 
our QTLs as they are most likely to contribute (protein function) to the SHRSPGla 
phenotype. This reductive and integrative strategy, can be thought of as a "Swiss 
cheese" model. Using this model we were able to identify a number of positional 
candidate genes. Gstm1, is one of the identified genes, and it was previously 
shown to influence blood pressure in the SHRSPGla (McBride et al., 2003; McBride 
et al., 2005) providing proof of concept for our model. In addition, we were able 
to validate some of the identified positional genes such as Ugt2b7 and Afm in 
kidney tissue between parental strains. Ugt2b7 plays important role in 
glucuronidation of lipids such as estrogens (Ohno et al., 2004) and Afm involves 
in the regulation and transport of vitamins (Boshtam et al., 2002; Jerkovic et al., 
2005); both of these functions, if impaired due to the identified sequence 
variants, can affect their protein function levels that may result in hypertension. 
 
We also used another integrative and reductive approach to identify disease-
causing genes in the SHRSPGla. This was carried out by isolating and annotating 
SHRSPGla unique sequence variants when compared to 27 rat genomes with no 
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stroke phenotype (Atanur et al., 2013). Deleterious protein coding variants were 
prioritised, especially if they mapped to blood pressure and stroke QTLs or/and 
were in common with published sequence variants of the SHRSPIzm (Gandolgor et 
al., 2013). One of the common variants between SHRSP strains identified in our 
analysis maps to Stim1, which was recently identified as a candidate gene for 
stroke in the SHRSPIzm (Ferdaus et al., 2014). Furthermore, we integrated all 
SHRSPGla unique sequence with published frontal and mid-coronal brain gene 
profiling at different time points (Bailey et al., 2014). This integrative strategy 
prioritised 39 stroke candidate genes that had not be chosen for validation 
previously (Bailey et al., 2014) and were further prioritised when considering 
deleterious sequence variants and our QTL regions. 
 
Our direct approach to translate renal candidate miRNA for hypertension 
between our rat and human studies using NGS, did not result in common 
differentially expressed miRNA. This might be due to (a) the differences of 
genetics between the two species, (b) different sections of kidney being used (in 
human study we analysed renal medulla and cortex separately, while in rats we 
used whole kidney), and (c) the human miRNA database being more fully 
established compared to rat miRNA database. Nevertheless, human renal miRNAs 
with functions related to hypertension were differentially expressed between 
hypertensive patients and controls. For example, the hsa-mir-216a and -217 are 
considered to be biomarkers for chronic kidney disease, and have been involved 
in the endothelial dysfunction (Menghini et al., 2009; Szeto et al., 2012). In 
addition, the identified miRNA in our study were not implicated previously in 
other miRNA studies between hypertensive patients and controls using Agilent 
Human miRNA microarray (Marques et al., 2011). In our rat miRNA study, we 
identified differentially expressed miRNA, rno-miR-672-5p and -148b-3p, 
between SP.WKYGla2c* and SHRSPGla where both target Gstm1 3'UTR that harbour 
sequence variants between SHRSPGla and WKYGla providing other possible 
mechanisms for its low mRNA and protein levels in the SHRSPGla kidney (McBride 
et al., 2005). 
 
False positive results are likely to be included in large-scale genome and genes’ 
(Larkin et al., 2005) survey analysis. However, due to time limitations we could 
not carry out all the necessary laboratory validation. The present work identifies 
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a number of high priority follow up studies. In human studies, Lamc2 was 
validated in a small subset of dilated cardiomyopathy heart failure samples. 
Increasing samples size and/or use of another type of cardiomyopathy that leads 
to heart failure could validate our study findings. Also, due to the limitations of 
time, we were not able to address the issue of Smoc2 fold change direction in 
our rat between qRT-PCR and microarray results and hence further laboratory 
validation should be carried out. Moreover, the identified candidate miRNA from 
human and rat studies should be validated. In rat studies, qRT-PCR validation for 
Gucy1a3 with appropriate Taqman probe that covers the alternate spliced exon 
as well as protein level validation. Luciferase reporter gene experiments (for 
Gucy1a3 and Gstm1) can also be used on rat kidney to confirm the predicted 
binding of the targeting miRNA identified from our rat study. Furthermore, qRT-
PCR validation is required for Atp11b on other implicated tissues between 
parental strains, at different time points, along with chromosome 2 congenic 
strains. The positional candidate genes identified by Swiss cheese model were 
validated between parental strains only this could be extended to include 
congenic strains. Although the quality control results of NGS sequence variants of 
SHRSPGla and WKYGla demonstrate high sensitivity and specificity when compared 
to three independent sequencing technologies. Nevertheless, Sanger sequencing 
is required to validate functional sequence variants implicated within our 
prioritised candidate genes for the SHRSPGla phenotype. Finally, transgenic 
strains can be constructed by introgressing of one of our strong candidate genes 
from the WKYGla into the SHRSPGla background. Transgenic strains are a powerful 
model to examine and demonstrate the phenotype improvements of the 
transgene when compared to the SHRSPGla. 
 
Future bioinformatics work in rat studies would also be sensible. Cluster analysis 
can be carried out using BioLayoutExpress3D between SHRSPGla and WKYGla from 
pre-hypertensive stage till severely hypertensive stage on each tissue separately, 
to identify tissue specific networks and pathways that may underline SHRSPGla 
traits. Moreover, we can integrate targeting genes of miRNAs affected by 
sequence variants with renal and cardiac transcriptomic data between SHRSPGla 
and WKYGla to prioritise candidate miRNAs for the SHRSPGla trait. Furthermore, 
the preliminary results of the customised Affymetrix array to our rat strains 
compared to the default led to the identification of additional positional 
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candidates. This can be extended to include other gene expression profiling 
data. Also, our rat gene expression profiling data can benefit from the new 
feature offered by IPA, called "Mechanistic networks", where probable signaling 
cascades are produced from connecting upstream regulators to predict how they 
might work together to achieve the changes in gene expression data 
(http://www.ingenuity.com/). In addition, a recent proteomics analysis on 
mesenteric resistance arteries from SHRSPGla, WKYGla and chromosome 2 
congenic strains, carried out in our laboratory, can be integrated with parental 
sequence variants to prioritise significant differentially expressed proteins for 
SHRSPGla traits. Moreover, a new BN reference genome was released (RGSC 6.0 
on July 2014) as well as new variants effect predictor annotation version 76. 
Extending our NGS analysis to include the latter can improve both of our 
coverage and genomics variants.  
 
The current study has some limitations. Although, we were able to identify 
significant bioinformatics results from our rat and human miRNA studies, 
however, additional biological replicates can improve the results. Also, in our 
miRNA study we used separated renal cortex and medulla sections in human 
study while we used a whole kidney in the rat study; this, might contribute to 
not finding a common significant miRNA between the two. In addition, we used 
human heart failure tissue for our translation study, which might not be ideal 
since SHRSPGla does not progress to the heart failure phenotype; instead, it has 
left ventricular hypertrophy, which is however a risk factor for heart failure. This 
is typical of issues with human translation using human tissues. In addition, 
quality control results show that NGS analysis did not capture a few Sanger 
sequence variants because these variants did not meet our calling parameters. 
As a result, lowering the NGS variants calling cut-off and re-running the quality 
control to adjust our parameters according to the best results could be done. 
Also, the BN reference genome used (RGSC 3.4 and Rnor 5.0) is a draft version, 
so we could have missed genomic variants for this reason. Finally, our gene 
expression analysis on chromosome 3 congenic strains shows that we can miss 
positional candidate genes due to no probes from Affymetrix or Illumina gene 
expression arrays representing these genes. 
 
192 
 
 
From the current work’s findings we can suggest a number of future projects. 
For instance, RNA-Seq NGS can be carried out on our rat strains tissues to 
identify positional candidate genes that may not be covered by commercial gene 
expression arrays, and to avoid false positive results caused by sequence 
variants. In addition, BioLayoutExpress3D cluster analysis could be conducted on 
gene expression profiling data from SHRSPGla with other hypertensive rat strains 
on public repository databases such as Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) and ArrayExpress 
(http://www.ebi.ac.uk/arrayexpress/). The clusters identified from this 
approach may uncover patho-physiological pathways that underline hypertension 
in rats, which is useful for human studies. This study can be further enhanced by 
integrating common genomics variants from hypertensive rats (Atanur et al., 
2013), which can also prioritise disease causal candidate genes. Furthermore, re-
analysis of NGS data from the 28 rats genomes (Atanur et al., 2013) could be 
performed against the BN reference genome RGSC 6.0, followed by isolation and 
annotation of SHRSPGla. SHRSPGla unique genomics variants can then be 
integrated with other SHRSP strain sequenced, such as SHRSPIzm (Gandolgor et 
al., 2013), in order to identify common stroke causal variants. This can be 
further enriched by integrating the findings with brain gene expression data 
from SHRSPGla and WKYGla (Bailey et al., 2014) and SHRSPIzm and WKYIzm strains 
(Yoshida et al., 2014) to identify common stroke candidate genes. Finally, 
integrating large scale data from multi-level -omics; transcriptomics, genomics 
variants, proteomics, and metabolomics into a unified mathematical model to 
obtain a better understating and wider view of the underlying drivers of 
pathways for SHRSPGla traits is challenging. Nevertheless, a number of 
integrative models has been developed (Bertero et al., 2014), in which most 
relay on Orthogonal projections to latent structures (Trygg & Wold, 2002), or use 
commercial software such as IPA. 
 
In conclusion, the current work established and improved methods that 
identified, prioritised and translated candidate genes for cardiovascular disease 
specifically hypertension, cardiomyopathies, and stroke using multi-level -omics 
integration strategies from rat and human studies. The implicated genes, 
clusters and pathways that may underline the pathogenesis process in the 
SHRSPGla can add to the current knowledge of human patho-physiological 
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mechanisms of cardiovascular disease and eventually lead to therapeutic 
targets.  
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